var title_f24_28_25024="DIP CT scan";
var content_f24_28_25024=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80527&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80527&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Desquamative interstitial pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 416px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High resolution computed tomographic scan shows diffuse ground glass abnormality, with some associated cystic changes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jess Mandel, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_28_25024=[""].join("\n");
var outline_f24_28_25024=null;
var title_f24_28_25025="Calculator: Fractional excretion of sodium (SI units)";
var content_f24_28_25025=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"FractExcSodium_SI_form\" name=\"FractExcSodium_SI_form\" onkeydown=\"clrResults();\" onkeyup=\"FractExcSodium_SI_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Fractional excretion of sodium (SI units)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_equation\">",
"      <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          FENa = (UrineNa / SerumNa) / (UrineCr / SerumCr) * 100",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </div>",
"    </center>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Urine Na",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Urine_Na_param\" onblur=\"FractExcSodium_SI_fx(); minMaxCheck();\" onchange=\"FractExcSodium_SI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Urine_Na_unit\" onchange=\"FractExcSodium_SI_fx();\" style=\"width:105px;\">",
"              <option value=\"0.001|0|mcmol/L\">",
"               mcmol/L",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mmol/L\">",
"               mmol/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Serum Na",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Serum_Na_param\" onblur=\"FractExcSodium_SI_fx(); minMaxCheck();\" onchange=\"FractExcSodium_SI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Serum_Na_unit\" onchange=\"FractExcSodium_SI_fx();\" style=\"width:105px;\">",
"              <option value=\"0.001|0|mcmol/L\">",
"               mcmol/L",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mmol/L\">",
"               mmol/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Urine Cr",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Urine_Cr_param\" onblur=\"FractExcSodium_SI_fx(); minMaxCheck();\" onchange=\"FractExcSodium_SI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Urine_Cr_unit\" onchange=\"FractExcSodium_SI_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|mcmol/L\">",
"               mcmol/L",
"              </option>",
"              <option value=\"1000|0|mmol/L\">",
"               mmol/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Serum Cr",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Serum_Cr_param\" onblur=\"FractExcSodium_SI_fx(); minMaxCheck();\" onchange=\"FractExcSodium_SI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Serum_Cr_unit\" onchange=\"FractExcSodium_SI_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|mcmol/L\">",
"               mcmol/L",
"              </option>",
"              <option value=\"1000|0|mmol/L\">",
"               mmol/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Result:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              FE Na",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"FE_Na_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"            <td valign=\"top\">",
"             <span class=\"medCalcFontOne\">",
"              <select class=\"medCalcFontSelect\" name=\"FE_Na_unit\" onchange=\"FractExcSodium_SI_fx();\" style=\"width:105px;\">",
"               <option selected=\"selected\" value=\"1|0|%\">",
"                %",
"               </option>",
"               <option value=\"100|0|fraction\">",
"                fraction",
"               </option>",
"               <option value=\"100|0|ratio\">",
"                ratio",
"               </option>",
"              </select>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"center\" colspan=\"3\">",
"             <span class=\"medCalcFontOneBold\">",
"              Decimal Precision:",
"             </span>",
"             <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"FractExcSodium_SI_fx();\">",
"              <option>",
"               0",
"              </option>",
"              <option>",
"               1",
"              </option>",
"              <option selected=\"selected\">",
"               2",
"              </option>",
"              <option>",
"               3",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       The fractional excretion of sodium (",
"       <b>",
"        FENa",
"       </b>",
"       ) can be calculated by entering the values from",
"simultaneously obtained urine and blood samples.",
"      </li>",
"      <li>",
"       For this calculation, the",
"       <b>",
"        Urine Cr",
"       </b>",
"       is entered as mcmol/L by default.  Change the unit selector if you have a value in mmol/L.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Stein JH, ed.",
"        <i>",
"         Internal Medicine",
"        </i>",
"        . 4th edition. Mosby-Year Book. 1994.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_28_25025=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function FractExcSodium_SI_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.FractExcSodium_SI_form){",
"",
"",
"doCalc = true;",
"if (Urine_Na_param.value.indexOf(',') >= 0){ Urine_Na_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Urine_Na_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Urine_Na_unit.options[Urine_Na_unit.selectedIndex].value.split('|');",
"Urine_Na = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Serum_Na_param.value.indexOf(',') >= 0){ Serum_Na_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Serum_Na_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Serum_Na_unit.options[Serum_Na_unit.selectedIndex].value.split('|');",
"Serum_Na = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Urine_Cr_param.value.indexOf(',') >= 0){ Urine_Cr_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Urine_Cr_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Urine_Cr_unit.options[Urine_Cr_unit.selectedIndex].value.split('|');",
"Urine_Cr = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Serum_Cr_param.value.indexOf(',') >= 0){ Serum_Cr_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Serum_Cr_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Serum_Cr_unit.options[Serum_Cr_unit.selectedIndex].value.split('|');",
"Serum_Cr = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"FE_Na =  (Urine_Na / Serum_Na) / (Urine_Cr / Serum_Cr) * 100;",
"",
"unit_parts = FE_Na_unit.options[FE_Na_unit.selectedIndex].value.split('|');",
"if (doCalc) FE_Na_param.value = fixDP((FE_Na - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.FractExcSodium_SI_form){",
"",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.FractExcSodium_SI_form){",
"",
"FE_Na_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f24_28_25025=null;
var title_f24_28_25026="Subchorionic bleeding";
var content_f24_28_25026=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Subchorionic bleeding in fetus at 5.5 weeks' gestational age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 198px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Transverse transvaginal sonogram reveals intrauterine gestational sac with yolk sac. Note small amount of blood (arrow) adjacent to gestational sac. B, Transvaginal sagittal sonogram obtained 2 weeks after (A) because of vaginal bleeding shows subchorionic hematoma (arrow) with debris. Collection could be mistake for second gestational sac with embryonic demise.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Trop, I, Levine, D. Hemorrage During Pregnancy: Sonography and MR Imaging. AJR Am J Roentgenol 2001; 176:607. Copyright 2001 American.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_28_25026=[""].join("\n");
var outline_f24_28_25026=null;
var title_f24_28_25027="Chondroblastoma sites";
var content_f24_28_25027=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skeletal distribution of chondroblastoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 247px; height: 605px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_28_25027=[""].join("\n");
var outline_f24_28_25027=null;
var title_f24_28_25028="Schematic geographic miss";
var content_f24_28_25028=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schematic representation of geographical miss and edge restenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During the procedure, there is geographical miss (+) in the proximal segment (treated lesion subjected to injury but not covered by the radiation catheter) ; there is no geographical miss of the distal segment (-) (panel A). During follow-up, the proximal edge with geographic miss (+) developed edge restenosis, which this did not occur at the distal edge without geographic mass (-).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kim, HS, Waksman, R, Cottin, Y. Edge stenosis and geographical miss following intracoronary gamma radiation therapy for in-stent restenosis. J Am Coll Cardiol 2001; 37:1026. Copyright &copy; 2001 American College of Cardiology.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.elsevier.com/locate/jacc\">",
"      file://www.elsevier.com/locate/jacc",
"     </a>",
"     <br/>",
"     <a href=\" file://www.sciencedirect.com\">",
"      file://www.sciencedirect.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_28_25028=[""].join("\n");
var outline_f24_28_25028=null;
var title_f24_28_25029="Fluocinolone (topical): Drug information";
var content_f24_28_25029=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluocinolone (topical): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/16/5380?source=see_link\">",
"    see \"Fluocinolone (topical): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/49/12052?source=see_link\">",
"    see \"Fluocinolone (topical): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8097444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Capex&reg;;",
"     </li>",
"     <li>",
"      Derma-Smoothe/FS&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8097445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Capex&reg;;",
"     </li>",
"     <li>",
"      Derma-Smoothe/FS&reg;;",
"     </li>",
"     <li>",
"      Synalar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8097458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8100671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Atopic dermatitis (Derma-Smoothe/FS&reg; body oil):",
"     </b>",
"     Apply thin film to affected area 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Corticosteroid-responsive dermatoses:",
"     </b>",
"     Topical: Cream, ointment, solution: Apply a thin layer to affected area 2-4 times/day; may use occlusive dressings to manage psoriasis or recalcitrant conditions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Inflammatory and pruritic manifestations (dental use):",
"     </b>",
"     Topical: Apply to oral lesion 4 times/day, after meals and at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Scalp psoriasis (Derma-Smoothe/FS&reg; scalp oil):",
"     </b>",
"     Topical: Massage thoroughly into wet or dampened hair/scalp; cover with shower cap. Leave on overnight (or for at least 4 hours). Remove by washing hair with shampoo and rinsing thoroughly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Seborrheic dermatitis of the scalp (Capex&reg;):",
"     </b>",
"     Topical: Apply no more than 1 ounce to scalp once daily; work into lather and allow to remain on scalp for ~5 minutes. Remove from hair and scalp by rinsing thoroughly with water.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8100670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/49/12052?source=see_link\">",
"      see \"Fluocinolone (topical): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Atopic dermatitis:",
"     </b>",
"     Topical: Children &ge;3 months (Derma-Smoothe/FS&reg; body oil): Moisten skin; apply a thin film to affected area twice daily; do not use for longer than 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Corticosteroid-responsive dermatoses:",
"     </b>",
"     Topical: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8100673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8100716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as acetonide: 0.01% (15 g, 60 g); 0.025% (15 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oil, topical, as acetonide [body oil]: 0.01% (118 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Derma-Smoothe/FS&reg;: 0.01% (120 mL) [contains isopropyl alcohol, peanut oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oil, topical, as acetonide [scalp oil]: 0.01% (118 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Derma-Smoothe/FS&reg;: 0.01% (120 mL) [contains isopropyl alcohol, peanut oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical, as acetonide: 0.025% (15 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo, topical, as acetonide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capex&reg;: 0.01% (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical, as acetonide: 0.01% (60 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8097456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes shampoo",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8100675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Apply thin film to affected area; avoid eyes.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8097446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of susceptible inflammatory dermatosis (low, medium corticosteroid); dermatitis or psoriasis of the scalp; atopic dermatitis in adults and children &ge;3 months of age",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8097421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Fluocinolone may be confused with fluocinonide",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8097487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Intracranial hypertension (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Telangiectasia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Acneiform eruptions, allergic contact dermatitis, atopic dermatitis (secondary), burning, dryness, erythema, folliculitis, irritation, itching, hypertrichosis, hypopigmentation, keratosis pilaris, miliaria, papules, perioral dermatitis, pustules, shiny skin, skin atrophy, striae",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Cushing's syndrome, HPA axis suppression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Otic: Ear infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Herpes simplex, secondary infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8097474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fluocinolone or any component of the formulation; TB of skin, herpes (including varicella)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8097475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact dermatitis: Allergic contact dermatitis can occur, it is usually diagnosed by failure to heal rather than clinical exacerbation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infection: Steroids may mask infection or enhance existing ocular infection; prolonged use may result in secondary infections due to immunosuppression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy of Derma-Smoothe/FS&reg; body oil have not been established in children &lt;3 months of age. Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing's syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peanut oil: Derma-Smoothe/FS&reg; and DermOtic&reg; Oil contain peanut oil; use caution in peanut-sensitive individuals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Topical: Not for oral, ophthalmic, or intravaginal use; do not apply to the face, axillae, groin,  or diaper area unless directed by healthcare provider. Discontinue use if irritation occurs.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8097493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8097469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8097470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed with corticosteroids in animal reproduction studies. In general, the use of topical corticosteroids during pregnancy is not considered to have significant risk; however, intrauterine growth retardation in the infant has been reported (rare). The use of large amounts or for prolonged periods of time should be avoided.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8097472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8097473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic corticosteroids are excreted in human milk. It is not known if sufficient quantities of fluocinolone are absorbed following topical administration to produce detectable amounts in breast milk. Hypertension in the nursing infant has been reported following corticosteroid ointment applied to the nipples. Use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8100718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Fluocinolone Acetonide External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.01% (15 g): $44.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025% (15 g): $33.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Synalar External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025% (120 g): $216.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Synalar (Cream) External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025% (375 g): $259.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Synalar (Ointment) External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025% (375 g): $259.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Synalar TS External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.01% (1): $326.59",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oil",
"     </b>",
"     (Derma-Smoothe/FS Body External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.01% (118.28 mL): $40.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oil",
"     </b>",
"     (Derma-Smoothe/FS Scalp External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.01% (118.28 mL): $41.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Fluocinolone Acetonide External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025% (15 g): $33.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Synalar External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025% (120 g): $216.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shampoo",
"     </b>",
"     (Capex External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.01% (120 mL): $396.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Fluocinolone Acetonide External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.01% (60 mL): $180.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Synalar External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.01% (60 mL): $261.82",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8100678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs of bacterial or fungal infection",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adermina (CN);",
"     </li>",
"     <li>",
"      Aplosyn (PH);",
"     </li>",
"     <li>",
"      Bratofil (VE);",
"     </li>",
"     <li>",
"      Cinolon (ID);",
"     </li>",
"     <li>",
"      Cortoderm (ZA);",
"     </li>",
"     <li>",
"      Dermalar (IL);",
"     </li>",
"     <li>",
"      Dermasolon Gel (ID);",
"     </li>",
"     <li>",
"      Emderm (IN);",
"     </li>",
"     <li>",
"      Esacinone (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Fluciderm (MY, SG);",
"     </li>",
"     <li>",
"      Flucinar (BG, CZ, DE, HN, PL);",
"     </li>",
"     <li>",
"      Flucort (IN, TW);",
"     </li>",
"     <li>",
"      Flucortone (TW);",
"     </li>",
"     <li>",
"      Flulone (AR);",
"     </li>",
"     <li>",
"      Flunolone (TW);",
"     </li>",
"     <li>",
"      Flunolone-V (SG, TH);",
"     </li>",
"     <li>",
"      Fluocinolona (PY);",
"     </li>",
"     <li>",
"      Fluoderm (ZA);",
"     </li>",
"     <li>",
"      Fluonid (MY);",
"     </li>",
"     <li>",
"      Gelargin (CZ);",
"     </li>",
"     <li>",
"      Jellin (DE);",
"     </li>",
"     <li>",
"      Localyn (IT);",
"     </li>",
"     <li>",
"      Paracort (TW);",
"     </li>",
"     <li>",
"      Radiocin (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Supricort (PE);",
"     </li>",
"     <li>",
"      Synalar (AE, AT, BE, BF, BH, BJ, CH, CI, CY, DK, EE, EG, ET, FR, GB, GH, GM, GN, GR, HK, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, NE, NG, NO, NZ, OM, PK, PT, QA, SA, SC, SD, SE, SK, SL, SN, SY, TH, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Synalar Simple (UY);",
"     </li>",
"     <li>",
"      Synarcus (ID);",
"     </li>",
"     <li>",
"      Syntopic (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8100660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A synthetic fluorinated corticosteroid of low-to-moderate potency. The mechanism of action for all topical corticosteroids is not well defined, however, is believed to be a combination of anti-inflammatory, antipruritic, and vasoconstrictive properties.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8100662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Dependent on strength of preparation, amount applied, nature of skin at application site, vehicle, and use of occlusive dressing; increased in areas of skin damage, inflammation, or occlusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Throughout local skin; absorbed drug is distributed rapidly into muscle, liver, skin, intestines, and kidneys",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily in skin; small amount absorbed into systemic circulation is primarily hepatic to inactive compounds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (primarily as glucuronide and sulfate, also as unconjugated products); feces (small amounts)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Reed, BR, &ldquo;Dermatologic Drugs, Pregnancy, and Lactation. A Conservative Guide,&rdquo;",
"      <i>",
"       Arch Dermatol",
"      </i>",
"      , 1997, 133(7):894-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/28/25029/abstract-text/9236528/pubmed\" id=\"9236528\" target=\"_blank\">",
"        9236528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9130 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3548BCC041-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_28_25029=[""].join("\n");
var outline_f24_28_25029=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097444\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097445\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097458\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100671\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100670\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100673\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100716\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097456\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100675\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097446\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097421\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097487\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097474\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097475\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299349\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097493\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097469\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097470\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097472\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097473\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100718\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100678\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961973\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100660\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100662\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9130\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9130|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/18/29987?source=related_link\">",
"      Fluocinolone (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/32/3587?source=related_link\">",
"      Fluocinolone (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/9/23699?source=related_link\">",
"      Fluocinolone (otic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/12/1220?source=related_link\">",
"      Fluocinolone (otic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/15/29938?source=related_link\">",
"      Fluocinolone (otic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/16/5380?source=related_link\">",
"      Fluocinolone (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/49/12052?source=related_link\">",
"      Fluocinolone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_28_25030="Metoprolol: Patient drug information";
var content_f24_28_25030=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Metoprolol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     see \"Metoprolol: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/11/15544?source=see_link\">",
"     see \"Metoprolol: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F195796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lopressor&reg;;",
"     </li>",
"     <li>",
"      Toprol-XL&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F195797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Metoprolol (Type L&reg;);",
"     </li>",
"     <li>",
"      Apo-Metoprolol SR&reg;;",
"     </li>",
"     <li>",
"      Apo-Metoprolol&reg;;",
"     </li>",
"     <li>",
"      Ava-Metoprolol;",
"     </li>",
"     <li>",
"      Ava-Metoprolol (Type L);",
"     </li>",
"     <li>",
"      Betaloc&reg;;",
"     </li>",
"     <li>",
"      Dom-Metoprolol-B;",
"     </li>",
"     <li>",
"      Dom-Metoprolol-L;",
"     </li>",
"     <li>",
"      JAMP-Metoprolol-L;",
"     </li>",
"     <li>",
"      Lopresor SR&reg;;",
"     </li>",
"     <li>",
"      Lopresor&reg;;",
"     </li>",
"     <li>",
"      Metoprolol Tartrate Injection, USP;",
"     </li>",
"     <li>",
"      Metoprolol-25;",
"     </li>",
"     <li>",
"      Metoprolol-L;",
"     </li>",
"     <li>",
"      Mylan-Metoprolol (Type L);",
"     </li>",
"     <li>",
"      Nu-Metop;",
"     </li>",
"     <li>",
"      PMS-Metoprolol-B;",
"     </li>",
"     <li>",
"      PMS-Metoprolol-L;",
"     </li>",
"     <li>",
"      Riva-Metoprolol-L;",
"     </li>",
"     <li>",
"      Sandoz-Metoprolol (Type L);",
"     </li>",
"     <li>",
"      Sandoz-Metoprolol SR;",
"     </li>",
"     <li>",
"      Teva-Metoprolol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10015231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700256",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not stop taking this drug all of a sudden. If you do, chest pain that is worse and in some cases heart attack may occur. The risk may be greater if you have certain types of heart disease. To avoid side effects, you will want to slowly stop this drug  as ordered by your doctor. Call your doctor right away if you have new or worse chest pain or if other heart problems occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691269",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used after a heart attack to stop future heart attacks and lengthen life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691384",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help a weak heart.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691785",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691662",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692070",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat side effects caused by drugs that are used for mood.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop tremor (essential).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691473",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop migraine headaches.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop performance anxiety.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702517",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to metoprolol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703694",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Poor blood flow to the legs, Raynaud's disease, or a slow heartbeat without a working pacemaker.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 12 weeks pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may hide the signs of low blood sugar. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697997",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698348",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Slow heartbeat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705529",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Short-acting products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695723",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tablet can be crushed and mixed with food or liquid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Long-acting products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695722",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tablet may be broken in half.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699443",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) at room temperature or in a refrigerator. Do not freeze. Throw away any part not used after 2 months.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699280",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect liquid (suspension) from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10864 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-7705E05A5A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_28_25030=[""].join("\n");
var outline_f24_28_25030=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195796\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195797\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015231\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015233\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015232\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015237\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015238\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015240\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015235\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015236\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015241\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015242\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=related_link\">",
"      Metoprolol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/11/15544?source=related_link\">",
"      Metoprolol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_28_25031="Role of methylxanthines in the treatment of COPD";
var content_f24_28_25031=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Role of methylxanthines in the treatment of COPD",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/28/25031/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/28/25031/contributors\">",
"     Carlos A Vaz Fragoso, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/28/25031/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/28/25031/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/28/25031/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/28/25031/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/28/25031/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The value of methylxanthines (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    ) in the management of patients with chronic obstructive pulmonary disease (COPD) is controversial. Current studies, in our view, continue to support a beneficial role in selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, methylxanthines have a narrow therapeutic index; as a result, toxicity can be a significant problem with chronic use, and careful monitoring is essential.",
"   </p>",
"   <p>",
"    The role of methylxanthines in the management of patients with COPD will be reviewed here. The role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    in the treatment of asthma and the management of acute exacerbations of COPD and of stable COPD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11161?source=see_link\">",
"     \"Theophylline use in asthma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=see_link\">",
"     \"Management of acute exacerbations of chronic obstructive pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link\">",
"     \"Management of stable chronic obstructive pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFECTS ON FUNCTIONAL IMPAIRMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with COPD seek assistance because of functional impairment. Four independent determinants of functional impairment have been identified: dyspnea ratings, exercise capacity, respiratory mechanics, and respiratory muscle strength [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/3\">",
"     3",
"    </a>",
"    ]. Dyspnea ratings appear to influence general health status to a greater extent than do physiologic data [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/4\">",
"     4",
"    </a>",
"    ], while performance in a standardized walking test correlates best with dyspnea ratings and the quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. It is within this context that the clinical indications for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    in COPD can be evaluated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4120?source=see_link\">",
"     \"Evaluation of health-related quality of life\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Dyspnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;One review of the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    in COPD found that 6 of 10 studies cited showed an improvement in dyspnea [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/6\">",
"     6",
"    </a>",
"    ]. Furthermore, those studies that utilized the more sensitive dyspnea ratings demonstrated the greatest benefit. Five additional studies, employing either theophylline alone or combination therapy (theophylline plus aerosolized beta 2-agonists and anticholinergics) in patients with stable COPD, have subsequently been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. Two of these trials showed a beneficial effect of theophylline. One report, for example, randomized 38 patients with severe COPD who were treated with theophylline to either continued therapy or replacement of theophylline by placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/7\">",
"     7",
"    </a>",
"    ]. The percentage of patients experiencing clinical deterioration was much lower in the group maintained on theophylline (15 versus 72 percent).",
"   </p>",
"   <p>",
"    The three other studies found no beneficial effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    in the population as a whole, but noted improvement in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. One report employing combination therapy concluded that, despite an overall lack of benefit, approximately one-third of patients were subjective responders in whom both dyspnea and FEV",
"    <sub>",
"     1",
"    </sub>",
"    improved [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/9\">",
"     9",
"    </a>",
"    ]. In contrast, the subjective nonresponders failed to achieve a postbronchodilator increase in FEV",
"    <sub>",
"     1",
"    </sub>",
"    .",
"   </p>",
"   <p>",
"    Part of the observed variability in response may be related to plasma",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    levels. One study, for example, noted symptomatic improvement at a theophylline level of 17",
"    <span class=\"nowrap\">",
"     mg/L,",
"    </span>",
"    but not at 10",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/11\">",
"     11",
"    </a>",
"    ]. The improvement in dyspnea was associated with a reduction in trapped gas volume and an increase in distance walked and vital capacity.",
"   </p>",
"   <p>",
"    In summary,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    can reduce dyspnea, but this effect is seen in only some patients and may be related to theophylline levels. The benefit may be mediated by increases in airway caliber or respiratory muscle function,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a decline in trapped gas volume. Antiinflammatory and immunomodulating actions of the drug may also be important in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/12\">",
"     12",
"    </a>",
"    ]. Because of the lack of predictable response, the efficacy of therapy needs to be assessed on an individual basis and objectively documented with ratings of dyspnea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8839?source=see_link\">",
"     \"Physiology of dyspnea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=see_link\">",
"     \"Approach to the patient with dyspnea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Exercise capacity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    on exercise capacity also appears to be variable. Four initial studies showed that theophylline therapy was associated with a number of hemodynamic benefits, including reductions in pulmonary arterial pressure, pulmonary vascular resistance, right and left ventricular end-diastolic pressures, and increases in ejection fraction or cardiac index; however, the effect on the anaerobic threshold and exercise capacity remained unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/6\">",
"     6",
"    </a>",
"    ]. Subsequent studies have generally [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/7,11,13-16\">",
"     7,11,13-16",
"    </a>",
"    ] but not always [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/10\">",
"     10",
"    </a>",
"    ] shown an improvement in exercise capacity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      withdrawal trial noted above, cessation of theophylline was associated with a deterioration in the six-minute walking distance [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second study, 22 patients with severe stable COPD were randomized to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/14\">",
"       14",
"      </a>",
"      ]. The theophylline group showed an improvement in maximum work rate that correlated with an increase in ventilatory capacity as assessed by the maximum voluntary ventilation (MVV). No changes were observed in pulmonary function, anaerobic threshold, or dyspnea index (minute ventilation at peak",
"      <span class=\"nowrap\">",
"       exercise/MVV).",
"      </span>",
"      This combination of results suggests that the improvement in MVV, and thus exercise capacity, may have been related to increases in respiratory muscle strength or central respiratory drive. However, neither of these parameters was directly addressed in the study.",
"     </li>",
"     <li>",
"      In a third trial, 34 patients were enrolled in single-patient, randomized, double-blind, multiple crossover comparisons of the effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      versus placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/15\">",
"       15",
"      </a>",
"      ]. Approximately 21 percent of patients manifested a positive response to theophylline as measured by the chronic respiratory disease questionnaire and the 6-minute walk test.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathophysiology of exercise intolerance in COPD and of the benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    are not completely understood. Factors other than the severity of lung dysfunction may play a contributory role. As an example, left ventricular dysfunction (ejection fraction less than 40 percent with wall motion abnormalities) has been noted in one-third of patients with progressive COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/17\">",
"     17",
"    </a>",
"    ], suggesting in some cases the possibility of clinically significant myocardial ischemia. The administration of a methylxanthine to patients with chronic stable coronary artery disease has been shown to improve indicators of myocardial ischemia in a concentration-dependent manner [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/18\">",
"     18",
"    </a>",
"    ] and to enhance exercise tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/19\">",
"     19",
"    </a>",
"    ]. Theophylline may act by blocking A1-adenosine receptors, resulting in redistribution of blood flow to the underperfused subendocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    can enhance exercise performance in COPD. This benefit may be mediated by improvements in respiratory mechanics (due to bronchodilation), gas exchange, respiratory muscle function, hemodynamics, and perhaps myocardial perfusion in patients with ischemic heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25144?source=see_link\">",
"     \"Exercise physiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Respiratory mechanics",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Stable COPD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous studies have shown that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    can induce significant bronchodilation in stable COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/1,6,8-11,13,20-29\">",
"     1,6,8-11,13,20-29",
"    </a>",
"    ]. The improvement in FEV",
"    <sub>",
"     1",
"    </sub>",
"    or vital capacity (VC) has ranged from 8 to 35 percent, with the greatest response seen with combination therapy, defined as theophylline plus either aerosolized beta 2-agonists or anticholinergics. The following observations have also been made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aerosolized",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      bromide appears to produce more bronchodilation than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      when only monotherapy is used. In one report of patients with COPD, ipratropium bromide was associated with a greater peak increase in FEV",
"      <sub>",
"       1",
"      </sub>",
"      (31 versus 17 percent with theophylline) and a higher frequency of patients achieving at least a 15 percent rise in FEV",
"      <sub>",
"       1",
"      </sub>",
"      (90 versus 50 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/21\">",
"       21",
"      </a>",
"      ]. Ipratropium bromide has also been shown to be more cost-effective than theophylline [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      significantly improved morning and evening peak expiratory flow rates compared to monotherapy with either drug [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with stable COPD who are already on two long acting aerosolized bronchodilators (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"       formoterol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/34/27173?source=see_link\">",
"       tiotropium",
"      </a>",
"      ), the addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      did not significantly improve the FEV",
"      <sub>",
"       1",
"      </sub>",
"      , FVC, dyspnea ratings, or frequency of rescue use of a short-acting beta 2-agonist, compared to the addition of placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/31\">",
"       31",
"      </a>",
"      ]. However, 28 percent of patients in the theophylline group had significant improvement in dyspnea ratings.",
"     </li>",
"     <li>",
"      Plasma",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      levels as high as 17",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      may be required to achieve efficacy in patients with COPD [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/11\">",
"       11",
"      </a>",
"      ]. However, increases in serum levels above 12",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      are not recommended due to the increased risk of toxicity. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Toxicity'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       Theophylline",
"      </a>",
"      -induced bronchodilation may be associated with improvements in air trapping [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/7,10,11,22\">",
"       7,10,11,22",
"      </a>",
"      ], gas exchange [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/7,22,27\">",
"       7,22,27",
"      </a>",
"      ], exercise capacity [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/7,11,13\">",
"       7,11,13",
"      </a>",
"      ], respiratory muscle strength [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/8,27,28\">",
"       8,27,28",
"      </a>",
"      ],",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dyspnea [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/7-9,11\">",
"       7-9,11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Acute exacerbation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methylxanthines do not appear to significantly affect respiratory mechanics in patients with mild to moderate exacerbations of COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. In the largest randomized trial that examined this issue, 80 non-acidotic (pH &gt;7.32) patients with an acute COPD exacerbation received nebulized bronchodilators and oral glucocorticoids, and were randomly assigned to receive intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14648?source=see_link\">",
"     aminophylline",
"    </a>",
"    (0.5",
"    <span class=\"nowrap\">",
"     mg/kg/hour)",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/34\">",
"     34",
"    </a>",
"    ]. No evidence was found for any clinically important additional effect of routine aminophylline treatment (eg, differences in spirometry, symptom scores, or length of stay) when used with high dose nebulized bronchodilators and oral glucocorticoids.",
"   </p>",
"   <p>",
"    These findings were similar to those in a prior meta-analysis of four smaller trials [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/33\">",
"     33",
"    </a>",
"    ]. In addition to lack of efficacy, methylxanthines caused significantly more nausea and vomiting than placebo and trended toward more frequent tremor, palpitations, and arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Respiratory muscle capacity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have evaluated the possible ability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    to increase diaphragmatic muscle strength",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    delay the onset of diaphragmatic muscle fatigue in patients with stable COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/8,14,27,28\">",
"     8,14,27,28",
"    </a>",
"    ]. Increases in maximal inspiratory pressure (Pimax) and MVV have been described, which may have been mediated in part by increases in muscle strength. It is unclear, however, if any improvement in diaphragmatic performance represents a direct effect of theophylline or is secondary to a reduction in the work of breathing or perhaps an increase in respiratory drive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EFFECT ON EXACERBATION FREQUENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    on exacerbation frequency was examined in a large retrospective study of patients with COPD; the use of theophylline was associated with a small reduction in the frequency of COPD exacerbations, compared to the use of long-acting beta-2 agonists [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/35\">",
"     35",
"    </a>",
"    ]. However, theophylline users were more likely to have a COPD exacerbation than users of inhaled glucocorticoids. As this was not a prospective or randomized trial, further data is needed before theophylline is employed for this reason.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DOSING",
"    </span>",
"    &nbsp;&mdash;&nbsp;A starting dose of 10 mg per kg of body weight per day (up to 300 mg for the initial dose) is generally appropriate. In obese patients, ideal body weight is used in this calculation. Long-acting extended-release preparations are preferred. The dose can be adjusted upwards, if there is no sign of benefit or adverse effect after a three to seven day interval.",
"   </p>",
"   <p>",
"    Monitoring of peak serum levels, rather than trough levels, is preferred. To properly measure the peak concentration, a blood sample should be obtained 3 to 7 hours after a morning dose of a twice-daily preparation, or 8 to 12 hours after a dose of a once daily preparation.",
"   </p>",
"   <p>",
"    In general, patients with COPD can be adequately treated with serum levels in the 8 to 12",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    range [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/2\">",
"     2",
"    </a>",
"    ]. Once an appropriate serum level has been achieved, subsequent measurements can be made at 6 to 12 month intervals or if the patient's clinical status or concomitant medications change.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    must be balanced against toxicity. This is particularly important because of theophylline's narrow therapeutic index [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/36\">",
"     36",
"    </a>",
"    ]. The following general observations have been made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When compared to acute intoxication, chronic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      overmedication is associated with a greater frequency of major toxicity, occurs at relatively lower theophylline levels, and cannot be predicted by the peak serum theophylline concentration [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/37\">",
"       37",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/16/13578?source=see_link\">",
"       \"Theophylline poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Seizures may occur at plasma",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      levels of 14 to 35",
"      <span class=\"nowrap\">",
"       mg/L;",
"      </span>",
"      the risk of seizures is more likely in patients who are older or who have previous brain injury, severe pulmonary disease, or hypoalbuminemia [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A clinical service providing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      pharmacokinetic analysis may result in more optimal therapy, while also significantly reducing the number of theophylline levels obtained [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It has also been proposed that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    might have an adverse effect on the quality of sleep. Of four studies reviewed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/22-25\">",
"     22-25",
"    </a>",
"    ], only one found that theophylline disrupted sleep architecture [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/22\">",
"     22",
"    </a>",
"    ]. These trials also showed that theophylline improved both morning lung function and overnight oxygenation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     FUTURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     Theophylline",
"    </a>",
"    may have an important anti-inflammatory mechanism of action. In a randomized crossover study of 16 patients with stable COPD, oral sustained-release theophylline reduced nitrative stress and neutrophil infiltration more than inhaled glucocorticoids at a mean serum concentration of only 6.32",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/40\">",
"     40",
"    </a>",
"    ]. It has been proposed that the anti-inflammatory effects of theophylline may be especially relevant to COPD patients with glucocorticoid resistance",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a clinical pattern of frequent exacerbations, and may reduce disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25031/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/13/1236?source=see_link\">",
"       \"Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/52/14148?source=see_link\">",
"       \"Patient information: Chronic obstructive pulmonary disease (COPD) treatments (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Chronic COPD",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       Theophylline",
"      </a>",
"      may favorably affect the major factors associated with functional impairment in COPD, such as dyspnea, exercise capacity, respiratory mechanics, and respiratory muscle strength. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Effects on functional impairment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       Theophylline",
"      </a>",
"      is generally considered a third-line bronchodilator drug in chronic COPD, after inhaled anticholinergics and beta-2 agonists. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link&amp;anchor=H19#H19\">",
"       \"Management of stable chronic obstructive pulmonary disease\", section on 'Theophylline'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with persistent functional impairment despite both smoking cessation and the use of inhaled bronchodilators,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      may reduce functional impairment and exacerbation frequency, although the effect in individual patients is variable. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Effects on functional impairment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, patients with COPD can be adequately treated with serum levels in the 8 to 12",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      range. Once an appropriate serum level has been achieved, subsequent measurements can be made at 6 to 12 month intervals or if the patient's clinical status or concomitant medications change. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When compared to acute intoxication, chronic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      overmedication is associated with a greater frequency of major toxicity, occurs at relatively lower theophylline levels, and cannot be predicted by the peak serum theophylline concentration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/16/13578?source=see_link\">",
"       \"Theophylline poisoning\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H11\">",
"       'Toxicity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Acute COPD exacerbation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Methylxanthines are NOT recommended for routine management of acute exacerbations of COPD. In addition to a lack of efficacy in this setting, methylxanthines increase the likelihood of side effects (eg, nausea, vomiting). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Acute exacerbation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/1\">",
"      Ram FS, Jardin JR, Atallah A, et al. Efficacy of theophylline in people with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Med 2005; 99:135.",
"     </a>",
"    </li>",
"    <li>",
"     Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the Diagnosis, Management, and Prevention of COPD, Updated 2010. www.goldcopd.org (Accessed on June 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/3\">",
"      Wegner RE, J&ouml;rres RA, Kirsten DK, Magnussen H. Factor analysis of exercise capacity, dyspnoea ratings and lung function in patients with severe COPD. Eur Respir J 1994; 7:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/4\">",
"      Mahler DA, Faryniarz K, Tomlinson D, et al. Impact of dyspnea and physiologic function on general health status in patients with chronic obstructive pulmonary disease. Chest 1992; 102:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/5\">",
"      Mahler DA. How should health-related quality of life be assessed in patients with COPD? Chest 2000; 117:54S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/6\">",
"      Vaz Fragoso CA, Miller MA. Review of the clinical efficacy of theophylline in the treatment of chronic obstructive pulmonary disease. Am Rev Respir Dis 1993; 147:S40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/7\">",
"      Kirsten DK, Wegner RE, J&ouml;rres RA, Magnussen H. Effects of theophylline withdrawal in severe chronic obstructive pulmonary disease. Chest 1993; 104:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/8\">",
"      Jaeschke R, Guyatt GH, Singer J, et al. Mechanism of bronchodilator effect in chronic airflow limitation. CMAJ 1991; 144:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/9\">",
"      Nishimura K, Koyama H, Ikeda A, et al. The additive effect of theophylline on a high-dose combination of inhaled salbutamol and ipratropium bromide in stable COPD. Chest 1995; 107:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/10\">",
"      Waterhouse JC, Pritchard SM, Howard P. Hyperinflation, trapped gas and theophylline in chronic obstructive pulmonary disease. Monaldi Arch Chest Dis 1993; 48:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/11\">",
"      McKay SE, Howie CA, Thomson AH, et al. Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. Thorax 1993; 48:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/12\">",
"      Peleman RA, Kips JC, Pauwels RA. Therapeutic activities of theophylline in chronic obstructive pulmonary disease. Clin Exp Allergy 1998; 28 Suppl 3:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/13\">",
"      Newman D, Tamir J, Speedy L, et al. Physiological and neuropsychological effects of theophylline in chronic obstructive pulmonary disease. Isr J Med Sci 1994; 30:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/14\">",
"      Fink G, Kaye C, Sulkes J, et al. Effect of theophylline on exercise performance in patients with severe chronic obstructive pulmonary disease. Thorax 1994; 49:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/15\">",
"      Mahon JL, Laupacis A, Hodder RV, et al. Theophylline for irreversible chronic airflow limitation: a randomized study comparing n of 1 trials to standard practice. Chest 1999; 115:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/16\">",
"      Tsukino M, Nishimura K, Ikeda A, et al. Effects of theophylline and ipratropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. Thorax 1998; 53:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/17\">",
"      Render ML, Weinstein AS, Blaustein AS. Left ventricular dysfunction in deteriorating patients with chronic obstructive pulmonary disease. Chest 1995; 107:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/18\">",
"      Barbour MM, Garber CE, Ahlberg AW, et al. Effects of intravenous theophylline on exercise-induced myocardial ischemia: II. A concentration-dependent phenomenon. J Am Coll Cardiol 1993; 22:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/19\">",
"      Gaspardone A, Crea F, Iamele M, et al. Bamiphylline improves exercise-induced myocardial ischemia through a novel mechanism of action. Circulation 1993; 88:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/20\">",
"      Karpel JP, Kotch A, Zinny M, et al. A comparison of inhaled ipratropium, oral theophylline plus inhaled beta-agonist, and the combination of all three in patients with COPD. Chest 1994; 105:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/21\">",
"      Bleecker ER, Britt EJ. Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease. Am J Med 1991; 91:24S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/22\">",
"      Mulloy E, McNicholas WT. Theophylline improves gas exchange during rest, exercise, and sleep in severe chronic obstructive pulmonary disease. Am Rev Respir Dis 1993; 148:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/23\">",
"      Brander PE, Salmi T. Nocturnal oxygen saturation and sleep quality in patients with advanced chronic obstructive pulmonary disease during treatment with moderate dose CR-theophylline. Eur J Clin Pharmacol 1992; 43:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/24\">",
"      Martin RJ, Pak J. Overnight theophylline concentrations and effects on sleep and lung function in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 145:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/25\">",
"      Berry RB, Desa MM, Branum JP, Light RW. Effect of theophylline on sleep and sleep-disordered breathing in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1991; 143:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/26\">",
"      Jubran A, Gross N, Ramsdell J, et al. Comparative cost-effectiveness analysis of theophylline and ipratropium bromide in chronic obstructive pulmonary disease. A three-center study. Chest 1993; 103:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/27\">",
"      Spinelli A, Fanelli A, Gorini M, et al. Control of breathing in patients with chronic pulmonary obstructive disease: response to bamiphylline. Respiration 1991; 58:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/28\">",
"      Umut S, Gemiciolu B, Yildirim N, et al. Effect of theophylline in chronic obstructive lung disease. Int J Clin Pharmacol Ther Toxicol 1992; 30:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/29\">",
"      Ram FS, Jones PW, Castro AA, et al. Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002; :CD003902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/30\">",
"      ZuWallack RL, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001; 119:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/31\">",
"      Cazzola M, Gabriella Matera M. The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: a pilot study. Respir Med 2007; 101:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/32\">",
"      Rice KL, Leatherman JW, Duane PG, et al. Aminophylline for acute exacerbations of chronic obstructive pulmonary disease. A controlled trial. Ann Intern Med 1987; 107:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/33\">",
"      Barr RG, Rowe BH, Camargo CA. Methylxanthines for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2003; :CD002168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/34\">",
"      Duffy N, Walker P, Diamantea F, et al. Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Thorax 2005; 60:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/35\">",
"      Cyr MC, Beauchesne MF, Lemi&egrave;re C, Blais L. Effect of theophylline on the rate of moderate to severe exacerbations among patients with chronic obstructive pulmonary disease. Br J Clin Pharmacol 2008; 65:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/36\">",
"      Snow V, Lascher S, Mottur-Pilson C, Joint Expert Panel on Chronic Obstructive Pulmonary Disease of the American College of Chest Physicians and the American College of Physicians-American Society of Internal Medicine. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2001; 134:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/37\">",
"      Shannon M. Predictors of major toxicity after theophylline overdose. Ann Intern Med 1993; 119:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/38\">",
"      Bahls FH, Ma KK, Bird TD. Theophylline-associated seizures with \"therapeutic\" or low toxic serum concentrations: risk factors for serious outcome in adults. Neurology 1991; 41:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/39\">",
"      Dager WE, Albertson TE. Impact of therapeutic drug monitoring of intravenous theophylline regimens on serum theophylline concentrations in the medical intensive care unit. Ann Pharmacother 1992; 26:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/40\">",
"      Hirano T, Yamagata T, Gohda M, et al. Inhibition of reactive nitrogen species production in COPD airways: comparison of inhaled corticosteroid and oral theophylline. Thorax 2006; 61:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25031/abstract/41\">",
"      Barnes PJ. Theophylline for COPD. Thorax 2006; 61:742.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1446 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-79.122.249.114-3C057D9C1B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_28_25031=[""].join("\n");
var outline_f24_28_25031=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFECTS ON FUNCTIONAL IMPAIRMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Dyspnea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Exercise capacity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Respiratory mechanics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Stable COPD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Acute exacerbation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Respiratory muscle capacity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EFFECT ON EXACERBATION FREQUENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DOSING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      FUTURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Chronic COPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Acute COPD exacerbation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=related_link\">",
"      Approach to the patient with dyspnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4120?source=related_link\">",
"      Evaluation of health-related quality of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25144?source=related_link\">",
"      Exercise physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=related_link\">",
"      Management of acute exacerbations of chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=related_link\">",
"      Management of stable chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/52/14148?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD) treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/13/1236?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8839?source=related_link\">",
"      Physiology of dyspnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/16/13578?source=related_link\">",
"      Theophylline poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11161?source=related_link\">",
"      Theophylline use in asthma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_28_25032="Intermediate case 21 answer";
var content_f24_28_25032=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 512px\">",
"   <div class=\"ttl\">",
"    Inferior MI with probable posterior involvement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 492px; height: 239px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADvAewDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD12y0rTnsbhm06wLBr4AnTDkYnIHPbA4B/hHBo1vStOj0XUXj06wV1tbxlZdMKkEHgg9iOx/h6Gixu7ZLG4Bt3zuvjldJn/wCe7Y5xwR6/wdDzRrd3bPouoqtu4Y2t4ATpM64OeOSMDHqeF6Gn7vKfXJ1vbLWXxPo+78i3faPpgW4xpmnjEjdNMKY/c579Oecdj83So7zSdNXVLFV03TwrXxVgNKOCPsznBX0yAdvqN1SX17ahbjFvIMSN00edMfuc9149cdj83So7y6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6U3y2MoOtbeXwvo+3oSW2j6YZbPOmaecxx5zphbPySdR/F9R14P8JqpbaTpxv5FOnWBUWtkwB0wnkySZPuTgZP8WMCrdte2plswbeQ5jjznR52z8knUY+b6jrwf4TVW2u7b7fI5gfBtbIf8gmcnPmSZzx3z16P0HQ0PluUnW97WWy6Pv6FpNH0zdL/xLNP/ANYn/MMJ/wCWzD8PTHcfL1FVLLStOexuGbTrAsGvgCdMORicgc9sDgH+EcGraXtrul/0eT/WJ/zB5z/y2YenHHGO4+XqKqWN3bJY3ANu+d18crpM/wDz3bHOOCPX+DoeaPduCdaz1luuj7PyDW9K06PRdRePTrBXW1vGVl0wqQQeCD2I7H+Hoat32j6YFuMaZp4xI3TTCmP3Oe/TnnHY/N0qprd3bPouoqtu4Y2t4ATpM64OeOSMDHqeF6Grd9e2oW4xbyDEjdNHnTH7nPdePXHY/N0oXLcE63KtZby6Py8iO80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdUlto+mGWzzpmnnMcec6YWz8knUfxfUdeD/CajvLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpUlte2plswbeQ5jjznR52z8knUY+b6jrwf4TQuXUmTrci1l8PZ935FS20nTjfyKdOsCotbJgDphPJkkyfcnAyf4sYFW00fTN0v8AxLNP/wBYn/MMJ/5bMPw9Mdx8vUVVtru2+3yOYHwbWyH/ACCZyc+ZJnPHfPXo/QdDVpL213S/6PJ/rE/5g85/5bMPTjjjHcfL1FC5SqrrXdnLp0fZeRUstK057G4ZtOsCwa+AJ0w5GJyBz2wOAf4RwaNb0rTo9F1F49OsFdbW8ZWXTCpBB4IPYjsf4ehosbu2SxuAbd87r45XSZ/+e7Y5xwR6/wAHQ80a3d2z6LqKrbuGNreAE6TOuDnjkjAx6nhehpe7ylp1vbLWXxPo+78i3faPpgW4xpmnjEjdNMKY/c579Oecdj83So7zSdNXVLFV03TwrXxVgNKOCPsznBX0yAdvqN1SX17ahbjFvIMSN00edMfuc9149cdj83So7y6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6U3y2MoOtbeXwvo+3oSW2j6YZbPOmaecxx5zphbPySdR/F9R14P8JqpbaTpxv5FOnWBUWtkwB0wnkySZPuTgZP8WMCrdte2plswbeQ5jjznR52z8knUY+b6jrwf4TVW2u7b7fI5gfBtbIf8gmcnPmSZzx3z16P0HQ0PluUnW97WWy6Pv6FpNH0zdL/AMSzT/8AWJ/zDCf+WzD8PTHcfL1FVLLStOexuGbTrAsGvgCdMORicgc9sDgH+EcGraXtrul/0eT/AFif8wec/wDLZh6cccY7j5eoqpY3dsljcA2753Xxyukz/wDPdsc44I9f4Oh5o924J1rPWW66Ps/INb0rTo9F1F49OsFdbW8ZWXTCpBB4IPYjsf4ehq3faPpgW4xpmnjEjdNMKY/c579Oecdj83Sqmt3ds+i6iq27hja3gBOkzrg545IwMep4Xoat317ahbjFvIMSN00edMfuc9149cdj83ShctwTrcq1lvLo/LyI7zSdNXVLFV03TwrXxVgNKOCPsznBX0yAdvqN1SW2j6YZbPOmaecxx5zphbPySdR/F9R14P8ACajvLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpUlte2plswbeQ5jjznR52z8knUY+b6jrwf4TQuXUmTrci1l8PZ935FS20nTjfyKdOsCotbJgDphPJkkyfcnAyf4sYFW00fTN0v/ABLNP/1if8wwn/lsw/D0x3Hy9RVW2u7b7fI5gfBtbIf8gmcnPmSZzx3z16P0HQ1aS9td0v8Ao8n+sT/mDzn/AJbMPTjjjHcfL1FC5SqrrXdnLp0fZeRUstK057G4ZtOsCwa+AJ0w5GJyBz2wOAf4RwaNb0rTo9F1F49OsFdbW8ZWXTCpBB4IPYjsf4ehosbu2SxuAbd87r45XSZ/+e7Y5xwR6/wdDzRrd3bPouoqtu4Y2t4ATpM64OeOSMDHqeF6Gl7vKWnW9stZfE+j7vyLd9o+mBbjGmaeMSN00wpj9znv055x2PzdKjvNJ01dUsVXTdPCtfFWA0o4I+zOcFfTIB2+o3VJfXtqFuMW8gxI3TR50x+5z3Xj1x2PzdKjvLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpTfLYyg61t5fC+j7ehJbaPphls86Zp5zHHnOmFs/JJ1H8X1HXg/wAJqpbaTpxv5FOnWBUWtkwB0wnkySZPuTgZP8WMCrdte2plswbeQ5jjznR52z8knUY+b6jrwf4TVW2u7b7fI5gfBtbIf8gmcnPmSZzx3z16P0HQ0PluUnW97WWy6Pv6FpNH0zdL/wASzT/9Yn/MMJ/5bMPw9Mdx8vUVUstK057G4ZtOsCwa+AJ0w5GJyBz2wOAf4Rwatpe2u6X/AEeT/WJ/zB5z/wAtmHpxxxjuPl6iqljd2yWNwDbvndfHK6TP/wA92xzjgj1/g6Hmj3bgnWs9Zbro+z8g1vStOj0XUXj06wV1tbxlZdMKkEHgg9iOx/h6Grd9o+mBbjGmaeMSN00wpj9znv055x2PzdKqa3d2z6LqKrbuGNreAE6TOuDnjkjAx6nhehq3fXtqFuMW8gxI3TR50x+5z3Xj1x2PzdKFy3BOtyrWW8uj8vIjvNJ01dUsVXTdPCtfFWA0o4I+zOcFfTIB2+o3VJbaPphls86Zp5zHHnOmFs/JJ1H8X1HXg/wmo7y6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6VJbXtqZbMG3kOY4850eds/JJ1GPm+o68H+E0Ll1Jk63ItZfD2fd+RUttJ0438inTrAqLWyYA6YTyZJMn3JwMn+LGBVtNH0zdL/xLNP8A9Yn/ADDCf+WzD8PTHcfL1FVba7tvt8jmB8G1sh/yCZyc+ZJnPHfPXo/QdDVpL213S/6PJ/rE/wCYPOf+WzD0444x3Hy9RQuUqq613Zy6dH2XkVLLStOexuGbTrAsGvgCdMORicgc9sDgH+EcGjW9K06PRdRePTrBXW1vGVl0wqQQeCD2I7H+HoaLG7tksbgG3fO6+OV0mf8A57tjnHBHr/B0PNGt3ds+i6iq27hja3gBOkzrg545IwMep4XoaXu8padb2y1l8T6Pu/It32j6YFuMaZp4xI3TTCmP3Oe/TnnHY/N0qO80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdUl9e2oW4xbyDEjdNHnTH7nPdePXHY/N0qO8urVtUscW7YW+OQdGnHH2Z+AuMnk529f4ulN8tjKDrW3l8L6Pt6Elto+mGWzzpmnnMcec6YWz8knUfxfUdeD/CaqW2k6cb+RTp1gVFrZMAdMJ5MkmT7k4GT/ABYwKt217amWzBt5DmOPOdHnbPySdRj5vqOvB/hNVba7tvt8jmB8G1sh/wAgmcnPmSZzx3z16P0HQ0PluUnW97WWy6Pv6FpNH0zdL/xLNP8A9Yn/ADDCf+WzD8PTHcfL1FVLLStOexuGbTrAsGvgCdMORicgc9sDgH+EcGraXtrul/0eT/WJ/wAwec/8tmHpxxxjuPl6iqljd2yWNwDbvndfHK6TP/z3bHOOCPX+DoeaPduCdaz1luuj7PyDW9K06PRdRePTrBXW1vGVl0wqQQeCD2I7H+Hoat32j6YFuMaZp4xI3TTCmP3Oe/TnnHY/N0qprd3bPouoqtu4Y2t4ATpM64OeOSMDHqeF6Grd9e2oW4xbyDEjdNHnTH7nPdePXHY/N0oXLcE63KtZby6Py8iO80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdUlto+mGWzzpmnnMcec6YWz8knUfxfUdeD/CajvLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpUlte2plswbeQ5jjznR52z8knUY+b6jrwf4TQuXUmTrci1l8PZ935FS20nTjfyKdOsCotbJgDphPJkkyfcnAyf4sYFW00fTN0v/Es0/8A1if8wwn/AJbMPw9Mdx8vUVVtru2+3yOYHwbWyH/IJnJz5kmc8d89ej9B0NWkvbXdL/o8n+sT/mDzn/lsw9OOOMdx8vUULlKqutd2cunR9l5FSy0rTnsbhm06wLBr4AnTDkYnIHPbA4B/hHBo1vStOj0XUXj06wV1tbxlZdMKkEHgg9iOx/h6Gixu7ZLG4Bt3zuvjldJn/wCe7Y5xwR6/wdDzRrd3bPouoqtu4Y2t4ATpM64OeOSMDHqeF6Gl7vKWnW9stZfE+j7vyLd9o+mBbjGmaeMSN00wpj9znv055x2PzdKjvNJ01dUsVXTdPCtfFWA0o4I+zOcFfTIB2+o3VJfXtqFuMW8gxI3TR50x+5z3Xj1x2PzdKjvLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpTfLYyg61t5fC+j7ehJbaPphls86Zp5zHHnOmFs/JJ1H8X1HXg/wmvNviRbQWuqaelrBDAjWMbFYrfygTubk/wB4/wC13r0m2vbUy2YNvIcxx5zo87Z+STqMfN9R14P8Jrzb4kSxy6pp7RIyD7DHnNs8BJ3Nzhh83+8ODUVbcuh6uTe1+uLmbtbr8/I9J09m+wXH7qYfPf8A/LWb/nu3qvbvng/xYNGvM39han+6m/49LzrLN6/7vbvng/xYNVbG4uvsM4SOwYbr7rqsmcmduMbOe+B/GOTisy88Rw6h/wAJLpED2bXum2s4u0GoT/u/NBZNpaIK5KgnAJ3fxYNXf3Ty1TarL/E+q7vzOpvmJW4/dTDMjdZZjj9z7r+PPOOPu81leLdXi0O3/ta8t7prexnlupFSabeVSzkYqCwHzYHGSD24XmrN9cXhW4xFp5zI2MatK+f3OO8fPpnufl6V5r+0neXcfww1RgbeLN5Eu631KSZirIFYYKrlSCQTn/ZxinJ6GCg4xcrbRl1Xb1PTNB1CLU7HR9QtYrg291awTxZkmUlWjcjovHB6DIGDjIzhtqzf2lL+6mP+iWP/AC1m/wCesv8As9+2OB/Dk1g/Die6HgrwhtjsCg0myALarIh/49264Q7T04HTOP4jWnbT3Qv5P3dhv+y2QIOqyADEkn+x165H8PUZzQ3sVThKUG2t0uq7rzNdGO6X91N/rE/5azf89m/2fw55zyPmyKp6ezfYLj91MPnv/wDlrN/z3b1Xt3zwf4sGhLi83S/utP8A9Yn/ADFpR/y2Y/8APPnjnPYfN1NVbG4uvsM4SOwYbr7rqsmcmduMbOe+B/GOTii+pSpOz06rquz8y1rzN/YWp/upv+PS86yzev8Au9u+eD/Fg1cvmJW4/dTDMjdZZjj9z7r+PPOOPu81ka3PdHRdRDx2AU2t4CV1WRjyew2cn0H8XU1bvri8K3GItPOZGxjVpXz+5x3j59M9z8vShPUFSfKtOsuq8vMnvnb+1dO/cT/8f54864z/AMesnH3c575644xjmpbZm86z/dTH93H0lmGfkk6YXj8Mjg44Jxn3lxc/2pYFk08f6cSuNYlIP+jOOW8vgdfm65+XpzU+n3Fyt5p5lSwSMLFvYapIdo2yZ42DB/2c4HA/iNCe5M6b9mtPs913fmc18NPFB8YaHba4unzWgubW2XyRdTSbfLuZ4/vBAOdmQO2eMnNdcjHdL+6m/wBYn/LWb/ns3+z+HPOeR82RXjX7NOrfavh9Fb2aQGSwMdtN5988GWNzNLlQFORtlGf7uMjk16ylxebpf3Wn/wCsT/mLSj/lsx/5588c57D5upoi9CVF1IKXfl6rsvMNPZvsFx+6mHz3/wDy1m/57t6r2754P8WDRrzN/YWp/upv+PS86yzev+72754P8WDVWxuLr7DOEjsGG6+66rJnJnbjGznvgfxjk4qlr+txRwXem3F1o0d9NZXjpbf22xmdcnlYygLcKxA6Ngk4xSuuU39m1WTf8z6ru/M6O+Ylbj91MMyN1lmOP3Puv48844+7zUV87f2rp37if/j/ADx51xn/AI9ZOPu5z3z1xxjHNeav8YbG60PTNTXSriOHV4tQuoUfUCXRbSBvMDgjGWwdvJz904FaHh34ix+JfEmlWP8AZUumXc6Jq9sl7qZxNbPBIgbfGHC4OM7iG+YLjGSByVjCmk9F/K/tLt6nf2zN51n+6mP7uPpLMM/JJ0wvH4ZHBxwTinas39pS/upj/olj/wAtZv8AnrL/ALPftjgfw5NFtcXgls8xaeMRx5zq0q4+STqfL+X6DpkD+I1Utp7oX8n7uw3/AGWyBB1WQAYkk/2OvXI/h6jOabepqqT97Touq7+prox3S/upv9Yn/LWb/ns3+z+HPOeR82RVPT2b7Bcfuph89/8A8tZv+e7eq9u+eD/Fg0JcXm6X91p/+sT/AJi0o/5bMf8AnnzxznsPm6mqtjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxRfUSpOz06rquz8y1rzN/YWp/upv+PS86yzev8Au9u+eD/Fg1cvmJW4/dTDMjdZZjj9z7r+PPOOPu81ka3PdHRdRDx2AU2t4CV1WRjyew2cn0H8XU1bvri8K3GItPOZGxjVpXz+5x3j59M9z8vShPUFSfKtOsuq8vMnvnb+1dO/cT/8f54864z/AMesnH3c575644xjmpbZm86z/dTH93H0lmGfkk6YXj8Mjg44Jxn3lxc/2pYFk08f6cSuNYlIP+jOOW8vgdfm65+XpzUltcXgls8xaeMRx5zq0q4+STqfL+X6DpkD+I0J7kypPkWn2e67vzC1Zv7Sl/dTH/RLH/lrN/z1l/2e/bHA/hyauIx3S/upv9Yn/LWb/ns3+z+HPOeR82RWRbT3Qv5P3dhv+y2QIOqyADEkn+x165H8PUZzVtLi83S/utP/ANYn/MWlH/LZj/zz545z2HzdTQmVVpO707dV2XmGns32C4/dTD57/wD5azf8929V7d88H+LBo15m/sLU/wB1N/x6XnWWb1/3e3fPB/iwaq2NxdfYZwkdgw3X3XVZM5M7cY2c98D+McnFJrc90dF1EPHYBTa3gJXVZGPJ7DZyfQfxdTSv7poqT9snb7T6ru/M175iVuP3UwzI3WWY4/c+6/jzzjj7vNRXzt/aunfuJ/8Aj/PHnXGf+PWTj7uc989ccYxzXO+IvFbad4k0vQ5bSB7rWGumgki1R3jXybYM24lAed2AcHJBU4Fc9B8U7PUdP8I60mm3EUOtax9ltonvpdyMVaDMrhdqLuOc7ixAICkBsNtWOeKUVr2f2l29fNHpFszedZ/upj+7j6SzDPySdMLx+GRwccE4p2rN/aUv7qY/6JY/8tZv+esv+z37Y4H8OTRbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNVLae6F/J+7sN/2WyBB1WQAYkk/2OvXI/h6jOaG9TVUn72nRdV39TXRjul/dTf6xP8AlrN/z2b/AGfw55zyPmyKp6ezfYLj91MPnv8A/lrN/wA929V7d88H+LBoS4vN0v7rT/8AWJ/zFpR/y2Y/88+eOc9h83U1Vsbi6+wzhI7BhuvuuqyZyZ24xs574H8Y5OKL6iVJ2enVdV2fmWteZv7C1P8AdTf8el51lm9f93t3zwf4sGrl8xK3H7qYZkbrLMcfufdfx55xx93msjW57o6LqIeOwCm1vASuqyMeT2Gzk+g/i6mrd9cXhW4xFp5zI2MatK+f3OO8fPpnufl6UJ6gqT5Vp1l1Xl5k987f2rp37if/AI/zx51xn/j1k4+7nPfPXHGMc1LbM3nWf7qY/u4+kswz8knTC8fhkcHHBOM+8uLn+1LAsmnj/TiVxrEpB/0Zxy3l8Dr83XPy9Oaktri8EtnmLTxiOPOdWlXHySdT5fy/QdMgfxGhPcmVJ8i0+z3Xd+YWrN/aUv7qY/6JY/8ALWb/AJ6y/wCz37Y4H8OTVxGO6X91N/rE/wCWs3/PZv8AZ/DnnPI+bIrItp7oX8n7uw3/AGWyBB1WQAYkk/2OvXI/h6jOatpcXm6X91p/+sT/AJi0o/5bMf8AnnzxznsPm6mhMqrSd3p26rsvMNPZvsFx+6mHz3//AC1m/wCe7eq9u+eD/Fg0a8zf2Fqf7qb/AI9LzrLN6/7vbvng/wAWDVWxuLr7DOEjsGG6+66rJnJnbjGznvgfxjk4pNbnujouoh47AKbW8BK6rIx5PYbOT6D+LqaV/dNFSftk7fafVd35mvfMStx+6mGZG6yzHH7n3X8eeccfd5qK+dv7V079xP8A8f54864z/wAesnH3c575644xjmoL64vCtxiLTzmRsY1aV8/ucd4+fTPc/L0ri5/iRbS3dvP9hIEPis6Bt/tN8mfyWj8zOP8AVfNnf97AxtxTbVjnUeRLm7P7S7ep6BbM3nWf7qY/u4+kswz8knTC8fhkcHHBOKdqzf2lL+6mP+iWP/LWb/nrL/s9+2OB/Dk1y+i+P7PUfHv/AAi1iltPf2Vms9xMupyCCIqCrRl9mQ4Mi5CgheVzncBu2090L+T93Yb/ALLZAg6rIAMSSf7HXrkfw9RnNDkrlxhzKTXl9pfzepoyXcUE6xzkxyXE6xwq88ymRxJI+1fl+Y7VY46/KxHOQIdPZvsFx+6mHz3/APy1m/57t6r2754P8WDXm3jea4Pxm+GrNFaeYJdRKlb92XG05y+zK8YOQD6967+xuLr7DOEjsGG6+66rJnJnbjGznvgfxjk4ovqEYNqSttJdV/L6lrXmb+wtT/dTf8el51lm9f8Ad7d88H+LBq5fMStx+6mGZG6yzHH7n3X8eeccfd5rI1ue6Oi6iHjsAptbwErqsjHk9hs5PoP4upq3fXF4VuMRaecyNjGrSvn9zjvHz6Z7n5elCeo1SfKtOsuq8vMnvnb+1dO/cT/8f54864z/AMesnH3c575644xjmpbZm86z/dTH93H0lmGfkk6YXj8Mjg44Jxn3lxc/2pYFk08f6cSuNYlIP+jOOW8vgdfm65+XpzUltcXgls8xaeMRx5zq0q4+STqfL+X6DpkD+I0J7kypPkWn2e67vzC1Zv7Sl/dTH/RLH/lrN/z1l/2e/bHA/hyauIx3S/upv9Yn/LWb/ns3+z+HPOeR82RWRbT3Qv5P3dhv+y2QIOqyADEkn+x165H8PUZzVtLi83S/utP/ANYn/MWlH/LZj/zz545z2HzdTQmVVpO707dV2XmGns32C4/dTD57/wD5azf8929V7d88H+LBo15m/sLU/wB1N/x6XnWWb1/3e3fPB/iwa81sLy7Pxuuog1uyL4bvGSJtSk2Bm1F9xB28sdqjbj5gASew7/W57o6LqIeOwCm1vASuqyMeT2Gzk+g/i6mlf3Rwi5V9tpPqv8zXvmJW4/dTDMjdZZjj9z7r+PPOOPu81FfO39q6d+4n/wCP88edcZ/49ZOPu5z3z1xxjHNQX1xeFbjEWnnMjYxq0r5/c47x8+me5+XpUd5cXP8AalgWTTx/pxK41iUg/wCjOOW8vgdfm65+XpzTb0Ip0nbb7L6rt6mhbM3nWf7qY/u4+kswz8knTC8fhkcHHBOPL/igSdX07Ksv+gR/eZzn5n5G4DA9hx6GvRLa4vBLZ5i08YjjznVpVx8knU+X8v0HTIH8Rrzf4kPI+qaeZlhVxYxjEVy0w+83UkDaf9kcCorP3T1slg44xN9u6ffzPSNPnkNhcA3kJy9+Meehzmdsj7nfqPXtt6Vx9v4dvdK8S/EbX5tQsHt9ctAIkjnzIPKiZGDgpj5icrt6j+70rrLK1vWsLg/btVUZ1AEbbbH+vO4n5M9eWx3+7xRrlrerompM1/qrKLS9JVltsEZ5BwmceuOf7tVf3djzOSDrp3j8T7+fkaF9PIy3GbyF8yMeJ0Of3OM8IM8cdueOvNeaftJx3OpfDe6s7eeO5nuNTto440mRi7ttUHhRx0Gcge3evRtRtL7Zc7tR1b/Wtnetr1+znrhOuPTjHvXH/FkXVvH4cjnvNUkNz4r02FfMW24fcrA8AfNheOq9MjqQN6bHNL2cYXvH4WuvVW7EvwX1ptV+HXhK5juEhEVlFagPKqbfJEsOeVOPuHrn7w9Rt6S1nkGpSgXkIxaWIx56cYllwPudup9O+7pXK/BzR5tN8J6fYWOoamLe0vLy3i8tLcZVLq7UEBlPJwTyf73+zXTWtre/bnUX2q8WlgdwW25HmybRynTPTvkndxihvbQqjCKp2bV7R/NeRoJPJul/0yEZkQ/69Of3zHP3PXn6HPIOBT0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pXN2/jLT5fiHeeDV1nWBrUYSVlZLRULCbf5YJUFpNrh8KCPvZOFIHQWVretYXB+3aqozqAI222P9edxPyZ68tjv93infXY0iqbi7OPxLv2fkSa9PIdC1MfbITm0vBjz05yeR9zv1Hr229KuX08jLcZvIXzIx4nQ5/c4zwgzxx254681n65a3q6JqTNf6qyi0vSVZbbBGeQcJnHrjn+7VvUbS+2XO7UdW/1rZ3ra9fs564Trj04x70J67Aow5VrHeXfy8gvrmX+1dPP2+DP28nd9oTGfssgzny+nbOMZ4xnmpbaeQTWZF5Cu2OMAmdBtwknB+TjGcc5xkdcgiveWt+NWsAb/AFcsdQIBK2u4H7K/I+TG7H4YPrVa9F7Y6eLv+1tRg8izWUSyJbFECxSncRs5UAE+uN3fFJPfQmUYezWsfh8+78jyz9ma3Om6HrUMcqQB5NNnIZ1TJe3ikzgqc8tnP4nNeyJPJul/0yEZkQ/69Of3zHP3PXn6HPIOB5b8Dormaz1TyJ763xb6FkQCE5/4l9rjO8H8MevzV6bHaX2+f/iY6t/rY84W16/aH6/J1zn2znPGKIvTYzhGHIrtfZ/JeRBp88hsLgG8hOXvxjz0Ocztkfc79R69tvSvPfij4DvfE+pR6vL4qC2Ont9tj0+RvMRXhd2YJtKKDJv6sjNxwwX5BX+IHinxbpk66N4GjutS1hIdQ1G/guEgIjsxcshZAFBd2cHhSSCp2rhhjuBerrngybVtK1jUb3TrqwvJopAtsFdCeQRsDDnhhwwOQMYNK/u7Gy9lPEct1dS8+78jlJvhdp1vr/jvV7XUYFuPEVvPaqVk3m386FjM3pIHcg9FwRtGM5EvgDwEvw+1ayi0nWLBrCeWMXCFUEjXKWsgaZZiCRG2W/dsGCsx2kZOe/1G0vtlzu1HVv8AWtnetr1+znrhOuPTjHvTLy1vxq1gDf6uWOoEAlbXcD9lfkfJjdj8MH1pvbYyp0aS1Tj8L6vt6eZYtp5BNZkXkK7Y4wCZ0G3CScH5OMZxznGR1yCKdrPINSlAvIRi0sRjz04xLLgfc7dT6d93SmaRJLe33k2uq6u8ti0NtMFjthscwGUKCY8H5JUI68MQeQBSWtre/bnUX2q8WlgdwW25HmybRynTPTvkndxim3rsaqMPe1jsu/8AN6Ggk8m6X/TIRmRD/r05/fMc/c9efoc8g4FPT55DYXAN5CcvfjHnoc5nbI+536j17belTx2l9vn/AOJjq3+tjzhbXr9ofr8nXOfbOc8YqpZWt61hcH7dqqjOoAjbbY/153E/Jnry2O/3eKL67Aows9Y7rv2fkSa9PIdC1MfbITm0vBjz05yeR9zv1Hr229KuX08jLcZvIXzIx4nQ5/c4zwgzxx254681n65a3q6JqTNf6qyi0vSVZbbBGeQcJnHrjn+7VvUbS+2XO7UdW/1rZ3ra9fs564Trj04x70J67Aow5VrHeXfy8gvrmX+1dPP2+DP28nd9oTGfssgzny+nbOMZ4xnmpbaeQTWZF5Cu2OMAmdBtwknB+TjGcc5xkdcgiveWt+NWsAb/AFcsdQIBK2u4H7K/I+TG7H4YPrT7S0vvPsNuo6tnyotu1bXONkuMZTp1xnnGc84pJ76EyjDkWsfh8+78iC1nkGpSgXkIxaWIx56cYllwPudup9O+7pVxJ5N0v+mQjMiH/Xpz++Y5+568/Q55BwOY8JauviK91g6VqGtPFpktrpk8xht1Vp43JZF3JyFLgA4znOcrtNdFHaX2+f8A4mOrf62POFtev2h+vydc59s5zximn5FVFTbesenfsvIg0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pRr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0qOytb1rC4P27VVGdQBG22x/rzuJ+TPXlsd/u8Ua5a3q6JqTNf6qyi0vSVZbbBGeQcJnHrjn+7Sv7uxoow9stY/E+/d+Rh/FvwnH498KXWkXOpwQuLtLmGfzBLsdI/vBVCbsruTrjLdMjNN8TeF4bu38H6VYalb2Vno2t2l1ApmEo2W1u21clQeihd5zz1BPNdTqNpfbLndqOrf61s71tev2c9cJ1x6cY96ZeWt+NWsAb/Vyx1AgEra7gfsr8j5Mbsfhg+tDemxzRo0ZLVx+F9+i9CxbTyCazIvIV2xxgEzoNuEk4PycYzjnOMjrkEU7WeQalKBeQjFpYjHnpxiWXA+526n077ulT2lpfefYbdR1bPlRbdq2ucbJcYynTrjPOM55xXns/juKD4r6T4Ls7rV57+6t4EupSLdBb7EaeNVzGRJlWz/Dt3DJblVbeuxbdKN03HWy69/Q9HSeTdL/AKZCMyIf9enP75jn7nrz9DnkHAp6fPIbC4BvITl78Y89DnM7ZH3O/Uevbb0qeO0vt8//ABMdW/1secLa9ftD9fk65z7ZznjFVLK1vWsLg/btVUZ1AEbbbH+vO4n5M9eWx3+7xRfXYpRhZ6x3Xfs/Ik16eQ6FqY+2QnNpeDHnpzk8j7nfqPXtt6Vcvp5GW4zeQvmRjxOhz+5xnhBnjjtzx15rP1y1vV0TUma/1VlFpekqy22CM8g4TOPXHP8Adq3qNpfbLndqOrf61s71tev2c9cJ1x6cY96E9dgUYcq1jvLv5eQX1zL/AGrp5+3wZ+3k7vtCYz9lkGc+X07ZxjPGM81LbTyCazIvIV2xxgEzoNuEk4PycYzjnOMjrkEV7y1vxq1gDf6uWOoEAlbXcD9lfkfJjdj8MH1p9paX3n2G3UdWz5UW3atrnGyXGMp064zzjOecUk99CZRhyLWPw+fd+RBazyDUpQLyEYtLEY89OMSy4H3O3U+nfd0q4k8m6X/TIRmRD/r05/fMc/c9efoc8g4Gfa2t79udRfarxaWB3BbbkebJtHKdM9O+Sd3GK4/xD4p1PTfix4V8J2mp3RXVfPmvFkhhMqqjyNEUYJsBLpJnOeR2GKafkVWVNPVx+z37LyO00+eQ2FwDeQnL34x56HOZ2yPud+o9e23pRr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0qOytb1rC4P27VVGdQBG22x/rzuJ+TPXlsd/u8Ua5a3q6JqTNf6qyi0vSVZbbBGeQcJnHrjn+7Sv7uxoow9stY/E+/d+RoX08jLcZvIXzIx4nQ5/c4zwgzxx254681wt34Ito/jbZ+Ok1K2FzIDatF5wyZPszjzt+NuPLAjxsxn35rtdRtL7Zc7tR1b/AFrZ3ra9fs564Trj04x70y8tb8atYA3+rljqBAJW13A/ZX5HyY3Y/DB9aG9NjnjTpSSu4vR9+3ocP4T+G2meGvHel65omoG0tLfTTZx2TXsjrGztJIzbnJAXlsxlSAzBvvHI7S1nkGpSgXkIxaWIx56cYllwPudup9O+7pU9paX3n2G3UdWz5UW3atrnGyXGMp064zzjOecVUtbW9+3OovtV4tLA7gttyPNk2jlOmenfJO7jFNvXYuFOnFSScenf+b0POPiZqcen/GT4XXN1OCpur2BXR1YK8jKiknaABucHODwc47V6Xp88hsLgG8hOXvxjz0Ocztkfc79R69tvSvN/ifpTz+PPCU9zc3sstnMLiF5Fg3xMdWsoyy4AXP7xuoIz2216BGlxBpF7cXGp6jb28Q1F5Hf7KqKqztvZiV4HGWP/AHzgUr+9sZwUeaabVrr/ANJfkL4q1KKy8NapPe6paQQC1u1Z5bqNV+ZsAZKDliRgd+2OlX570XNtJNDqFvPDKxdHjuEdZAYOGBCDII4BHB6dfmrxu9trr4vWtzqVzNfv4F0lrq5sUubeNZNSmRX3TZAQpErOoxhtxDjg8JufCiLVdN0vXfBuq6pqTah4bvGgACwkNaSW7NbuS28glAw2BjtVQOCBTT12FCUW4r3bNys9fLy/r7r+j31zL/aunn7fBn7eTu+0JjP2WQZz5fTtnGM8YzzUttPIJrMi8hXbHGATOg24STg/JxjOOc4yOuQRXvLW/GrWAN/q5Y6gQCVtdwP2V+R8mN2PwwfWn2lpfefYbdR1bPlRbdq2ucbJcYynTrjPOM55xST30NJRhyLWPw+fd+RBazyDUpQLyEYtLEY89OMSy4H3O3U+nfd0q4k8m6X/AEyEZkQ/69Of3zHP3PXn6HPIOBn2tre/bnUX2q8WlgdwW25HmybRynTPTvkndxircdpfb5/+Jjq3+tjzhbXr9ofr8nXOfbOc8Ypp+RVWMLvWPTv2XkeQnV2sf2h7WA3ETHUdCvrXdvDf8vlzLjIUAE+X6c54xkY9X16eQ6FqY+2QnNpeDHnpzk8j7nfqPXtt6V4FeXjX/wC1DptpHd3Znsbe/tpHKxh0Yrdykfd2nIkBOAfvNjGAB7f4vnbSPC2rX2qavqENnFaXm9pvsqocuBtOFycsQuBySQF61Kfu7EUuRV5Sk0vfe/8AwxZ8U+I9P0S1kn1rW7G1hluPLVpbpPnZotvHyDI5wTwBznGCwuX1zL/aunn7fBn7eTu+0JjP2WQZz5fTtnGM8YzzXnuiaNqHjHVLvxf4jg1a1jCXGn6dp2oQQ70gaNvMlmjddoklUAEKgHlgDc+Qag+EceraXJL4N1TU9Sk1Lw5rBt02LCT9le0ka3ky+8AlAwCbiEUAYBApt6bGVGUW9bWcZW+702fQ9Otp5BNZkXkK7Y4wCZ0G3CScH5OMZxznGR1yCPL/AIoOX1fTt0qybbCMDa4baNz8HAGD7cn3Nel2lpfefYbdR1bPlRbdq2ucbJcYynTrjPOM55xXmXxMjmi1TTFnmuJj/Z8RVpxGCBufgbABt+vPrU1X7ux7uSRisarNbdPn5HU+ILTxINAB8G2+mC+F3emc6si+WIVmcNt8v5t4O36c4rmNV1T4j2ukXtvqfgOx1CVba587ULHVLeGFhn5mWORDINmcEE5JB2kCu5stK057G4ZtOsCwa+AJ0w5GJyBz2wOAf4RwaNb0rTo9F1F49OsFdbW8ZWXTCpBB4IPYjsf4ehqteU82UVKsrTafM/s+b7tnHXen/EbxEbieT7P4GggYxi2WC11OWdvKLMzONqooULgKM5Lk8hc8943i8Ywv8P7PxjpWmNIPFVisuoadOhVpB92PyWjXBZWJyGKZU5AyK9dvtH0wLcY0zTxiRummFMfuc9+nPOOx+bpVbU9B0ebVNMWbR9LkVdR3KG0ckAi2cghfY8465+am72OV0lOFlJ3tfZ9LPvp9xw/gnxn4X0m8ufD+uaimnarb3t5PNFeoluuyS5nkRg8wCNuSWJhycg5HQYtav4/8PWPnyaLIniHVJbW1jtNO0poLma4lDTMy4jDMqhRksQSB94HKg9vbaPphls86Zp5zHHnOmFs/JJ1H8X1HXg/wmqltpOnG/kU6dYFRa2TAHTCeTJJk+5OBk/xYwKHc3SSUkpdF9nz9TiNL+Er/ANgWst5fXdt4xgvX1J9Vsli8sXk0jJJmJvlaI7UUoAobZztDGtnSNE8Yw6UyNrWkymM3YaWXQV3OUmIZjtuQASeeANucKCK6lNH0zdL/AMSzT/8AWJ/zDCf+WzD8PTHcfL1FVLLStOexuGbTrAsGvgCdMORicgc9sDgH+EcGjW4oU6cU7N7ro+z8/wATF1rR/F66NqDSaropRbW6ZgNC2kheG5+1HH1wcdsisvULj4maPPeLdeF9F1+3MzrDLp1zHYtGFjJzIsu/llKthGIBVuSSDXXa3pWnR6LqLx6dYK62t4ysumFSCDwQexHY/wAPQ1bvtH0wLcY0zTxiRummFMfuc9+nPOOx+bpRrcdouKtJrV9PTuzz+7j+JWsanayHStH8K28VydkNyYb+WSZYGfaxTYiwsmQcfMpBI5xWF441H4jaJ4G1iXxDoOiX9rPYmNZ9GlMb2qPHIoldXQlwM7uMEBCSRwy+s3mk6auqWKrpunhWvirAaUcEfZnOCvpkA7fUbqkttH0wy2edM085jjznTC2fkk6j+L6jrwf4TSV9TOcIumvffw9vXz/r1PFfhtq9t4MTVdQ8Uw6ra6Nc6ToFxb3K2DTwAfZUjdiyoyplgFGcFiADnFd/qPxJ8D2GjXWptrtlcRRqkqwW8ttJO4Mp+VYs7t2COMAD+LCiujTTrGfVZ2msLF2a2s5DnTCcs0sm4/U4GT/FjAqwmj6Zul/4lmn/AOsT/mGE/wDLZh+HpjuPl6imm7CjSVKPJzdvs97Pv5nG/CrQZv7P1rxRqmmXFjq3iCS4uZrVlQG1jibZHEQx6r8xYhUbL42jbTfE3wr8Prp2s3mkw6xoVzNDPNM2k3a2yP5OQoaJTs2jJ3ALnJOOprqbLStOexuGbTrAsGvgCdMORicgc9sDgH+EcGjW9K06PRdRePTrBXW1vGVl0wqQQeCD2I7H+HoaWvKbKnT9ooybfvP7Pm/M4+9+Eklok0un+MfHUV3DIfJa71GKeJWWLeN8eAHGRkrnBXjrRqPw21vVdXs/+El8Ya9J/pC28S6NFBpoUi2ZmYhWcM7FVPYDL4+9gd3faPpgW4xpmnjEjdNMKY/c579Oecdj83Sk1HTbB9WsN9hYtm98s50tjlBavhcegwML7A9KHexjCnT7v4X0fb1PC7HSn8Ha74n0CC91aOLWdS0O1t7qSeN7hvtYk+0SKxUgSMFlwx242gk5Vc+h6j4R8Uz6gn9h+Mb6zxaWjTNd6TYXJk3yOF27Vj2jIPXJbPzEAV5h8XIoYPjz8PrGCCGOzuBpcksKWzJHIwupVy0fSQ4YjOOQSB1Ne7W2k6cb+RTp1gVFrZMAdMJ5MkmT7k4GT/FjAo1MsPGL9pFt2VraP+b1OS8JeMBa6zqXhbxwPsWvafmWO6liggh1G1SRi1yuflU7QSyhiBtbnarKmf4YstV8epqOsx6pqWm+ExPNPobab9nhluBHM5klnDIxKbztCHGQv3PX0C58N6FfJJFe6JpNxGsyMEm0gOAfOcZAI444x3Hy9Qai03RtKTTJUTS9OVIzeoirpZUKqzEKB6AAADsg4p63Noxeqcnyp9nd6Pz6eupyPir4Ym6ttT1CbxT4387yLmUxx38EMP7vgfu40CgY+8ABk9OpNLd/CCKFZivi74hDY7KN+rx8Yi384Xrnnjt711+t6Vp0ei6i8enWCutreMrLphUgg8EHsR2P8PQ1bvtH0wLcY0zTxiRummFMfuc9+nPOOx+bpRrcpUqTSbb3fR+XmcDd/CV7TULM6f4t8cLeC8KQNd38NzGji3eRS0ZAV/mAypOGUlc5NXLP4c6tqQtF8UeL/EV7NsxEdKWDTFCPG2CRHkuwKZDMexBX16680nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdUlto+mGWzzpmnnMcec6YWz8knUfxfUdeD/CaSvqTKnTUE7v4ez7v+8fP2peEG8FeILbQtJutWtNK1TWNAA8m68uV45o7qOX51bILvEW/hHAyBtWvULX4bajpltfDQfGHiqO9do0STU2ttQjT9+y8pIo6gY+VlyeuVrzz4p+TF8Z/A2iWul2ZivH0i7kZLIggRT3IYFf41KyEsR12D0r3RNH0zdL/xLNP/ANYn/MMJ/wCWzD8PTHcfL1FNXOWjCDlNXdk+z7+p594F8YeTPqPhnxxHDp3iWwiu7hpgsUdteRh2ZpomdV4UrIGAyQEJXADBK99oI+JGlaprmqtqyeFVhuJNHsIwlot3Eig/aLgA73Bk5RTt2rGpAO811V/4K8N+ILGJtX0axuGs7m9nhP2GSMhlnYAEqRuXGBtbKgABgcCtTW9K06PRdRePTrBXW1vGVl0wqQQeCD2I7H+HoaWvKdsaadZQnK65u2+++v8Aw5mSfDjRLG3aK2HiSGG3PlRoNbuAqKsO4LgTcYwOnG3jrUWqfDXQLi/0q3vbTXL62j1IMLe+1SS5iLLbu4zHJIyE5HcEFcg5yRXR32j6YFuMaZp4xI3TTCmP3Oe/TnnHY/N0qO80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdTd7ExhSas/5X9ny9Tnrv4V+FNTeGKTRrm3tLq3hS4tNPlW0huMeY6M6RMquykHazc4LZ/hxxn/AAruw8M/FHwFL4csHttM3v58TS+a7zT28xDLuLDbttm+8RjAyOTXrFto+mGWzzpmnnMcec6YWz8knUfxfUdeD/Ca8k+Ptk2m+GLbWdIsbENo0+m37qbIorDdcJhuzBmaMN0DD6UpXRM406cJyj0S+z/eXmO8A+Fbn4j+FrbxXq3iPxbZXmpSF3ttJvo7e1iH2mSILHGQSo2oAMknOSTzmtKP4X6jZ6Xd3nhzxb4sj1aL7b9n/tK7iubUlJWT95GV5yuctyQxDKDjFdF8MNK0+X4c+GZJdPsXdtNsSWfT/MJJ6kt3z39fu9RW1ZaVpz2NwzadYFg18ATphyMTkDntgcA/wjg0a3CnSh7P3pO910fZ+ZyNp8NrODQtY1XxbZRax4lvbW6nuriWGGWGBkyBHbq+THGmSMjDHqOMAdLffD/wpGtyR4S0pcSMOdNtOP3Gey/jxxjn71Wdb0rTo9F1F49OsFdbW8ZWXTCpBB4IPYjsf4ehq3faPpgW4xpmnjEjdNMKY/c579Oecdj83Smr3LjSoqMfWX2fTzOCvPgX4CXUrOJfDl6FlvDC6i9bJX7O8mP9ZgHIB9Mcdavy/CfRrpdLtIbrxXaaesUayWVvq7+VPGUb92Vd2wmEwACpwWzztrqrzSdNXVLFV03TwrXxVgNKOCPsznBX0yAdvqN1SW2j6YZbPOmaecxx5zphbPySdR/F9R14P8JpK+pLpUlBW093+XzfmcLo/wAK7DTNVf8AsLVfFOl2q29lLHaW95DJAheZidqyq/ysyZwe7OG+ViKx/Gfhy08K+NfC3ii5uNU1LU7jXLfS2lvpLdVigkF1GwVI0VB2bkYyp6A8+j22k6cb+RTp1gVFrZMAdMJ5MkmT7k4GT/FjAry79prRVj+HZvdKs4IHsNRhnllgtDCyJunQHcOnzPGMfQdVo1sRioU6cZSi3dWto+y8y9ocPxD8Q6DD4m0a60bTrS7jmurTR7i2iuInhZwxeW4TDhxvYgKoxtQYBLgX/FvjK/8ADdhqKeMvCV7YWEsM0UGpac8V9bhiQpMpEaPEqs6qCVySTtwBzf8AhLpthP8ACnw3LPY2csraW5LvYF2JBABL9yOzdF6Gul1vStOj0XUXj06wV1tbxlZdMKkEHgg9iOx/h6GjXlN4x/eL33fm/l66+f5WOKvNZ1Xx7qWpwfD7UY9M0PTZmim1lrKC5+1TiLJhhXhNigMzOCckoVHdtDWvB/jGW601bbxjLb3rX8qyH+w7J4QTCzoI4ycqFTKkM7g5DZBGD2F9o+mBbjGmaeMSN00wpj9znv055x2PzdKjvNJ01dUsVXTdPCtfFWA0o4I+zOcFfTIB2+o3UO9jOEINayez6NdPKX/DmJp+h+M0SxibXNHnk8mL97JoC7pPkf5iBdBSTtJ6DPoMAVz0Fx8RtM1i4F14W0nxBFLHa+VLptzFZmOHzZAhdZg253yeA3G35iRivQLbR9MMtnnTNPOY4850wtn5JOo/i+o68H+E1UttJ0438inTrAqLWyYA6YTyZJMn3JwMn+LGBTdzTljaSUmtF08/U+efiv4un1658SWb6ZeaTd6LogFxbTpEGhum1K0L7XT78eBHtcYJ6gBTivRfD+hXXxO0NdY18XNt4QuluLqz0OERo8pWQ4luJ1COy72ciNQFAERBbBrQ+OujQt8IvFa6dptv5qLDNiDTyrKqXRLNn+EBA2Sf4QR2NXPhLpthP8KfDcs9jZyytpbku9gXYkEAEv3I7N0XoaWtzkp0l7SSlJtadN9+l/8AgHWatpsFr4avobayeGCGxu1jjSKBVRU4AAA4Cjjjp/DxXP8AjvwVeXGsnxH4YuX03xDbI1mTcwxS29xbhPN8mRB9z5hnenIBPU4xs63pWnR6LqLx6dYK62t4ysumFSCDwQexHY/w9DVu+0fTAtxjTNPGJG6aYUx+5z36c847H5ulPW52NQlBJt7y6enmchJP48j1jR7O88HaTPN537y8g1WJLczfZpMpsaAuuQCw4ZRkDJOWGhB/wmzXtqR4c0BoGhTbH/avzMxDkNuNrjBAPBBPy8k8Y27zSdNXVLFV03TwrXxVgNKOCPsznBX0yAdvqN1SW2j6YZbPOmaecxx5zphbPySdR/F9R14P8JoTepDSUE3N7fy+vn/wTk7i38dXFzGdN03w1ZSslmJmnuWuysJeQB1QQxZLMehf+AhuGBFVE+I2hR3Mcuj6Z4ujWaKOGaCWHTrjBdwzSIyvHyw2jYwwAMgg8dXbaTpxv5FOnWBUWtkwB0wnkySZPuTgZP8AFjAq2mj6Zul/4lmn/wCsT/mGE/8ALZh+HpjuPl6ihXHVirv330+z5LzsfLVvqQ0f4r+I/F3iWxbTb7Trx4m0/wA+OVVeSyu9sZdV2kl4o1DKMDceOmPYNJ8M6z4h8Px+JvHconlGnz31lpNvZxwW9jLswXcMS8jqD/GMxszbOxGL8fPDB1fwRpFvpVpaQzvr7wtKLUwhFaeSJdzckqGdBgfdHFeqa3pWnR6LqLx6dYK62t4ysumFSCDwQexHY/w9DU68pFKmliWnJtc3bd3e+vp5eRr31mEW4/0eZdsjDlIRj9zu7fnxxj/arj/GHgaS88Z6Tr2g3E+l69HP9haWW1guYZbfyWlMbw7lGcg/MpXhjyTjHSX2j6YFuMaZp4xI3TTCmP3Oe/TnnHY/N0qO80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdVNuxSUJJXb2f2X29TQtrRWmsx9nmO6OM4CQ85SQ8Z+nfng55xXl/xQiEWr6dhGTdYRt8wQZyz8jb2+vPrXolto+mGWzzpmnnMcec6YWz8knUfxfUdeD/AAmvNviRbQWuqaelrBDAjWMbFYrfygTubk/3j/td6itflPYyVr64rPp2t38zvrG7tksbgG3fO6+OV0mf/nu2OccEev8AB0PNGt3ds+i6iq27hja3gBOkzrg545IwMep4Xoat6ezfYLj91MPnv/8AlrN/z3b1Xt3zwf4sGjXmb+wtT/dTf8el51lm9f8Ad7d88H+LBqteU89Ne2Wj+J9V3fkF9e2oW4xbyDEjdNHnTH7nPdePXHY/N0qO8urVtUscW7YW+OQdGnHH2Z+AuMnk529f4ulaF8xK3H7qYZkbrLMcfufdfx55xx93mor52/tXTv3E/wDx/njzrjP/AB6ycfdznvnrjjGOabvYxptW2fwvqu3oQW17amWzBt5DmOPOdHnbPySdRj5vqOvB/hNVba7tvt8jmB8G1sh/yCZyc+ZJnPHfPXo/QdDWtbM3nWf7qY/u4+kswz8knTC8fhkcHHBOKdqzf2lL+6mP+iWP/LWb/nrL/s9+2OB/Dk0O90UnH3tHsuq7+gJe2u6X/R5P9Yn/ADB5z/y2YenHHGO4+XqKqWN3bJY3ANu+d18crpM//Pdsc44I9f4Oh5rXRjul/dTf6xP+Ws3/AD2b/Z/DnnPI+bIqnp7N9guP3Uw+e/8A+Ws3/PdvVe3fPB/iwaNbgnHlej3XVdn5FTW7u2fRdRVbdwxtbwAnSZ1wc8ckYGPU8L0NW769tQtxi3kGJG6aPOmP3Oe68euOx+bpRrzN/YWp/upv+PS86yzev+72754P8WDVy+Ylbj91MMyN1lmOP3Puv48844+7zQr3BOPKtHvLqvLyM+8urVtUscW7YW+OQdGnHH2Z+AuMnk529f4ulSW17amWzBt5DmOPOdHnbPySdRj5vqOvB/hNT3zt/aunfuJ/+P8APHnXGf8Aj1k4+7nPfPXHGMc1LbM3nWf7qY/u4+kswz8knTC8fhkcHHBOBX1Jk1yLR/D3Xd+RkwXls2oyyNbt81rZdNImznzZM8Ad89ejdB0q0l7a7pf9Hk/1if8AMHnP/LZh6cccY7j5eootWb+0pf3Ux/0Sx/5azf8APWX/AGe/bHA/hyauIx3S/upv9Yn/AC1m/wCezf7P4c855HzZFCuVVcU9n06rsvIyLG7tksbgG3fO6+OV0mf/AJ7tjnHBHr/B0PNGt3ds+i6iq27hja3gBOkzrg545IwMep4Xoat6ezfYLj91MPnv/wDlrN/z3b1Xt3zwf4sGjXmb+wtT/dTf8el51lm9f93t3zwf4sGlrymia9stH8T6ru/IL69tQtxi3kGJG6aPOmP3Oe68euOx+bpTLy6tG1Kx/wBGb5b89dGnAx9lfjbjJ5IO0c/xdKv3zErcfuphmRussxx+591/HnnHH3eaivnb+1dO/cT/APH+ePOuM/8AHrJx93Oe+euOMY5pu9jGDjbZ/C+q7eh4Z8StG/tT47/DW7hJSN4omKHTpgT9mdp3ym3MmVbGV/HAr2K2u7b7fI5gfBtbIf8AIJnJz5kmc8d89ej9B0NRXfh621Hxb4W12YXgutHhkWBI5ZQr+dEysW+Qt0XgKcdeozi/as39pS/upj/olj/y1m/56y/7Pftjgfw5NDTuRSgoOo7PW3Vd15dxEvbXdN/o8vEiD/kDzn/ls3tx6Y7j5eoqrY3dsljcA2753Xxyukz/APPdsc44I9f4Oh5rXRjul/dTf6xP+Ws3/PZv9n8Oec8j5siqens32C4/dTD57/8A5azf8929V7d88H+LBo1uapx5Xo911XZ+RU1u7tn0XUVW3cMbW8AJ0mdcHPHJGBj1PC9DVu+vbULcYt5BiRumjzpj9znuvHrjsfm6Ua8zf2Fqf7qb/j0vOss3r/u9u+eD/Fg1cvmJW4/dTDMjdZZjj9z7r+PPOOPu80K9wTjyrR7y6ry8jPvLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpUlte2plswbeQ5jjznR52z8knUY+b6jrwf4TU987f2rp37if/j/PHnXGf+PWTj7uc989ccYxzUtszedZ/upj+7j6SzDPySdMLx+GRwccE4FfUmTXItH8Pdd35HjnjB7UfHv4a3SW5BazmSQ/YJFZwI3xlCN0n3jyODk16ul7a7pf9Hk/1if8wec/8tmHpxxxjuPl6iuR1vwzd6r8UPCWvwOqW+iWqieJzMXkEwkRSh2HHIHA45+Uk8V3SMd0v7qb/WJ/y1m/57N/s/hzznkfNkUK4pRjGUvde67dl5GRY3dsljcA2753Xxyukz/892xzjgj1/g6HmjW7u2fRdRVbdwxtbwAnSZ1wc8ckYGPU8L0NW9PZvsFx+6mHz3//AC1m/wCe7eq9u+eD/Fg0a8zf2Fqf7qb/AI9LzrLN6/7vbvng/wAWDS15TdNe2Wj+J9V3fkF9e2oW4xbyDEjdNHnTH7nPdePXHY/N0qO8urVtUscW7YW+OQdGnHH2Z+AuMnk529f4ulaF8xK3H7qYZkbrLMcfufdfx55xx93mor52/tXTv3E//H+ePOuM/wDHrJx93Oe+euOMY5pu9jGm1bZ/C+q7ehBbXtqZbMG3kOY4850eds/JJ1GPm+o68H+E15l8eJ4JPhd4n2QsrNY6bgtp0sZB+1HJ3kYGf7x4boORXrNszedZ/upj+7j6SzDPySdMLx+GRwccE45Pxp4cTxhoGs6DM9xbLe6fYoJ1aV9jCaRlYqVww3AfLnGM7Tk8EkxVEpQqRinql1Xf0LPgyGPRfCmk6VdRvLcWNra2sjjSrhwzI5RiCVBwcdwCR8vBFXLG7tksbgG3fO6+OV0mf/nu2OccEev8HQ81rox3S/upv9Yn/LWb/ns3+z+HPOeR82RVPT2b7Bcfuph89/8A8tZv+e7eq9u+eD/Fg0a3LjyqL0e66rs/Iqa3d2z6LqKrbuGNreAE6TOuDnjkjAx6nhehq3fXtqFuMW8gxI3TR50x+5z3Xj1x2PzdKNeZv7C1P91N/wAel51lm9f93t3zwf4sGrl8xK3H7qYZkbrLMcfufdfx55xx93mhXuCceVaPeXVeXkZ95dWrapY4t2wt8cg6NOOPsz8BcZPJzt6/xdKktr21MtmDbyHMcec6PO2fkk6jHzfUdeD/AAmp752/tXTv3E//AB/njzrjP/HrJx93Oe+euOMY5qW2ZvOs/wB1Mf3cfSWYZ+STphePwyODjgnAr6kya5Fo/h7ru/Iyba7tvt8jmB8G1sh/yCZyc+ZJnPHfPXo/QdDXDfH+5t5PhD4oWOF1b/R8FtNmjA/0wfxMMJwMc+y9RXodqzf2lL+6mP8Aolj/AMtZv+esv+z37Y4H8OTUWv6Vb6/oeraRfwTG1vk+zyYeRioaVxkbkI3DPBIOGGQC2RQk7CxSUoyik7u3Vdl5FXSHsbLSGtre0aOGIXqxomkT4VRMdoBxxgcD+50PNSa3d2z6LqKrbuGNreAE6TOuDnjkjAx6nhehq3p7N9guP3Uw+e//AOWs3/PdvVe3fPB/iwaNeZv7C1P91N/x6XnWWb1/3e3fPB/iwaWvKbpx9stH8T6ru/IL69tQtxi3kGJG6aPOmP3Oe68euOx+bpUd5dWrapY4t2wt8cg6NOOPsz8BcZPJzt6/xdK0L5iVuP3UwzI3WWY4/c+6/jzzjj7vNRXzt/aunfuJ/wDj/PHnXGf+PWTj7uc989ccYxzTd7GNNq2z+F9V29CC2vbUy2YNvIcxx5zo87Z+STqMfN9R14P8JqrbXdt9vkcwPg2tkP8AkEzk58yTOeO+evR+g6Gta2ZvOs/3Ux/dx9JZhn5JOmF4/DI4OOCcU7Vm/tKX91Mf9Esf+Ws3/PWX/Z79scD+HJod7opOPvaPZdV39CtqA03VNP1CwvrSaS0uh5EqDSrlSyPK6sAVAK5BxwQcfKORTbG6tY7CceQ+d18QRpM//Pc45xwR6/wdDzWujHdL+6m/1if8tZv+ezf7P4c855HzZFU9PZvsFx+6mHz3/wDy1m/57t6r2754P8WDRrcE42ej3XVdn5FTW7u2fRdRVbdwxtbwAnSZ1wc8ckYGPU8L0NW769tQtxi3kGJG6aPOmP3Oe68euOx+bpRrzN/YWp/upv8Aj0vOss3r/u9u+eD/ABYNXL5iVuP3UwzI3WWY4/c+6/jzzjj7vNCvcE48q0e8uq8vIz7y6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6VJbXtqZbMG3kOY4850eds/JJ1GPm+o68H+E1PfO39q6d+4n/wCP88edcZ/49ZOPu5z3z1xxjHNS2zN51n+6mP7uPpLMM/JJ0wvH4ZHBxwTgV9SZNci0fw913fkZNtd232+RzA+Da2Q/5BM5OfMkznjvnr0foOhq0l7a7pf9Hk/1if8AMHnP/LZh6cccY7j5eootWb+0pf3Ux/0Sx/5azf8APWX/AGe/bHA/hyauIx3S/upv9Yn/AC1m/wCezf7P4c855HzZFCuVVau9H06rsvI5u7gstS0SW1nW6iRbqa63QaXMpJhvVmQE7SMZRQf7oypweRd1u7tn0XUVW3cMbW8AJ0mdcHPHJGBj1PC9DVvT2b7Bcfuph89//wAtZv8Anu3qvbvng/xYNGvM39han+6m/wCPS86yzev+72754P8AFg0teUtcvt1o/ifVd35BfXtqFuMW8gxI3TR50x+5z3Xj1x2PzdKjvLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpWhfMStx+6mGZG6yzHH7n3X8eeccfd5qK+dv7V079xP/x/njzrjP8Ax6ycfdznvnrjjGOabvYyptW2fwvqu3oQW17amWzBt5DmOPOdHnbPySdRj5vqOvB/hNebfEiWOXVNPaJGQfYY85tngJO5ucMPm/3hwa9VtmbzrP8AdTH93H0lmGfkk6YXj8Mjg44Jx5f8UCTq+nZVl/0CP7zOc/M/I3AYHsOPQ1Fa/LqevkrX1xWT27rz8jurG4uvsM4SOwYbr7rqsmcmduMbOe+B/GOTik1ue6Oi6iHjsAptbwErqsjHk9hs5PoP4upq3p88hsLgG8hOXvxjz0Ocztkfc79R69tvSjXp5DoWpj7ZCc2l4MeenOTyPud+o9e23pVWfKecn++Xur4n1fdhfXF4VuMRaecyNjGrSvn9zjvHz6Z7n5elR3lxc/2pYFk08f6cSuNYlIP+jOOW8vgdfm65+XpzWhfTyMtxm8hfMjHidDn9zjPCDPHHbnjrzUV9cy/2rp5+3wZ+3k7vtCYz9lkGc+X07ZxjPGM802nbcxpvT4V8L6y7EFtcXgls8xaeMRx5zq0q4+STqfL+X6DpkD+I1Utp7oX8n7uw3/ZbIEHVZABiST/Y69cj+HqM5rXtp5BNZkXkK7Y4wCZ0G3CScH5OMZxznGR1yCKdrPINSlAvIRi0sRjz04xLLgfc7dT6d93Shp33KT+L3Vsur7glxebpf3Wn/wCsT/mLSj/lsx/5588c57D5upqrY3F19hnCR2DDdfddVkzkztxjZz3wP4xycVrJPJul/wBMhGZEP+vTn98xz9z15+hzyDgU9PnkNhcA3kJy9+Meehzmdsj7nfqPXtt6UWdwT91+6t11fZlTW57o6LqIeOwCm1vASuqyMeT2Gzk+g/i6mrd9cXhW4xFp5zI2MatK+f3OO8fPpnufl6Ua9PIdC1MfbITm0vBjz05yeR9zv1Hr229KuX08jLcZvIXzIx4nQ5/c4zwgzxx254680JO4J+6vdW8ur8jPvLi5/tSwLJp4/wBOJXGsSkH/AEZxy3l8Dr83XPy9Oaktri8EtnmLTxiOPOdWlXHySdT5fy/QdMgfxGp765l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5qW2nkE1mReQrtjjAJnQbcJJwfk4xnHOcZHXIIEnrqTJ+4vdXw95d2ZFtPdC/k/d2G/7LZAg6rIAMSSf7HXrkfw9RnNW0uLzdL+60/8A1if8xaUf8tmP/PPnjnPYfN1NFrPINSlAvIRi0sRjz04xLLgfc7dT6d93SriTybpf9MhGZEP+vTn98xz9z15+hzyDgCTKqvV+6unV9kZNjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxSa3PdHRdRDx2AU2t4CV1WRjyew2cn0H8XU1b0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pRr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0pWfKaJ/vl7q+J9X3YX1xeFbjEWnnMjYxq0r5/c47x8+me5+XpUd5cXP9qWLMmng/biQRrEpB/0Zxy3l5A6/N1z8vTmtC+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmor65l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5ptO25jB6fCvhfWXYgtri8EtnmLTxiOPOdWlXHySdT5fy/QdMgfxGqltPdC/k/d2G/wCy2QIOqyADEkn+x165H8PUZzWvbTyCazIvIV2xxgEzoNuEk4PycYzjnOMjrkEU7WeQalKBeQjFpYjHnpxiWXA+526n077ulDTvuUn8XurZdX3BLi83S/utP/1if8xaUf8ALZj/AM8+eOc9h83U1Vsbi6+wzhI7BhuvuuqyZyZ24xs574H8Y5OK1knk3S/6ZCMyIf8AXpz++Y5+568/Q55BwKenzyGwuAbyE5e/GPPQ5zO2R9zv1Hr229KLO4J+6/dW66vsyprc90dF1EPHYBTa3gJXVZGPJ7DZyfQfxdTVu+uLwrcYi085kbGNWlfP7nHePn0z3Py9KNenkOhamPtkJzaXgx56c5PI+536j17belXL6eRluM3kL5kY8Toc/ucZ4QZ447c8deaEncE/dXureXV+Rn3lxc/2pYFk08f6cSuNYlIP+jOOW8vgdfm65+XpzUltcXgls8xaeMRx5zq0q4+STqfL+X6DpkD+I1PfXMv9q6eft8Gft5O77QmM/ZZBnPl9O2cYzxjPNS208gmsyLyFdscYBM6DbhJOD8nGM45zjI65BAk9dSZP3F7q+HvLuzItp7oX8n7uw3/ZbIEHVZABiST/AGOvXI/h6jOatpcXm6X91p/+sT/mLSj/AJbMf+efPHOew+bqaLWeQalKBeQjFpYjHnpxiWXA+526n077ulXEnk3S/wCmQjMiH/Xpz++Y5+568/Q55BwBJlVXq/dXTq+yMmxuLr7DOEjsGG6+66rJnJnbjGznvgfxjk4pNbnujouoh47AKbW8BK6rIx5PYbOT6D+Lqat6fPIbC4BvITl78Y89DnM7ZH3O/Uevbb0o16eQ6FqY+2QnNpeDHnpzk8j7nfqPXtt6UrPlNE/3y91fE+r7sL64vCtxiLTzmRsY1aV8/ucd4+fTPc/L0qO8uLn+1LAsmnj/AE4lcaxKQf8ARnHLeXwOvzdc/L05rQvp5GW4zeQvmRjxOhz+5xnhBnjjtzx15qK+uZf7V08/b4M/byd32hMZ+yyDOfL6ds4xnjGeabTtuY03p8K+F9ZdiC2uLwS2eYtPGI4851aVcfJJ1Pl/L9B0yB/EaqW090L+T93Yb/stkCDqsgAxJJ/sdeuR/D1Gc1r208gmsyLyFdscYBM6DbhJOD8nGM45zjI65BFO1nkGpSgXkIxaWIx56cYllwPudup9O+7pQ077lJ/F7q2XV9wS4vN0v7rT/wDWJ/zFpR/y2Y/88+eOc9h83U1Vsbi6+wzhI7BhuvuuqyZyZ24xs574H8Y5OK1knk3S/wCmQjMiH/Xpz++Y5+568/Q55BwKenzyGwuAbyE5e/GPPQ5zO2R9zv1Hr229KLO4J+6/dW66vsyprc90dF1EPHYBTa3gJXVZGPJ7DZyfQfxdTVu+uLwrcYi085kbGNWlfP7nHePn0z3Py9KNenkOhamPtkJzaXgx56c5PI+536j17belXL6eRluM3kL5kY8Toc/ucZ4QZ447c8deaEncE/dXureXV+Rn3lxc/wBqWBZNPH+nErjWJSD/AKM45by+B1+brn5enNSW1xeCWzzFp4xHHnOrSrj5JOp8v5foOmQP4jU99cy/2rp5+3wZ+3k7vtCYz9lkGc+X07ZxjPGM81LbTyCazIvIV2xxgEzoNuEk4PycYzjnOMjrkECT11Jk/cXur4e8u7Mezubs30hMNir/AGazBVtVkGAJZOeE+pI/gGCOTgXEuLzdL+60/wD1if8AMWlH/LZj/wA8+eOc9h83U0Ws8g1KUC8hGLSxGPPTjEsuB9zt1Pp33dKuJPJul/0yEZkQ/wCvTn98xz9z15+hzyDgCTKqvV+6unV9kZNjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxSa3PdHRdRDx2AU2t4CV1WRjyew2cn0H8XU1b0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pRr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0pWfKaJ/vl7q+J9X3YX1xeFbjEWnnMjYxq0r5/c47x8+me5+XpUd5cXP9qWBZNPH+nErjWJSD/ozjlvL4HX5uufl6c1oX08jLcZvIXzIx4nQ5/c4zwgzxx254681FfXMv9q6eft8Gft5O77QmM/ZZBnPl9O2cYzxjPNNp23Mab0+FfC+suxBbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNVLae6F/J+7sN/2WyBB1WQAYkk/wBjr1yP4eozmte2nkE1mReQrtjjAJnQbcJJwfk4xnHOcZHXIIp2s8g1KUC8hGLSxGPPTjEsuB9zt1Pp33dKGnfcpP4vdWy6vuCXF5ul/daf/rE/5i0o/wCWzH/nnzxznsPm6mqtjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxUt14hs7HW7LS7nU4o7/AFJ2a1j35EvlSl3O4RlRgNu5I4OQCPlEunzyGwuAbyE5e/GPPQ5zO2R9zv1Hr229KLO+4Jqz91brq+z8yprc90dF1EPHYBTa3gJXVZGPJ7DZyfQfxdTVu+uLwrcYi085kbGNWlfP7nHePn0z3Py9KNenkOhamPtkJzaXgx56c5PI+536j17belXL6eRluM3kL5kY8Toc/ucZ4QZ447c8deaEncE/dXureXV+Rn3lxc/2pYFk08f6cSuNYlIP+jOOW8vgdfm65+XpzUltcXgls8xaeMRx5zq0q4+STqfL+X6DpkD+I1PfXMv9q6eft8Gft5O77QmM/ZZBnPl9O2cYzxjPNS208gmsyLyFdscYBM6DbhJOD8nGM45zjI65BAk9dSZP3F7q+HvLuzItp7oX8n7uw3/ZbIEHVZABiST/AGOvXI/h6jOatpcXm6X91p/+sT/mLSj/AJbMf+efPHOew+bqaLWeQalKBeQjFpYjHnpxiWXA+526n077ulXEnk3S/wCmQjMiH/Xpz++Y5+568/Q55BwBJlVXq/dXTq+yMmxuLr7DOEjsGG6+66rJnJnbjGznvgfxjk4pNbnujouoh47AKbW8BK6rIx5PYbOT6D+Lqat6fPIbC4BvITl78Y89DnM7ZH3O/Uevbb0o16eQ6FqY+2QnNpeDHnpzk8j7nfqPXtt6UrPlNE/3y91fE+r7sL64vCtxiLTzmRsY1aV8/ucd4+fTPc/L0qO8uLn+1LAsmnj/AE4lcaxKQf8ARnHLeXwOvzdc/L05rQvp5GW4zeQvmRjxOhz+5xnhBnjjtzx15qK+uZf7V08/b4M/byd32hMZ+yyDOfL6ds4xnjGeabTtuY03p8K+F9ZdiC2uLwS2eYtPGI4851aVcfJJ1Pl/L9B0yB/Ea83+JDyPqmnmZYVcWMYxFctMPvN1JA2n/ZHAr1S2nkE1mReQrtjjAJnQbcJJwfk4xnHOcZHXII8v+KDl9X07dKsm2wjA2uG2jc/BwBg+3J9zUVl7p62Su+MXu207vz7noFla3rWFwft2qqM6gCNttj/XncT8mevLY7/d4rjPFvjyy02y8bW1zd+IZJPD8Hl3i+TabXN06iMKQASMsN/Qj+Gu30+0UWFwfs8ww9+clIeNs7Dt6d8cj+HivPvGvwubULP4g3f26aIa9DFMF+yxn7P9jZc8iQbt23BwF2543CqsuU8irUkp/u+W/M7aLz/U9I1G0vtlzu1HVv8AWtnetr1+znrhOuPTjHvVLxFNLo5XUdR1PV47S0upJ5pTHbM0apZyMzAKnLBQeMEY7bsVpX1mEW4/0eZdsjDlIRj9zu7fnxxj/arh/jpPa6N8PtZubyG4jibzrVT5UJw8tpIiA7f9t1JxwBz1oklYmNRKP2fhfRdjq9EM+o22j3tjqmrSW1zawTQOqWwLI0chUgMnAIPG7nGc84plra3v251F9qvFpYHcFtuR5sm0cp0z075J3cYrP+GlmG8D+Dh9nmO/SLE4CQ85t2PGfp354OecVf2W9rcXd1dq0NvFY2css0ggVEXzJdzFj0GB1P8AwLim0tB06vNFt8uy6Lui5HaX2+f/AImOrf62POFtev2h+vydc59s5zxiqlla3rWFwft2qqM6gCNttj/XncT8mevLY7/d4q1YrbX1uLmzBuLWUxvFLEIHR1aZgCCOCCMYI4P+7iodPtFFhcH7PMMPfnJSHjbOw7enfHI/h4osrlKouVv3d10XZkeuWt6uiakzX+qsotL0lWW2wRnkHCZx645/u1b1G0vtlzu1HVv9a2d62vX7OeuE649OMe9Qa9aKNC1M/Z5hi0vDnZDxtOO3p37j+Hirl9ZhFuP9HmXbIw5SEY/c7u358cY/2qElcFUXKvh3l0XkV7y1vxq1gDf6uWOoEAlbXcD9lfkfJjdj8MH1ojhuoPsk0uqanFFHBG5ci0AVRHKc5KYAAz17Zz2p99Yr/aunr9ln/wCP8rjy7fP/AB6yHHpnv6Y96p6zIdM0WfUI7QyPbWP2kJJ5KI5WKVuWIOFO3qQTgEnkLSSWpMqiVNfD8PZd2V9DmOqN9q0zWb27tXtbLZcWz2kiPiaVcBgpGAysB3zkN7akdpfb5/8AiY6t/rY84W16/aH6/J1zn2znPGK8s/ZpNvefDmySFWmkt0jimCLEdjteXDYO7nJVl/PnjFei+IdR03w3o2oavrfnW2nWjRmaXyI32A3DIPlUEnnA4HXr8uKIpWFKspLmfKvh6Lsh9la3rWFwft2qqM6gCNttj/XncT8mevLY7/d4qh4hvobeK70y48QXA1KaxvZI7GWWzWWVMsSQgUMV+R8kf3Tt4Bpvg/VNM1/StSl0pbpxaXN/BOstqkLRSLIH2srqrAhZFzxkE4GMEVyvxN+Gt54h1JdY/tq9hsrDN6tg8CMitbu5O3ZIijcHALMjsCPlO35QW9009reqnDlfvdl3Y6b4oaZd6Hp2pxXfidrbV49RuoA8FmGC2lsxl3gDgkDAxkEHsa7PTbqfW4PD+q2d9rX2fUJ0uYfMS0Eih7JnXIC43bTjuME965C4+EWn2mt+OtUtmuIZdfgmtEDRoRaeZAzTE/Ph9zlXwAu0LhTzxv8AhbwzqWgQ6JpOp3EV/BZzx2luYNPigcKlnIPnLSyBiQFPGBwTyTwNaHPQqTv73LblfRdv6ZmeCNR1vUPiV4s0mfVdTe00saaLVUS23IJLSR25KY65I9s55rqbW1vftzqL7VeLSwO4LbcjzZNo5Tpnp3yTu4xXknguMt+1V4lt9krRvpMLmNRH8x8i2IOD8p6nrzg+tev2toDqUp+zzHNpYnISHndLKO/r27n+LihpFUal1O9vuX839WJ47S+3z/8AEx1b/Wx5wtr1+0P1+TrnPtnOeMVUsrW9awuD9u1VRnUARttsf687ifkz15bHf7vFaCWgLS/6PMcSIPuQ8ZmYf0xxxkc/Liqen2iiwuD9nmGHvzkpDxtnYdvTvjkfw8U7K5qqis/h3XRdmR65a3q6JqTNf6qyi0vSVZbbBGeQcJnHrjn+7VvUbS+2XO7UdW/1rZ3ra9fs564Trj04x71Br1oo0LUz9nmGLS8OdkPG047enfuP4eKuX1mEW4/0eZdsjDlIRj9zu7fnxxj/AGqElcFUXKvh3l0XkV7y1vxq1gDf6uWOoEAlbXcD9lfkfJjdj8MH1p9paX3n2G3UdWz5UW3atrnGyXGMp064zzjOecUX1iv9q6ev2Wf/AI/yuPLt8/8AHrIceme/pj3qW2tFaazH2eY7o4zgJDzlJDxn6d+eDnnFJRWpMprkXw/D2XdnnvgeXVbr4lePrSTVdYeGzXRVhXdAwQNFuwFZSFGSSNoGSctk5rvY7S+3z/8AEx1b/Wx5wtr1+0P1+TrnPtnOeMV5J4HW7k+PniuSJWfR7y2hj+RYjvuLdbJWGGGRtFwR0wd/JbBNewJaAtL/AKPMcSIPuQ8ZmYf0xxxkc/LimkjGlVvGV7fF2Xf+rGfZWt61hcH7dqqjOoAjbbY/153E/Jnry2O/3eKNctb1dE1Jmv8AVWUWl6SrLbYIzyDhM49cc/3ak0+0UWFwfs8ww9+clIeNs7Dt6d8cj+HijXrRRoWpn7PMMWl4c7IeNpx29O/cfw8UrLlOxTXtl8PxPou7MvxLrB03xHpuhXV9rpvNYe6aA+XaFF8m1DPvIXIO1h0B4965dfiXbX+l6b4gsIvGd1pzPc6g8ws7RRBHDBKjkuwEZk+RyEDMdgJxnFb3xZ8B2/jXwrdaTL51nIl0s0NwYYm8pki3H5UZc5UuMZxhs4LCs3xl8PrrUZ/DukaZPBa+H7G5jhTTbvT0uRK8duWTzWEyF1UIP3Z+Unli54oaONVJ625fhdtI9v0/I6/RDPqNto97Y6pq0ltc2sE0DqlsCyNHIVIDJwCDxu5xnPOKzbe+C+LF0Q6rqo1OTS7O9SMRW/zQrOyZ3bNuAzKAPvZY5yOm3p1nJt05bmJpZ2gi8xo4YVV2KSZKqxOASMgMScDkkgGvHvEUs9p+054Lt7fzY4r/AENYp0Cx/vk3Tvj0I3Ih+bnI5puKKnXcHb3dbLZdz2CO0vt8/wDxMdW/1secLa9ftD9fk65z7ZznjFVLK1vWsLg/btVUZ1AEbbbH+vO4n5M9eWx3+7xWgloC0v8Ao8xxIg+5DxmZh/THHGRz8uKp6faKLC4P2eYYe/OSkPG2dh29O+OR/DxRZXNlUVn8O66LsyPXLW9XRNSZr/VWUWl6SrLbYIzyDhM49cc/3at6jaX2y53ajq3+tbO9bXr9nPXCdcenGPeoNetFGhamfs8wxaXhzsh42nHb079x/DxVy+swi3H+jzLtkYcpCMfud3b8+OMf7VCSuCqLlXw7y6LyK95a341awBv9XLHUCAStruB+yvyPkxux+GD60+0tL7z7DbqOrZ8qLbtW1zjZLjGU6dcZ5xnPOKL6xX+1dPX7LP8A8f5XHl2+f+PWQ49M9/THvUttaK01mPs8x3RxnASHnKSHjP0788HPOKSitSZTXIvh+Hsu7M+1tb37c6i+1Xi0sDuC23I82TaOU6Z6d8k7uMVQl1K5g8Z2+gm/1Hzbu3kvA261Dgx3aqF2+Xg5MjEEHqh4K8jTtbQHUpT9nmObSxOQkPO6WUd/Xt3P8XFeS+K2eP8Aah8GWixlY5LCUMvlRb2BkueMgY/gXg8Ag9jQkhYiryyVuXVx6Lsj1aytb1rC4P27VVGdQBG22x/rzuJ+TPXlsd/u8Ua5a3q6JqTNf6qyi0vSVZbbBGeQcJnHrjn+7Umn2iiwuD9nmGHvzkpDxtnYdvTvjkfw8Ua9aKNC1M/Z5hi0vDnZDxtOO3p37j+Hiiy5TdTXtl8PxPou7J9RtL7Zc7tR1b/Wtnetr1+znrhOuPTjHvXGT+OLaS+t5hdeIysfi0+HSWis9wuvIaPcOMbcnGT/AA54zXcX1mEW4/0eZdsjDlIRj9zu7fnxxj/ariLv4b2kfxns/GKJOHkJs2tfKiyZfsz/AL3O/ZnYAu3ZjHOd1EkrHK5yaXI47PotrakHw8+IFt401DTYdEudeLNCCd82mCSJUWVSTEHMgGcAEp/ECeqmuutbW9+3OovtV4tLA7gttyPNk2jlOmenfJO7jFc1pfgTUpvGHhzV9d1eTUl0uOb7GkenwQSOJ0YDzW3lH2quAQiE4ycEYPU2toDqUp+zzHNpYnISHndLKO/r27n+LihrUunN2lzcvTou6PNPG/mn47/De0N7qDXatfybnWDegbeBtwu3JKNncCM9OMV6PZWt61hcH7dqqjOoAjbbY/153E/Jnry2O/3eK8j8WwAftVeCo/LdQ1hINrCME/PdjAx8ueMc9+OmK9g0+0UWFwfs8ww9+clIeNs7Dt6d8cj+HiiyuTRqXU7tfF2XZkeuWt6uiakzX+qsotL0lWW2wRnkHCZx645/u1b1G0vtlzu1HVv9a2d62vX7OeuE649OMe9Qa9aKNC1M/Z5hi0vDnZDxtOO3p37j+Hirl9ZhFuP9HmXbIw5SEY/c7u358cY/2qaSuaqouVfDvLovIr3lrfjVrAG/1csdQIBK2u4H7K/I+TG7H4YPrT7S0vvPsNuo6tnyotu1bXONkuMZTp1xnnGc84ovrFf7V09fss//AB/lceXb5/49ZDj0z39Me9S21orTWY+zzHdHGcBIecpIeM/Tvzwc84pKK1JlNci+H4ey7sz7W1vftzqL7VeLSwO4LbcjzZNo5Tpnp3yTu4xVuO0vt8//ABMdW/1secLa9ftD9fk65z7ZznjFQWtoDqUp+zzHNpYnISHndLKO/r27n+LiriWgLS/6PMcSIPuQ8ZmYf0xxxkc/Limkiqs1d/D9nouyPK9Pgum+O9+outQV/wDhF7wlwIN2P7SkBB+XG3OScDOc44wK9E1y1vV0TUma/wBVZRaXpKsttgjPIOEzj1xz/drxjTPEEQ/aYvtLNo25dPvNNBAjyGEkl1uIxjgDbxz6HtXtevWijQtTP2eYYtLw52Q8bTjt6d+4/h4qUlyk0Zr272+N9ET6jaX2y53ajq3+tbO9bXr9nPXCdcenGPemXlrfjVrAG/1csdQIBK2u4H7K/I+TG7H4YPrVi+swi3H+jzLtkYcpCMfud3b8+OMf7VRX1iv9q6ev2Wf/AI/yuPLt8/8AHrIceme/pj3pySsEJq32fhfRdgtLS+8+w26jq2fKi27Vtc42S4xlOnXGecZzzivMviZHNFqmmLPNcTH+z4irTiMEDc/A2ADb9efWvUra0VprMfZ5jujjOAkPOUkPGfp354OecV5f8UIhFq+nYRk3WEbfMEGcs/I29vrz61NZJRPXySd8attuiXmdzZaVpz2NwzadYFg18ATphyMTkDntgcA/wjg0a3pWnR6LqLx6dYK62t4ysumFSCDwQexHY/w9DWVrC3d74dubfRL86ReGW8f7UPD8twVUXBOAG+UE8DJzsBIwGwRieIj4ytvDTw6fe6DqU4t7iOeS98OXlozIODJvRmXf0x8qquTkjpT93lOB1K8ay0k1zPp5s7u+0fTAtxjTNPGJG6aYUx+5z36c847H5uled/tDaDHdfD+ey0fTrVb671S1toVgsTAzs5UBdx6Akj5fXmrOqeH9dv7641K98X6jZ3UQZbW10vw9JBaQubf5i6SK5lGQCA5BX5mXbnjkfiDr+u6d4w8F+GtYjtb+yn1nT7hdVTSJbOSZ4nUSxtAWO7O6JyFCjLcLyMN8tjknWrRp++pWaa189Do/hVdaRp3wj0XVvFttptjHZRPDdS3Wnk7PLlniAbPLMdijA5LYAGVxWV4a8Mj4keIbLxH4g02LTvDtnFby6Zo62TYvFaR1W4uhgBshdwUZDKyjJG7f0mhfD7wfaay1/eabc6tc3TtMP7T0ue5jgWUySNFHFt2bA+WBC7ssx3YzXW213bfb5HMD4NrZD/kEzk58yTOeO+evR+g6Gl7t0VGlXlFwqOVklprrrbtt5HF+CdI07QfH3inwzNBp0kFy8Ws6ZA+nu7RQvO0c0YGAscayKMRjs+Mk5x2dlpWnPY3DNp1gWDXwBOmHIxOQOe2BwD/CODWN4v0Kw8SfZ54pr/TNW06fzbG+ttImLQu0jqQVKkMhGNyH7wATsa5Swu/idFYugtvBbgfat0jabqO4t5h3HiMAEN06bRwcHij3blQdelFwSla6tZdLPQ9E1vStOj0XUXj06wV1tbxlZdMKkEHgg9iOx/h6Grd9o+mBbjGmaeMSN00wpj9znv055x2PzdK5DxE/ib+wNR+zXehyzG2usJJ4YvYFPzY/1nnNtwM4JBC9D61kar4y8eWU0ts/w2t78pjfeWMrwwu5hG7YssQdQMlsMOCM5I5LTjctVK1lfn69H5dkehXmk6auqWKrpunhWvirAaUcEfZnOCvpkA7fUbq574iaVp0fw81949PsVddFnYMun7SD9mmOc+uQDu9gf4TXIXV/8SLy6ttbk0zTrBoLwPD4bj02R2uB5Tl0knZMK2wfKEyCX3EKFzWd4s+JU6eFNZ0zxt4XfwxcX+kzx6czjz1u28p0xkAFWJkQ5wQepI2gMLl1M6taqqXv8yXL1Xr/AFqUPgpL4Y8F+HtWj8U6lpEayfYb6I30AZ2WS1hnkWNSSTtEgBC5LcYAyBXV6X4ZtvH3iu08Tz2os/C2nSo+k2a2RRdSYzN/pciAArH0CIxywUdASG1fD3gnwxo3iG7vBpsl1KbbSxD9t0aSZrUwgxL5ZKBlJEaEt/GwOMYwO0S9td0v+jyf6xP+YPOf+WzD0444x3Hy9RSjykxp1+RRldJW0s+y8jzm40+LSfifpcsOn2Mtj4hg1KxuI20zYsMtq80scoY9XKFowONqqM52gDu9b0rTo9F1F49OsFdbW8ZWXTCpBB4IPYjsf4ehrmvGXh6w8XeFJLCSS8sLq3urq9tLy10y4V4JkuGKMMYBwCRgn5MkHDAEYvjXwnqXibTHg8Q+IZG0u3e6vHtLHw7PZ/adpBjjkkLNiNWHf7o6nO0qvdsbL6xCu1FSacm123e/56I73xIvhvRbSa41ZNE0+BpzEstzZC3UsYCQoZsAE4yF65G7pVexn8La3fWkmhPoGoQC/KSNZ2QlTH2aQgEKTxkZ2+o3VWu/DXg6Pznj8KaUjrKxVk8MshGIcjB2fLzzjsfm6VJrOieGNQ122ub3w5p1xPJfYlkm8NyM0gFq2AcrluQPl68bugpvlsTCWKt1+F9+3oeeaRcWEfx0sbOGy0+6tL25vLVlNr5iRsmnWMjERjqwaIqfcsa9SttJ0438inTrAqLWyYA6YTyZJMn3JwMn+LGBXCH4a6Favo0nhC41Lw7fWW+e3lj0me8QSTx7ZGeOYNvykQAwQOSR0NWvDHj+zGuDSPGFpDoviF4LOKKF7CQx3+JpB5tufvMrgqcEBjkrglSafu3IhKrSclNtc1rb73XlvudJ4sbTfD3h3VNTTQbS+mgMYgtI9MO6eVrhkjjGAdu5iq9DwcdRXG+EvF2jQWcul/ESy0Hw74mRbqRoJ7QLFIjSAo0UpYocEtGBuJUxOCOOJTPB4x+Kgl8uVtA8KSgFV02VkuNQeQjDIAwIiQ9G2OrkAA9a6u40/QdVsWGr6La3xia/MZuNBkl2ZnPQlTtPA/3cYPNHu3KTxE7zhKVr22fZ36A0vhnV/D2qXWhNod8kVtdgzWVosgRhgr8yk7Tggg/wgjPWtq+0fTAtxjTNPGJG6aYUx+5z36c847H5ulctrHhjwcNIvzF4U0hJBa3ZVh4bZNpB4O4p8uOx/g6GseX4VfD60jvFtdDv4lkJicJHqSB1CCQK2X6b1VsHOCoboKS5blKWK5Vvu+/l/dO9vNJ01dUsVXTdPCtfFWA0o4I+zOcFfTIB2+o3VJbaPphls86Zp5zHHnOmFs/JJ1H8X1HXg/wmuEvfh74Z/tWzSBvEMNjJcSQXVmp1LyrpGtCo3hnLkgKFCqwO0nOUGBPqHw78A6x/Z0d34YijWOJADa6TdW5OUfJbytpkPyjk5z1HRsi5dRSliuRb7efd/wB08g8FXMl38d7SG4WGSGXW9StXjMCsjRRxRhFKAc48tOnJx6k19Jpo+mbpf+JZp/8ArE/5hhP/AC2Yfh6Y7j5eorw+6+H1z4T1jTPEHgs6lr+oafMt9NZapbS77s3OY5QJNgGQEBBbhizEEldp9J8G+O9N16a7sL2wk0vxDavGLvSprB5JYj5gLFdmcx/vFAYgbgVGBxlx5eouarCTg+ZXt37Ly+8d4jv/AA/4V8I6hrOr6faNbwSXaYTTBvYm52Iq7iBkZAHPygYNVtN1zwz4i0bVorTT7aw1m1tLt59MvNL8i9tcYKsyZJUYZSrjIXcBnNc79tXxd4+SxWwmXQPC9zfXc9wums6XV8Wby4vlyyGJZd2T91vlZeFJ7PxXpfh7VbC9uNQ0KzurtLO7SOa40CRmQBiVw7L8oBJwc4TJzS05TSM8RKteDbXM+/d9bfI3b7R9MC3GNM08YkbpphTH7nPfpzzjsfm6VHeaTpq6pYqum6eFa+KsBpRwR9mc4K+mQDt9RurDvvC/gwLcY8JaQMSN08Msn/LHPdOOecdj83Ss3xH4A8C6veWMVx4YtooxesrC00a5tCy/ZycfutpPKqdvJ6t0zQ+WxEZYq3X4X37f4TsrbR9MMtnnTNPOY4850wtn5JOo/i+o68H+E14I2ny3v7T9m7Wds2kae1tZFRagIDLYyTKGQcuSVlOe+PpXdH4U/D27uLRrrQr6ZmhhUtJHqTnaI2Cj7+SAEUDHGAMYAIrB1Sx8JfDTUvDl9punmx0+XU7E3bTQ3AC74L2MuzSk/Ku8MQMBwpxjBNNtGNZYmXvTulGz69/RHr6aPpm6X/iWaf8A6xP+YYT/AMtmH4emO4+XqKxr9dG0jwxquqX+n2Rgs49QlfGm/MQkzYVSSBnAAXJwvANReH/HvhPxBqN5ZaJqVpf3UJR2jt9OmkOzzj8wwOV+ZQcZ4ZV69eY8crH4ifSfCsCMLaa7vNS1UJprA/Y4bgsqFT82HlMSZTlPm3cBhQ+W5u6tX2blGT3SXrZrt3OK0lr7wLZR6v46vJL/AEzxJpMrrJcaZIf7JveXEKqPliVjIQCg4bjaoUmvS18afDW+huGtdY8Kgb8gPbrASGgBGA5BAywGOzZzyCB0mt3ds+i6iq27hja3gBOkzrg545IwMep4Xoat317ahbjFvIMSN00edMfuc9149cdj83ShctwhDEQikpStd9H5df66lC3i8P6rLpl5pEWjXlhPfMqzWun+ZFIBbyZAKkggMv3fUZ7VJdweH9KtoL3VYNGsrKOOIyz3NiEjXKuBuJwDkkDPc4x0rG1Dwn4MlvrWL/hFNJWN7xkcL4adCVNs/AAUHrg7RyCN3QUuneEvBUC6dCnhPTGRIIlBk8OSSsQEk5YlCXPAyxPzHnsaS5dRSliuRb/D5+f90n8Oz+F9dvLr+xn0LUYoLeyWT7LaLOI3MkmQxUkBiAM/3sYHSvNPFWn2g/ak8GWyWlosD2MjNELTYjYa76ofvdBx14C9RXct4Q8GXbXNvN4W00QTWVoh8vw/Ijjc8gYhlUMpIx84wWx8pyK434gaZ4Z8G6b4QTSbGHStPg8U2MtzNJYTJmNHuSTJJJ8zgAtwxJxwPumjQyxX1m3NK+jT69l5HqtlpWnPY3DNp1gWDXwBOmHIxOQOe2BwD/CODUHim10bTPDOrXtxZ6dbxQWd45l/s0qVweCD69h/d6daydE8c+GLqWLToboC/vYbu9tYX0e5ia4heVnSSPco3AoCysM7QG9Djnvjlcx6rpWi+HLTbG+qX0z3EUmnTQ+ba2+ZpAGKkggonTBXOCQNxB7vKdHt6kpc9KTfvO3a93bocl4Su7zwl4qjPxEj0+Cx8VW0moQtcwlIdNuArubVRKQY1CSxjkYDbAMhST7leaTpq6pYqum6eFa+KsBpRwR9mc4K+mQDt9Ruqv4ig0XVbWaDU9JhvIUnZ1juNClZVYQHBAZSFPJ9xnd0rJuvC/g7+0rMJ4T0cL9uIZf+EYYBl+zOcbdnIzg7euRu6Ch8tjOmsTBWTk1Z9+3ozorbR9MMtnnTNPOY4850wtn5JOo/i+o68H+E1Vt9J07+0JEbTrAqtrZHH9mlhkySAnPQk4GT/FjArjr74eeGbuRDo7674bmuhA80uh213bB9sbgAxgGM9ASVUEnJB+9mhpkvjDwxfPbW9pH4us5xZRw3F7ay2txaQ7pMeaVhPmqCMNIMu+eA3IVvluWp4hX5ubp3fX0OS+K+gZ+OfhC9tLOBNOt7nToLhY7QomZb24A3J/ECI2GPTC9jXtllpWnPY3DNp1gWDXwBOmHIxOQOe2BwD/CODXjOman4k8cSfEi2awGga8kmkRWttLZyyi0aK4eXlo4zj5izDKncCAMgV18lt4t1u3vILm+svDmm+ZcOP7J0m5urqVTIwljM0karFyfldU3JwDgggrS5zYeVZc8oqTvLouykM+Juvx2C3WieCvDVhrXiBYpzeCOw2R6bEcsJJXyArlVOxSQR3/hDdP4SvdC8XeD7TXbHTdMRLtSzxx6eSIZBCd8e4gfdcEdOo39KgsNF0Xw54Vv7XTbSZrh7O7E97caVMbi6cE/vJpSvzNlmO48JuI4FZfijR9S0rV9R1fwC1rby30pF7p2oaRdJaO/k5+0JsXdHL2IHD8O3K5IuW5uvrMUpNye+ln5eR2t5pOmrqliq6bp4Vr4qwGlHBH2Zzgr6ZAO31G6pLbR9MMtnnTNPOY4850wtn5JOo/i+o68H+E15pqfi/wAfWepWsMnw3s9TmguA/wBosnkihncwMCiJLGHAAYtgjqpPI5rorPXPFL/Y2PhbRFZoozskkvSfuP8AexZnJ65IyCQCCQDTXLqN1KzgtZbdn5+RvW2k6cb+RTp1gVFrZMAdMJ5MkmT7k4GT/FjAq2mj6Zul/wCJZp/+sT/mGE/8tmH4emO4+XqK80tdZ8d620qw+HtM8MM6W1vJPdW899OsW98TxIkewsSx4cgNsxipLL/hZGlvqNvHd+H9eiMiG2u9R0a7tpVPmgENHDFt28OMZycjnjYBOI6tWvd2U+nTyR5rpunJL+1LqJNtE1lFdXERQ252KTZzFRs/h+4cA9MZ7GvobW9K06PRdRePTrBXW1vGVl0wqQQeCD2I7H+Hoa+c9Fn1PWw3jDR9OvrnULjxJay31vptpIRFHHbfvlGflVc3Dpy3AIycEGvRNVXxZ410+dfENifCehpa3TT6fa20s1zeOGB2STCMLHF/DlWyF3K3DDC05dTOhOoqrdO7vNvTbV9XZjNY8Tanq9xrl/8AD/wt4a1rw1pVyIXnS1YTXzCIGZbcAYXYCTzu3HDLu6V6Jp58O64mj6lokOk3enXd4THNDpZKOv2Z8gjrww5Q8hhk4xirQ/svTbKW107TltLaOR9kVvok0KJmEscALheSTj1+bpXnkdlrHg/4iQQ+G9Div/Buoaksxthp0sLabK0W2UorjLRlXeQRLnlPlCD74+WwU3iYWcnJ3T6PTT0/rc9LttH0wy2edM085jjznTC2fkk6j+L6jrwf4TXm3xItoLXVNPS1ghgRrGNisVv5QJ3Nyf7x/wBrvXpNte2plswbeQ5jjznR52z8knUY+b6jrwf4TXm3xIljl1TT2iRkH2GPObZ4CTubnDD5v94cGpq25dD28m9r9cXM3a3X5+R6Tp7N9guP3Uw+e/8A+Ws3/PdvVe3fPB/iwaNeZv7C1P8AdTf8el51lm9f93t3zwf4sGqtjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxSa3PdHRdRDx2AU2t4CV1WRjyew2cn0H8XU1d/dPMVJ+2Tt9p9V3fma98xK3H7qYZkbrLMcfufdfx55xx93mq+ogPq+ls9tKzR6izJmWclT9kkHB25BwTz1wSPu81HfXF4VuMRaecyNjGrSvn9zjvHz6Z7n5elR3lxc/2pYFk08f6cSuNYlIP+jOOW8vgdfm65+XpzTb0MYUXbVfZfVdvU0LZm86z/dTH93H0lmGfkk6YXj8Mjg44JxTtWb+0pf3Ux/0Sx/5azf89Zf9nv2xwP4cmi2uLwS2eYtPGI4851aVcfJJ1Pl/L9B0yB/EaqW090L+T93Yb/stkCDqsgAxJJ/sdeuR/D1Gc0N6lqk/e06Lqu/qa6Md0v7qb/WJ/wAtZv8Ans3+z+HPOeR82RVPT2b7Bcfuph89/wD8tZv+e7eq9u+eD/Fg0JcXm6X91p/+sT/mLSj/AJbMf+efPHOew+bqaq2NxdfYZwkdgw3X3XVZM5M7cY2c98D+McnFF9RKk7PTquq7PzLWvM39han+6m/49LzrLN6/7vbvng/xYNXL5iVuP3UwzI3WWY4/c+6/jzzjj7vNZGtz3R0XUQ8dgFNreAldVkY8nsNnJ9B/F1NW764vCtxiLTzmRsY1aV8/ucd4+fTPc/L0oT1BUnyrTrLqvLzJ752/tXTv3E//AB/njzrjP/HrJx93Oe+euOMY5rJ8SeGNH8XWNhp3iLTJL+yQwzCJri5QFxHKAcoAejHgZHpnki3eXFz/AGpYFk08f6cSuNYlIP8AozjlvL4HX5uufl6c061u7rzLNhHp5ASNSRq0owQsgIJEfy4PBHbp3NCa1InRvTSa+z3Xd+Y61Zv7Sl/dTH/RLH/lrN/z1l/2e/bHA/hyauIx3S/upv8AWJ/y1m/57N/s/hzznkfNkVkW090L+T93Yb/stkCDqsgAxJJ/sdeuR/D1Gc1bS4vN0v7rT/8AWJ/zFpR/y2Y/88+eOc9h83U0Jl1aTu9O3Vdl5hp7N9guP3Uw+e//AOWs3/PdvVe3fPB/iwaNeZv7C1P91N/x6XnWWb1/3e3fPB/iwaq2NxdfYZwkdgw3X3XVZM5M7cY2c98D+McnFJrc90dF1EPHYBTa3gJXVZGPJ7DZyfQfxdTSv7poqT9snb7T6ru/M175iVuP3UwzI3WWY4/c+6/jzzjj7vNRXzt/aunfuJ/+P88edcZ/49ZOPu5z3z1xxjHNQX1xeFbjEWnnMjYxq0r5/c47x8+me5+XpUd5cXP9qWBZNPH+nErjWJSD/ozjlvL4HX5uufl6c029DGnSdtvsvqu3qaFszedZ/upj+7j6SzDPySdMLx+GRwccE4xL7SdO1u5e21nSYNRt1trF1julklQNvmG4KyEAkMwGOmTtzkir9tcXgls8xaeMRx5zq0q4+STqfL+X6DpkD+I1Utp7oX8n7uw3/ZbIEHVZABiST/Y69cj+HqM5ob1KVJ+9p0XVd/Us6Lpen6LbzW2j6VDYWxmRzFarJEm7zWGcKgGcADJ5445yA7T2b7Bcfuph89//AMtZv+e7eq9u+eD/ABYNCXF5ul/daf8A6xP+YtKP+WzH/nnzxznsPm6mqtjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxRfUFSfK9Oq6rs/Mta8zf2Fqf7qb/j0vOss3r/ALvbvng/xYNXL5iVuP3UwzI3WWY4/c+6/jzzjj7vNZGtz3R0XUQ8dgFNreAldVkY8nsNnJ9B/F1NW764vCtxiLTzmRsY1aV8/ucd4+fTPc/L0oT1BUnyrTrLqvLzJ752/tXTv3E//H+ePOuM/wDHrJx93Oe+euOMY5qW2ZvOs/3Ux/dx9JZhn5JOmF4/DI4OOCcZ95cXP9qWBZNPH+nErjWJSD/ozjlvL4HX5uufl6c1JbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNCe5MqT5Fp9nuu78wtWb+0pf3Ux/0Sx/5azf89Zf9nv2xwP4cmuc8aeCbfxNqNjqttLd6Vr+m3CNa6nbGRpUQzPujYMhDKQSMHocnB3OjbFtPdC/k/d2G/wCy2QIOqyADEkn+x165H8PUZzVtLi83S/utP/1if8xaUf8ALZj/AM8+eOc9h83U0Jqw61HmbTXbquy8zM8G6PbaD4eltLSK6di9809zNNM01zJ5xDSytsG9ztGScA4GduAK09eZv7C1P91N/wAel51lm9f93t3zwf4sGqtjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxSa3PdHRdRDx2AU2t4CV1WRjyew2cn0H8XU0r+6aRo8tVJLRS7ru/M175iVuP3UwzI3WWY4/c+6/jzzjj7vNRXzt/aunfuJ/+P88edcZ/49ZOPu5z3z1xxjHNQX1xeFbjEWnnMjYxq0r5/c47x8+me5+XpUd5cXP9qWBZNPH+nErjWJSD/ozjlvL4HX5uufl6c029DKnSdtvsvqu3qaFszedZ/upj+7j6SzDPySdMLx+GRwccE48f/aOsPtvw41WdlK/YYNOuAXEr5zLLHxnAX/WHnkYBA+8SPVLa4vBLZ5i08YjjznVpVx8knU+X8v0HTIH8Rrgfi1p2p+IPA+taTYwWj3l3a6ZCqJqLvj/SjyVKAYHJYHAQDdnrRJkVqT9lU06Lqu/qWdC+H9jceCfDNpqlheafrOk2McMVzY3U1vNZTSErMyGMbdxYHJO4E5PzEsKv+DPCq6TfaxrV5e6lquqXiXVsbi8YjyokuHwqBIl2gk7nH3Wb5iEPFdMlxebpf3Wn/wCsT/mLSj/lsx/5588c57D5upqrY3F19hnCR2DDdfddVkzkztxjZz3wP4xycUXVyo4ayvbW66rs/Mta8zf2Fqf7qb/j0vOss3r/ALvbvng/xYNXL1223H7mUfvG+9LMcfue+5efXnnHH3eayNbnujouoh47AKbW8BK6rIx5PYbOT6D+Lqat31xeFbjEWnnMjYxq0r5/c47x8+me5+XpQnqWqT5UrdZdV5eZPfO39q6d+4n/AOP88edcZ/49ZOPu5z3z1xxjHNS2zN51n+6mP7uPpLMM/JJ0wvH4ZHBxwTjPvLi5/tSwLJp4/wBOJXGsSkH/AEZxy3l8Dr83XPy9Oaktri8EtnmLTxiOPOdWlXHySdT5fy/QdMgfxGhPcmVJ8i0+z3Xd+YWrN/aUv7qY/wCiWP8Ay1m/56y/7Pftjgfw5NeUftTWVzefDRpoIJDFZ6jFPOxeQhEJnjBO4D+KRR6/iWx6ZbT3Qv5P3dhv+y2QIOqyADEkn+x165H8PUZzWF8S9C1Pxf4H1vQbR9JtprwwhJZtUlZF23W8kjy/mGB+obuaL6EYyjJwlZdF1XZeYqeCdFvfBdpo1zYSvHpiXcNjd+ZKLi0KTYWSJ9g2OCikkYBI+b0rA0fwVrthc6hqnjDVF12TT9GuLHTLjE6OMlzLNIrKQJSGCblb5lzv+YnPeWNxdfYZwkdgw3X3XVZM5M7cY2c98D+McnFJrc90dF1EPHYBTa3gJXVZGPJ7DZyfQfxdTS05Tb6sniFK32u67vzNe+Ylbj91MMyN1lmOP3Puv48844+7zUV87f2rp37if/j/ADx51xn/AI9ZOPu5z3z1xxjHNQX1xeFbjEWnnMjYxq0r5/c47x8+me5+XpUd5cXP9qWBZNPH+nErjWJSD/ozjlvL4HX5uufl6c029CKdJ22+y+q7epoWzN51n+6mP7uPpLMM/JJ0wvH4ZHBxwTinas39pS/upj/olj/y1m/56y/7Pftjgfw5NFtcXgls8xaeMRx5zq0q4+STqfL+X6DpkD+I1Utp7oX8n7uw3/ZbIEHVZABiST/Y69cj+HqM5ob1LVJ+9p0XVd/Uu2lla219qF3b6esV1dyxG4mj81XmKysF3sFyxA+UFuRjjnIpuns32C4/dTD57/8A5azf8929V7d88H+LBoS4vN0v7rT/APWJ/wAxaUf8tmP/ADz545z2HzdTVWxuLr7DOEjsGG6+66rJnJnbjGznvgfxjk4ovqJUnyvTquq7PzLWvM39han+6m/49LzrLN6/7vbvng/xYNXL5iVuP3UwzI3WWY4/c+6/jzzjj7vNZGtz3R0XUQ8dgFNreAldVkY8nsNnJ9B/F1NW764vCtxiLTzmRsY1aV8/ucd4+fTPc/L0oT1BUnyrTrLqvLzJ752/tXTv3E//AB/njzrjP/HrJx93Oe+euOMY5qW2ZvOs/wB1Mf3cfSWYZ+STphePwyODjgnGfeXFz/algWTTx/pxK41iUg/6M45by+B1+brn5enNSW1xeCWzzFp4xHHnOrSrj5JOp8v5foOmQP4jQnuTKk+RafZ7ru/MLVm/tKX91Mf9Esf+Ws3/AD1l/wBnv2xwP4cmriMd0v7qb/WJ/wAtZv8Ans3+z+HPOeR82RWRbT3Qv5P3dhv+y2QIOqyADEkn+x165H8PUZzVtLi83S/utP8A9Yn/ADFpR/y2Y/8APPnjnPYfN1NCZVWk7vTt1XZeZR8OaXZ6XZ6s9hZSwtfXmoXdwfOuD5krTbS5yMdEUEcA4+bBq9rzN/YWp/upv+PS86yzev8Au9u+eD/Fg1Vsbi6+wzhI7BhuvuuqyZyZ24xs574H8Y5OKTW57o6LqIeOwCm1vASuqyMeT2Gzk+g/i6mlf3S40eWqklpzPqu78zXvmJW4/dTDMjdZZjj9z7r+PPOOPu81FfO39q6d+4n/AOP88edcZ/49ZOPu5z3z1xxjHNQX1xeFbjEWnnMjYxq0r5/c47x8+me5+XpUd5cXP9qWBZNPH+nErjWJSD/ozjlvL4HX5uufl6c029DKnSdtvsvqu3qaFszedZ/upj+7j6SzDPySdMLx+GRwccE48v8AigSdX07Ksv8AoEf3mc5+Z+RuAwPYcehr0S2uLwS2eYtPGI4851aVcfJJ1Pl/L9B0yB/Ea83+JDyPqmnmZYVcWMYxFctMPvN1JA2n/ZHAqKz909bJYOOMTfbun38z0jT55DYXAN5CcvfjHnoc5nbI+536j17belGvTyHQtTH2yE5tLwY89Ocnkfc79R69tvSo7K1vWsLg/btVUZ1AEbbbH+vO4n5M9eWx3+7xRrlrerompM1/qrKLS9JVltsEZ5BwmceuOf7tVf3djzVGHtlrH4n37vyNC+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmor65l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5o1G0vtlzu1HVv9a2d62vX7OeuE649OMe9MvLW/GrWAN/q5Y6gQCVtdwP2V+R8mN2PwwfWhvTYxhGFt4/C+/b0LFtPIJrMi8hXbHGATOg24STg/JxjOOc4yOuQRTtZ5BqUoF5CMWliMeenGJZcD7nbqfTvu6VPaWl959ht1HVs+VFt2ra5xslxjKdOuM84znnFVLW1vftzqL7VeLSwO4LbcjzZNo5Tpnp3yTu4xTb12KUYe9rHZd/5vQ0Enk3S/wCmQjMiH/Xpz++Y5+568/Q55BwKenzyGwuAbyE5e/GPPQ5zO2R9zv1Hr229KnjtL7fP/wATHVv9bHnC2vX7Q/X5Ouc+2c54xVSytb1rC4P27VVGdQBG22x/rzuJ+TPXlsd/u8UX12BRhZ6x3Xfs/Ik16eQ6FqY+2QnNpeDHnpzk8j7nfqPXtt6Vcvp5GW4zeQvmRjxOhz+5xnhBnjjtzx15rP1y1vV0TUma/wBVZRaXpKsttgjPIOEzj1xz/dq3qNpfbLndqOrf61s71tev2c9cJ1x6cY96E9dgUYcq1jvLv5eQX1zL/aunn7fBn7eTu+0JjP2WQZz5fTtnGM8YzzUttPIJrMi8hXbHGATOg24STg/JxjOOc4yOuQRXvLW/GrWAN/q5Y6gQCVtdwP2V+R8mN2PwwfWn2lpfefYbdR1bPlRbdq2ucbJcYynTrjPOM55xST30JlGHItY/D5935EFrPINSlAvIRi0sRjz04xLLgfc7dT6d93SriTybpf8ATIRmRD/r05/fMc/c9efoc8g4Gfa2t79udRfarxaWB3BbbkebJtHKdM9O+Sd3GKtx2l9vn/4mOrf62POFtev2h+vydc59s5zximn5FVYwu9Y9O/ZeRBp88hsLgG8hOXvxjz0Ocztkfc79R69tvSjXp5DoWpj7ZCc2l4MeenOTyPud+o9e23pUdla3rWFwft2qqM6gCNttj/XncT8mevLY7/d4o1y1vV0TUma/1VlFpekqy22CM8g4TOPXHP8AdpX93Y0UYe2Wsfiffu/I0L6eRluM3kL5kY8Toc/ucZ4QZ447c8deaivrmX+1dPP2+DP28nd9oTGfssgzny+nbOMZ4xnmjUbS+2XO7UdW/wBa2d62vX7OeuE649OMe9MvLW/GrWAN/q5Y6gQCVtdwP2V+R8mN2PwwfWhvTYxhGFt4/C+/b0LFtPIJrMi8hXbHGATOg24STg/JxjOOc4yOuQRTtZ5BqUoF5CMWliMeenGJZcD7nbqfTvu6VPaWl959ht1HVs+VFt2ra5xslxjKdOuM84znnFVLW1vftzqL7VeLSwO4LbcjzZNo5Tpnp3yTu4xTb12KUYe9rHZd/wCb0NBJ5N0v+mQjMiH/AF6c/vmOfuevP0OeQcCnp88hsLgG8hOXvxjz0Ocztkfc79R69tvSp47S+3z/APEx1b/Wx5wtr1+0P1+TrnPtnOeMVUsrW9awuD9u1VRnUARttsf687ifkz15bHf7vFF9dgUYWesd137PyJNenkOhamPtkJzaXgx56c5PI+536j17belXL6eRluM3kL5kY8Toc/ucZ4QZ447c8deaz9ctb1dE1Jmv9VZRaXpKsttgjPIOEzj1xz/dq3qNpfbLndqOrf61s71tev2c9cJ1x6cY96E9dgUYcq1jvLv5eQX1zL/aunn7fBn7eTu+0JjP2WQZz5fTtnGM8YzzUttPIJrMi8hXbHGATOg24STg/JxjOOc4yOuQRXvLW/GrWAN/q5Y6gQCVtdwP2V+R8mN2PwwfWn2lpfefYbdR1bPlRbdq2ucbJcYynTrjPOM55xST30JlGHItY/D5935EFrPINSlAvIRi0sRjz04xLLgfc7dT6d93SriTybpf9MhGZEP+vTn98xz9z15+hzyDgZ9ra3v251F9qvFpYHcFtuR5sm0cp0z075J3cYq3HaX2+f8A4mOrf62POFtev2h+vydc59s5zximn5FVYwu9Y9O/ZeRBp88hsLgG8hOXvxjz0Ocztkfc79R69tvSjXp5DoWpj7ZCc2l4MeenOTyPud+o9e23pUdla3rWFwft2qqM6gCNttj/AF53E/Jnry2O/wB3ijXLW9XRNSZr/VWUWl6SrLbYIzyDhM49cc/3aV/d2NFGHtlrH4n37vyNC+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmor65l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5o1G0vtlzu1HVv9a2d62vX7OeuE649OMe9MvLW/GrWAN/q5Y6gQCVtdwP2V+R8mN2PwwfWhvTYxhGFt4/C+/b0LFtPIJrMi8hXbHGATOg24STg/JxjOOc4yOuQRTtZ5BqUoF5CMWliMeenGJZcD7nbqfTvu6VPaWl959ht1HVs+VFt2ra5xslxjKdOuM84znnFVLW1vftzqL7VeLSwO4LbcjzZNo5Tpnp3yTu4xTb12KUYe9rHZd/5vQ0Enk3S/wCmQjMiH/Xpz++Y5+568/Q55BwKenzyGwuAbyE5e/GPPQ5zO2R9zv1Hr229KnjtL7fP/wATHVv9bHnC2vX7Q/X5Ouc+2c54xVSytb1rC4P27VVGdQBG22x/rzuJ+TPXlsd/u8UX12BRhZ6x3Xfs/Ik16eQ6FqY+2QnNpeDHnpzk8j7nfqPXtt6Vcvp5GW4zeQvmRjxOhz+5xnhBnjjtzx15rP1y1vV0TUma/wBVZRaXpKsttgjPIOEzj1xz/dq3qNpfbLndqOrf61s71tev2c9cJ1x6cY96E9dgUYcq1jvLv5eQX1zL/aunn7fBn7eTu+0JjP2WQZz5fTtnGM8YzzUttPIJrMi8hXbHGATOg24STg/JxjOOc4yOuQRXvLW/GrWAN/q5Y6gQCVtdwP2V+R8mN2PwwfWn2lpfefYbdR1bPlRbdq2ucbJcYynTrjPOM55xST30JlGHItY/D5935EFrPINSlAvIRi0sRjz04xLLgfc7dT6d93SriTybpf8ATIRmRD/r05/fMc/c9efoc8g4Gfa2t79udRfarxaWB3BbbkebJtHKdM9O+Sd3GKtx2l9vn/4mOrf62POFtev2h+vydc59s5zximn5FVYwu9Y9O/ZeRBp88hsLgG8hOXvxjz0Ocztkfc79R69tvSjXp5DoWpj7ZCc2l4MeenOTyPud+o9e23pUdla3rWFwft2qqM6gCNttj/XncT8mevLY7/d4o1y1vV0TUma/1VlFpekqy22CM8g4TOPXHP8AdpX93Y0UYe2Wsfiffu/I0L6eRluM3kL5kY8Toc/ucZ4QZ447c8deaivrmX+1dPP2+DP28nd9oTGfssgzny+nbOMZ4xnmjUbS+2XO7UdW/wBa2d62vX7OeuE649OMe9MvLW/GrWAN/q5Y6gQCVtdwP2V+R8mN2PwwfWhvTYxhGFt4/C+/b0LFtPIJrMi8hXbHGATOg24STg/JxjOOc4yOuQRTtZ5BqUoF5CMWliMeenGJZcD7nbqfTvu6VPaWl959ht1HVs+VFt2ra5xslxjKdOuM84znnFVLW1vftzqL7VeLSwO4LbcjzZNo5Tpnp3yTu4xTb12KUYe9rHZd/wCb0NBJ5N0v+mQjMiH/AF6c/vmOfuevP0OeQcCnp88hsLgG8hOXvxjz0Ocztkfc79R69tvSp47S+3z/APEx1b/Wx5wtr1+0P1+TrnPtnOeMVUsrW9awuD9u1VRnUARttsf687ifkz15bHf7vFF9dgUYWesd137PyJNenkOhamPtkJzaXgx56c5PI+536j17belXL6eRluM3kL5kY8Toc/ucZ4QZ447c8deaz9ctb1dE1Jmv9VZRaXpKsttgjPIOEzj1xz/dq3qNpfbLndqOrf61s71tev2c9cJ1x6cY96E9dgUYcq1jvLv5eQX1zL/aunn7fBn7eTu+0JjP2WQZz5fTtnGM8YzzUttPIJrMi8hXbHGATOg24STg/JxjOOc4yOuQRXvLW/GrWAN/q5Y6gQCVtdwP2V+R8mN2PwwfWn2lpfefYbdR1bPlRbdq2ucbJcYynTrjPOM55xST30JlGHItY/D5935EFrPINSlAvIRi0sRjz04xLLgfc7dT6d93SriTybpf9MhGZEP+vTn98xz9z15+hzyDgZ9ra3v251F9qvFpYHcFtuR5sm0cp0z075J3cYq3HaX2+f8A4mOrf62POFtev2h+vydc59s5zximn5FVYwu9Y9O/ZeRBp88hsLgG8hOXvxjz0Ocztkfc79R69tvSjXp5DoWpj7ZCc2l4MeenOTyPud+o9e23pUdla3rWFwft2qqM6gCNttj/AF53E/Jnry2O/wB3ijXLW9XRNSZr/VWUWl6SrLbYIzyDhM49cc/3aV/d2NFGHtlrH4n37vyNC+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmor65l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5o1G0vtlzu1HVv9a2d62vX7OeuE649OMe9MvLW/GrWAN/q5Y6gQCVtdwP2V+R8mN2PwwfWhvTYxhGFt4/C+/b0LFtPIJrMi8hXbHGATOg24STg/JxjOOc4yOuQR5f8UHL6vp26VZNthGBtcNtG5+DgDB9uT7mvS7S0vvPsNuo6tnyotu1bXONkuMZTp1xnnGc84rzL4mRzRappizzXEx/s+Iq04jBA3PwNgA2/Xn1qar93Y9fJIxWNVmtunz8j0bT7RRYXB+zzDD35yUh42zsO3p3xyP4eKNetFGhamfs8wxaXhzsh42nHb079x/DxVSy0rTnsbhm06wLBr4AnTDkYnIHPbA4B/hHBrjfFni/wxpdn41gfRkE/h+FUuHj0yMZa5YCIxkuCNu4csF29BuNVd8p50qkIVeaUre8+nr5npN9ZhFuP9HmXbIw5SEY/c7u358cY/wBqor6xX+1dPX7LP/x/lceXb5/49ZDj0z39Me9c7Fd6BqPiTxJodvpFsl3o7Qmd20sIjCa2Z12ckjG05BAwfmGRmte80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdTbdjOlKDV1J/C/s+XqaFtaK01mPs8x3RxnASHnKSHjP0788HPOKp2toDqUp+zzHNpYnISHndLKO/r27n+Lii20fTDLZ50zTzmOPOdMLZ+STqP4vqOvB/hNVLbSdON/Ip06wKi1smAOmE8mSTJ9ycDJ/ixgUNu5Scfe1ey+z5+prpaAtL/AKPMcSIPuQ8ZmYf0xxxkc/Liqen2iiwuD9nmGHvzkpDxtnYdvTvjkfw8UJo+mbpf+JZp/wDrE/5hhP8Ay2Yfh6Y7j5eoqpZaVpz2NwzadYFg18ATphyMTkDntgcA/wAI4NF3cE48r1e6+z5PzLevWijQtTP2eYYtLw52Q8bTjt6d+4/h4q5fWYRbj/R5l2yMOUhGP3O7t+fHGP8AarI1vStOj0XUXj06wV1tbxlZdMKkEHgg9iOx/h6Grd9o+mBbjGmaeMSN00wpj9znv055x2PzdKE3cE48q1e8vs+nmT31iv8Aaunr9ln/AOP8rjy7fP8Ax6yHHpnv6Y96ltrRWmsx9nmO6OM4CQ85SQ8Z+nfng55xWfeaTpq6pYqum6eFa+KsBpRwR9mc4K+mQDt9RuqS20fTDLZ50zTzmOPOdMLZ+STqP4vqOvB/hNCb1Jk48i1fw/y+b8wtbQHUpT9nmObSxOQkPO6WUd/Xt3P8XFXEtAWl/wBHmOJEH3IeMzMP6Y44yOflxWRbaTpxv5FOnWBUWtkwB0wnkySZPuTgZP8AFjAq2mj6Zul/4lmn/wCsT/mGE/8ALZh+HpjuPl6ihNlVXG71fT7PkvMNPtFFhcH7PMMPfnJSHjbOw7enfHI/h4o160UaFqZ+zzDFpeHOyHjacdvTv3H8PFVLLStOexuGbTrAsGvgCdMORicgc9sDgH+EcGqPiF/Ddql3prf2JDq8lleSwWpswk7AbiGVc7uAj4YD5drA9DSu+U0Tj7Zav4n9nzfmdLfWYRbj/R5l2yMOUhGP3O7t+fHGP9qor6xX+1dPX7LP/wAf5XHl2+f+PWQ49M9/THvXmr/ELwfc6HpmpxaEVg1aLULmBRpUQZEtIGMgbEhAJwdoBPPzErXReHbvT/Ef9lX0Xhf+zrK6uEmha60yEi4je1kYYWKRzjhW2tg/MG55AG3Y56VSm9FL7L+z5ep1ttaK01mPs8x3RxnASHnKSHjP0788HPOKp2toDqUp+zzHNpYnISHndLKO/r27n+Lii20fTDLZ50zTzmOPOdMLZ+STqP4vqOvB/hNVLbSdON/Ip06wKi1smAOmE8mSTJ9ycDJ/ixgU23c0Tj72r2X2fP1NdLQFpf8AR5jiRB9yHjMzD+mOOMjn5cVT0+0UWFwfs8ww9+clIeNs7Dt6d8cj+HihNH0zdL/xLNP/ANYn/MMJ/wCWzD8PTHcfL1FVLLStOexuGbTrAsGvgCdMORicgc9sDgH+EcGi7uCceV6vdfZ8n5lvXrRRoWpn7PMMWl4c7IeNpx29O/cfw8VcvrMItx/o8y7ZGHKQjH7nd2/PjjH+1WRreladHouovHp1grra3jKy6YVIIPBB7Edj/D0NW77R9MC3GNM08YkbpphTH7nPfpzzjsfm6UJu4Jx5Vq95fZ9PMnvrFf7V09fss/8Ax/lceXb5/wCPWQ49M9/THvUttaK01mPs8x3RxnASHnKSHjP0788HPOKz7zSdNXVLFV03TwrXxVgNKOCPsznBX0yAdvqN1SW2j6YZbPOmaecxx5zphbPySdR/F9R14P8ACaE3qTJx5Fq/h/l835ha2gOpSn7PMc2lichIed0so7+vbuf4uKuJaAtL/o8xxIg+5DxmZh/THHGRz8uKyLbSdON/Ip06wKi1smAOmE8mSTJ9ycDJ/ixgVbTR9M3S/wDEs0//AFif8wwn/lsw/D0x3Hy9RQmyqrjd6vp9nyXmGn2iiwuD9nmGHvzkpDxtnYdvTvjkfw8Ua9aKNC1M/Z5hi0vDnZDxtOO3p37j+HiqllpWnPY3DNp1gWDXwBOmHIxOQOe2BwD/AAjg0a3pWnR6LqLx6dYK62t4ysumFSCDwQexHY/w9DSu+U0Tj7Zav4n9nzfma99ZhFuP9HmXbIw5SEY/c7u358cY/wBqor6xX+1dPX7LP/x/lceXb5/49ZDj0z39Me9c74iu9A0zxJpehzaRbG71d7o27x6WFRBDbB23ZOV+8MAA8/McDGeSn8f+H5dF0TxHZ+D7ufSb6+8qIw6XbFpZCskQgEfn7mcuoYIMjGGzkFQ23Y541aaWsvsv7Pl6+Z6pbWitNZj7PMd0cZwEh5ykh4z9O/PBzzisPR7zT9Q8SavYWomlu9Ot9OS6QQxDy2lLuvJHO5WBBBPo3pVzTtL06ZdOkk0eyhaSGJmik0wMykpISG2khj6lSQSMg4WuA8BabYSfFP4jRyWNm8cf9i7FawLhcwc4HbPf+/2603e4p1VGSSe9l8Pq+/kenpaAtL/o8xxIg+5DxmZh/THHGRz8uKp6faKLC4P2eYYe/OSkPG2dh29O+OR/DxQmj6Zul/4lmn/6xP8AmGE/8tmH4emO4+XqKqWWlac9jcM2nWBYNfAE6YcjE5A57YHAP8I4NK7uapx5Xq919nyfmW9etFGhamfs8wxaXhzsh42nHb079x/DxVy+swi3H+jzLtkYcpCMfud3b8+OMf7VZGt6Vp0ei6i8enWCutreMrLphUgg8EHsR2P8PQ1bvtH0wLcY0zTxiRummFMfuc9+nPOOx+bpQm7gnHlWr3l9n08ye+sV/tXT1+yz/wDH+Vx5dvn/AI9ZDj0z39Me9S21orTWY+zzHdHGcBIecpIeM/Tvzwc84rPvNJ01dUsVXTdPCtfFWA0o4I+zOcFfTIB2+o3VJbaPphls86Zp5zHHnOmFs/JJ1H8X1HXg/wAJoTepMnHkWr+H+XzfmFraA6lKfs8xzaWJyEh53Syjv69u5/i4rjvBM11dfFH4k2M7XUtpZXOmiCFvLZYN6HcADwuSBwvyk9eK6a20nTjfyKdOsCotbJgDphPJkkyfcnAyf4sYFeeeCU0ofHH4j6VNY2jSObCeFGsN6oiBVfA/gyZV+Xv060JsnEyipx1e66f3fU9O0+0UWFwfs8ww9+clIeNs7Dt6d8cj+HijXrRRoWpn7PMMWl4c7IeNpx29O/cfw8VUstK057G4ZtOsCwa+AJ0w5GJyBz2wOAf4RwaNb0rTo9F1F49OsFdbW8ZWXTCpBB4IPYjsf4ehpXfKdCcfbLV/E/s+b8zXvrMItx/o8y7ZGHKQjH7nd2/PjjH+1UV9Yr/aunr9ln/4/wArjy7fP/HrIceme/pj3qC+0fTAtxjTNPGJG6aYUx+5z36c847H5ulcXP4q8MPeW8kejRrGnis+HXX+yVAafyWXON/Me4g7fvZGdueKbbsc6qU4JOUuj+z5ep6BbWitNZj7PMd0cZwEh5ykh4z9O/PBzziqdraA6lKfs8xzaWJyEh53Syjv69u5/i4rn/CeoaH4j1BRpegxTaZEBGuqHTEa2uHRWDCPD75PmLDeF2kxtg/Lzq22k6cb+RTp1gVFrZMAdMJ5MkmT7k4GT/FjAobd0aRlBqTUnsvs/wB71NdLQFpf9HmOJEH3IeMzMP6Y44yOflxVPT7RRYXB+zzDD35yUh42zsO3p3xyP4eK5vw9faZq3jHxboZ0HTohok9monFjv84TFn+7j5MfdwSSwwOMVs2Wlac9jcM2nWBYNfAE6YcjE5A57YHAP8I4NF3cUZQcXaT+L+XyfmW9etFGhamfs8wxaXhzsh42nHb079x/DxVy+swi3H+jzLtkYcpCMfud3b8+OMf7VZGt6Vp0ei6i8enWCutreMrLphUgg8EHsR2P8PQ1bvtH0wLcY0zTxiRummFMfuc9+nPOOx+bpQm7jTjyrV7y+z6eZPfWK/2rp6/ZZ/8Aj/K48u3z/wAeshx6Z7+mPepba0VprMfZ5jujjOAkPOUkPGfp354OecVn3mk6auqWKrpunhWvirAaUcEfZnOCvpkA7fUbqkttH0wy2edM085jjznTC2fkk6j+L6jrwf4TQm9SZOPItX8P8vm/MLW0B1KU/Z5jm0sTkJDzullHf17dz/FxVxLQFpf9HmOJEH3IeMzMP6Y44yOflxWRbaTpxv5FOnWBUWtkwB0wnkySZPuTgZP8WMCraaPpm6X/AIlmn/6xP+YYT/y2Yfh6Y7j5eooTZVVxu9X0+z5LzDT7RRYXB+zzDD35yUh42zsO3p3xyP4eKNetFGhamfs8wxaXhzsh42nHb079x/DxXG+EtV0/WfFPjPQH0HTo/wCwWcLc/ZN7TeazsPlxmPYBtBJOBXT63pWnR6LqLx6dYK62t4ysumFSCDwQexHY/wAPQ0rvlLUousve+0/s+b8zXvrMItx/o8y7ZGHKQjH7nd2/PjjH+1UV9Yr/AGrp6/ZZ/wDj/K48u3z/AMeshx6Z7+mPeoL7R9MC3GNM08YkbpphTH7nPfpzzjsfm6VHeaTpq6pYqum6eFa+KsBpRwR9mc4K+mQDt9RuptuxlTcbbv4X9ny9TQtrRWmsx9nmO6OM4CQ85SQ8Z+nfng55xXl/xQiEWr6dhGTdYRt8wQZyz8jb2+vPrXolto+mGWzzpmnnMcec6YWz8knUfxfUdeD/AAmvNviRbQWuqaelrBDAjWMbFYrfygTubk/3j/td6itflPWyVr64rPp2t38zvrG7tksbgG3fO6+OV0mf/nu2OccEev8AB0PNefeMvAVtqlt4/uV1K6iPiGKKQIdEnC232RlIAJIGH24JOAgODmvTNPZvsFx+6mHz3/8Ay1m/57t6r2754P8AFg0a8zf2Fqf7qb/j0vOss3r/ALvbvng/xYNVrynmThCpV5ZJ/E+q812Ods9GtdL8X+LNeEk8n9sNbr9nGiTxiDybVl4Jz97dnGBjAPIrevLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpWhfMStx+6mGZG6yzHH7n3X8eeccfd5qprN5FZ3VrdXm6C2gvHlllluJ0WNVtJCSzFeAACSTzj/Z5ptOxnSUYqyT2l1Xb0Etr21MtmDbyHMcec6PO2fkk6jHzfUdeD/Ca8y1D4ni3nvNW0PwzLrPhy0hs0u9RitXT5FebzJYQV2yopUozF03EYHyguL9hJqHxP+zyxyXNh4GbbbmFGl+0awiiQOS4BMMLEFdoG9lD/dDcdbBo9g+nzaE9jK2ktpNlZGAz3GDDulTbnGcFeOvHVSTQ73IcnU5nTulZdtdfTbr5mil7a7pf9Hk/1if8wec/8tmHpxxxjuPl6iqljd2yWNwDbvndfHK6TP8A892xzjgj1/g6HmuW+BV9cP4DGlXyXD6hoV2dJusvIu14p22qAgIwEZF+oJGTXaaezfYLj91MPnv/APlrN/z3b1Xt3zwf4sGjW6NKc4yhzWerXVdn5FTW7u2fRdRVbdwxtbwAnSZ1wc8ckYGPU8L0NW769tQtxi3kGJG6aPOmP3Oe68euOx+bpRrzN/YWp/upv+PS86yzev8Au9u+eD/Fg1cvmJW4/dTDMjdZZjj9z7r+PPOOPu80K9yk48q0e8uq8vIz7y6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6VJbXtqZbMG3kOY4850eds/JJ1GPm+o68H+E1PfO39q6d+4n/4/wA8edcZ/wCPWTj7uc989ccYxzUtszedZ/upj+7j6SzDPySdMLx+GRwccE4FfUmTXItH8Pdd35GTbXdt9vkcwPg2tkP+QTOTnzJM547569H6Doa868Q/EfVJ7bUtY8DaRpupeHdHcSXl1c20qC9VZGZ1tyAVVVXOWcjdwqhtvzTaP9o+Jev6tJdXF2ngu1WGxitbWWeMasAWjZ5JUJ3QhzOFVCATjqUw3oFloGlWnh2Xw/baUI9G8sWptFecJ5bSuGU/Lk5yQSeSSTyxIoVzOs3Ub5bpadV2Xlt+ZBo+p6fc6O1xaBbi3mF7NFNBpczo6GYlWVwCMYIwf4ehrhPiR4HbxLqw1c6/qUNpZt9sj086PcCJHgdzhSCqqH38u6syYA3Bflre+ESNpvg258Oyfa55/D899pklxI0iCUBxIjqo3BV8uSP5SRg5DYwCet15m/sLU/3U3/HpedZZvX/d7d88H+LBpWfKa05RrSjKSesu67vyPOrj4c6Lba1461S1e5jm8QQTWiL/AGPdbbTzIGaVgGOG3SEPggbdoxhc10/hnSNL8MadoOk2VquLW4RJpV0GaM3DrZlTIygZLMQCRyf4s4FdB4g1K00yxu7vVJlsrVZcNNc3MqIpaLaAWcAZJI68nOOnNT3kzrqdkBBKd98QcyTk/wDHs54JTIPHUfNjj7pNDTsZUoU46xi78r6rt6Fa2vbUy2YNvIcxx5zo87Z+STqMfN9R14P8JrC1fxLpWgiS8vo3Jkt7KG3t10qUzXUxeUiKMHG53xgdA3PIAJGJqvxXsNM8Zr4WstC1zVPEESwRxW1rIQJ2aBpAQxYFFAcZOMKASMrk03wfoOv33i6TxD40lf7RDDaSabpdrcz+RZI3mIC+FxJKA0q7gSo8x9mcqEbvcbqqXNGmnfTqtNfT8DpvDfijSdfsZbqyhlDJMkNxbvpMxltZRM26GRVzsdcgFcnIwAT1Nmxu7ZLG4Bt3zuvjldJn/wCe7Y5xwR6/wdDzXIxW1x4S+K8txEs6+HvFMoV4VmZUi1JXZg2MKf3kcTjIDsz8nBwB3Ons32C4/dTD57//AJazf8929V7d88H+LBo1uVTleD5k73V9V2flsVNbu7Z9F1FVt3DG1vACdJnXBzxyRgY9TwvQ1bvr21C3GLeQYkbpo86Y/c57rx647H5ulGvM39han+6m/wCPS86yzev+72754P8AFg1cvmJW4/dTDMjdZZjj9z7r+PPOOPu80K9y048q0e8uq8vIz7y6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6VJbXtqZbMG3kOY4850eds/JJ1GPm+o68H+E1PfO39q6d+4n/AOP88edcZ/49ZOPu5z3z1xxjHNS2zN51n+6mP7uPpLMM/JJ0wvH4ZHBxwTgV9SZNci0fw913fkZNtd232+RzA+Da2Q/5BM5OfMkznjvnr0foOhrK8V+OND8LxJ9uhmmvbudIrOwh0qQ3F23nkFYlbaDgEZGRxheuM8xYfF7RpNf1+yXTdWnv9PltdOgsbR3mub5onlMjRRr2XDnkgKoUg7m2jY8FeFJm1i58WeLbIzeJp591srzTSHSrdpSBaowG0kfMDIACS74LEnIrmdWtGo2qV76dtNl2/rU0fCXiXSda0Ka5so33hr3z4DpUvm2shlLeXIFyEdQw7kL7ggnS1u7tn0XUVW3cMbW8AJ0mdcHPHJGBj1PC9DXn2pxxeEPiPpuvwpNb2fiee+0nU2eeYo04kb7KwXAJclfLycrjO4ISSfTNeZv7C1P91N/x6XnWWb1/3e3fPB/iwaWvKbUZP2qjO7al5ffaxyvxZ8Nad448K3ekymezkW6WeC4TRrgGJkiz93jgqWXaTxu3dqyvG3giz1kaZpljMlrpkEMmmRW114ZlufIU2pCyxO2JRIAo43sCQrkfKSfS75iVuP3UwzI3WWY4/c+6/jzzjj7vNRXzt/aunfuJ/wDj/PHnXGf+PWTj7uc989ccYxzRJOxiqdOW8XrF9V0XoUNGktbO10q1Iu7nybaCMy3GlTySS4jcbnO352OMlh948/wmvKvBur+V+0N4ytBGTZ3On2M7KdPkdt6JbKDsA3DiV8no2f8AaFe02zN51n+6mP7uPpLMM/JJ0wvH4ZHBxwTjwH4UXN5qX7QPizVLqIlGjmsUKNIM/Z57SMcgHnbs+hPH8IqnczruKnBJPddV5+R7kl7a7pf9Hk/1if8AMHnP/LZh6cccY7j5eorGvfEOj6B4evdQ1dha2cT3m+ZtJnwpa52pyFODlgB/dzg810qMd0v7qb/WJ/y1m/57N/s/hzznkfNkV5XeGHxr4/GgS2kd1pHhr7bfajFcBpkkuZnlWCMo6ZGxGaTcMqSQGwwpO9zeckoPlTvdduz8jtrvV9N1TwtcXenqZra6sLmaCVdJnVXRuUYMRgDBGCeFHBrSvr21C3GLeQYkbpo86Y/c57rx647H5ulebeDpbrw0fFPgHUJr67j0/Tp7zSJ7iV9zWLYTYQq4AjkVly23du+6oUCvTddv7ewsru61BxaWySEvNcXEqomYcDJdQO464Pb7vNCvccJxcItp7y6ry8iveXVq2qWOLdsLfHIOjTjj7M/AXGTyc7ev8XSpLa9tTLZg28hzHHnOjztn5JOox831HXg/wmsC8+IXg9tRsJF8TaKUW9MjEaw3C/Z3XJPXqQM9ecdOa3NQ1vTdDisrrWryDT7bbEglurySFGbZJgBiOM84Az0OMjdgV9QlKPItH8Pdd35EFtd232+RzA+Da2Q/5BM5OfMkznjvnr0foOhrwr4Vag1z+0h46uL0yz/8fEKbrOSQqiXkKIvlgblARQuD0A29SK920PUrXU5mu9MlW8tHtbMJPb3MskbFZpVOGUEdQRwcAg4yeK828EabNb/F+TVPIYQXlrqsQKtIGaSPWyWyQmTxIgycn8QFpK5hi7OtBpPddV2Xkej2N3bJY3ANu+d18crpM/8Az3bHOOCPX+Doeag8U6xpll4c1Ka+ZLSH7NdJ5s+mTRIGZwqAuwAUksACfu5weTWlp7N9guP3Uw+e/wD+Ws3/AD3b1Xt3zwf4sGvP/igza94o0rw4Gd7G2sdQ1fVLJpJ8SRqdtuW+XDATDdtzglMuBgUa8p1Tmo1VZO/N3Xd+R3b6rp13ZNdWS+dbTHzIpodKm2Ohg3KytjGDkEf99dK4+58G6SvxmtfGqeeJWzavaHRrnYZPs7DzQD32AL5YH+361R8O60PBXiO+8D66biGyknebQLq5uJFja3aMKtmu75i0ZYKNx3MMDCqVz23iDxHpGl6xbJqeoW1nJb3H2qZLi/ljaOJoHjDtuAIUuQoY9yF6UO7RzwdOpFc0Xon1W6Xp9xwfgH4dWHhfxBoV5b3kzwWEM6Ikfh+dJbpZy7AXTjPnhMALhVHCkfdIrv7a7tvt8jmB8G1sh/yCZyc+ZJnPHfPXo/QdDV3RNStNTgsLvTZlvLV0QJNbXMro5USqdrKD0II+XIGCB/Fhlqzf2lL+6mP+iWP/AC1m/wCesv8As9+2OB/Dk02noa04wgpKCdrLqu68jynwbrkcH7QHxA042e6G7S0uBIbGVnQxeUm0RgblBExzn+6B3Fel2N3bJY3ANu+d18crpM//AD3bHOOCPX+Doea8y8K2s8f7TXi+9aKTyJrXyVw0gO5DYswyFyeJF688564z6xp7N9guP3Uw+e//AOWs3/PdvVe3fPB/iwaFe5nh2uSWj+LuvPyKmt3ds+i6iq27hja3gBOkzrg545IwMep4Xoat317ahbjFvIMSN00edMfuc9149cdj83SvN/iD8Rbv7Rq+keEdKfVl0qGd9euhcOUsoWY71CsybpAqsSM4yBuBO4L6LY61Y6/ow1TR5vten3LM8U8c8zKw8kgjlRyCDkHBGCCAM0K9y4VqcrRV7q/VeXl/XUS8urVtUscW7YW+OQdGnHH2Z+AuMnk529f4ulSW17amWzBt5DmOPOdHnbPySdRj5vqOvB/hNT3zt/aunfuJ/wDj/PHnXGf+PWTj7uc989ccYxzUtszedZ/upj+7j6SzDPySdMLx+GRwccE4FfUcmuRaP4e67vyMm2u7b7fI5gfBtbIf8gmcnPmSZzx3z16P0HQ1aS9td0v+jyf6xP8AmDzn/lsw9OOOMdx8vUUWrN/aUv7qY/6JY/8ALWb/AJ6y/wCz37Y4H8OTVxGO6X91N/rE/wCWs3/PZv8AZ/DnnPI+bIoVyqrV3o+nVdl5Hhfw/wBVNv8AH/4kWfl5s7i1e4Kiwd2DxsgQhQN0eBI/XgcZr13W7u2fRdRVbdwxtbwAnSZ1wc8ckYGPU8L0NeQ+GtYQfGe9uksWFzqmqa3pM0vmOG8u3gtWQH5fmAMbHB5+c7vU+068zf2Fqf7qb/j0vOss3r/u9u+eD/Fg0teUxwdRVKnM09ZN7rrr2C+vbULcYt5BiRumjzpj9znuvHrjsfm6VHeXVq2qWOLdsLfHIOjTjj7M/AXGTyc7ev8AF0rhNZ+KrSahqz6J4cv9T8N6ddCHUNaju5fKgJj2y7EKFpRGPmYjnA/uYY+gPeRXl1pF1Z757ae882KWK4ndZFa0cgqwXkEEEEc4/wBnmh3sVRqQnpG+kX1Xb0/4Alte2plswbeQ5jjznR52z8knUY+b6jrwf4TXm3xIljl1TT2iRkH2GPObZ4CTubnDD5v94cGvVbZm86z/AHUx/dx9JZhn5JOmF4/DI4OOCceX/FAk6vp2VZf9Aj+8znPzPyNwGB7Dj0NTWvy6ns5K19cVk9u68/I7WKS8l0m8igaziZ/t6iVNUcujGZuVDRlSQeQCCHxkjtXMeI/DetXWg6hFdeMdW8k29wzCLVLdGIVs4BS0Vvmx0DDeO4HFdtp88hsLgG8hOXvxjz0Ocztkfc79R69tvSjXp5DoWpj7ZCc2l4MeenOTyPud+o9e23pVWfLueY4qVazj9p9Zd35nGf8ACF3mnXdxdaV4j1W3lkQRzg6/9rW5cQqDMyz27gyMEVCy7eBsAAJrzv4x2Wr+AvBtxcw+JdV1eO/uzYSwalrBvlKS2kyF1HlIwIDH5g2MgBlYCvoO+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmvK/2pG8/4WX5lnhnKajA64lVyG2hdwwg7EjPHcY70ONkcU6S9n7kUnZ9X21/A77QoJtKstI0+2j077PZ2sFuh/taZRtSN1HJjyvQcdsgfxGktp7oX8n7uw3/ZbIEHVZABiST/AGOvXI/h6jOa17aeQTWZF5Cu2OMAmdBtwknB+TjGcc5xkdcgirbXLfbnQXNupW1svm89c4EkmFI2Y+XBPqM8luAG09NTqj7qaUei6vv6nnl9oXj2DxR4lvPDmueHbSw1qWCRlurqeWSzkX915kQACO2EVizg5ATjjnOh8MfEtreRrX4lWSxA3AZHtomLMJCJMfJ0d9zAdx16V68k8m6X/TIRmRD/AK9Of3zHP3PXn6HPIOBT0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pRy6kQppRlppzLq+z7HlepeGPicum3jXPxMsJIBBOZEW0jy6j76j5erdR61sa34G1nUWaW98b+IGmTKH7Jr6wI+Iid2yO2AOSSuTz0XPGa7zXp5DoWpj7ZCc2l4MeenOTyPud+o9e23pVy+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmjl1HyRcVePV/al5eZ5vHo/jrRJ7Cz07xNompW66kTDLrd1cT3EamByd00ZTzABuAJUHJC7toArOuNR8UeC9a0DVfF3jLT7nR7q9NvNbL+4hiWSCUwrvWNpECMpBJY8OucDcT6pfXMv8Aaunn7fBn7eTu+0JjP2WQZz5fTtnGM8YzzXmH7SUEN38IL2S5aOd7X7HLBibJjfeUzgAchZHGDnG7ucEKz1MqseSleMfsrrLu/Ms/BCyvNG8A6NbMdOld7C1uQRqUkeEluJ5lBAQ4YCTDD+HGQTmu/S4vN0v7rT/9Yn/MWlH/AC2Y/wDPPnjnPYfN1NUPC1tJo9nY6Z/aFtIbHStMtd6zKofy2dc4KEjpkg9M856VtpPJul/0yEZkQ/69Of3zHP3PXn6HPIOA4p2NF7sUnHpHq+yPMo/CeuQ+MdQ8ReGtb0jS4tQ89NStpmkuvtTRyyqGJyjZCuoVQyhvLBbqRTdX0n4hXmm39xqfi7RrFRY3K/ZdKy0e4OSWJnV2fcpI2gpnAOcglvQ9PnkNhcA3kJy9+Meehzmdsj7nfqPXtt6Ua9PIdC1MfbITm0vBjz05yeR9zv1Hr229KVnymns06+32n1l3epwVn8PI0luL3xVcQeLdSYFTJq2pmeGJjFudoIfJ2oGcLgc42KgOMk5PiH4eX+irFL4D1q80mW2uvMsNKi8QSS2QdYWcqEdVP7whlLF8ZcgjFev308jLcZvIXzIx4nQ5/c4zwgzxx254681FfXMv9q6eft8Gft5O77QmM/ZZBnPl9O2cYzxjPNNx0MY0oSVuRbPq+x5v8JxqerS3HiXxD4f06y1G51BprRbu6eGe1iFutvgEozoSIRk/LnjChWArtrae6F/J+7sN/wBlsgQdVkAGJJP9jr1yP4eozmte2nkE1mReQrtjjAJnQbcJJwfk4xnHOcZHXIIp2s8g1KUC8hGLSxGPPTjEsuB9zt1Pp33dKGndGlNcsZJq+i6vXVGR4l0hfEemz2WoQ2SlZ45re4h1eRJraVZn2zRP5Zw65yG7A5IO4g87Y+G/ENvoMttpnjXUVaMXqRPc6hBcHd5zff3Wu6TJJOC4LjuowB6Kk8m6X/TIRmRD/r05/fMc/c9efoc8g4FPT55DYXAN5CcvfjHnoc5nbI+536j17belHK7hyxd5OCvddZdn5nArpvxCsNA1CLUvFvh3VFMNyzSzwSiUJgBlURyIpzgsuQc5Oc8AXIdB8ZLFdtq/jc3EzTuyixmgiiCmIkALJbyM393Jbn7vvXZa9PIdC1MfbITm0vBjz05yeR9zv1Hr229KuX08jLcZvIXzIx4nQ5/c4zwgzxx254680JO+40lyr3er+1Ly8zy/Ufhtb6hq8I8T6xqHiKznvWJstS8Ru1tv8h2EgEcKbSOQGHA+7t7jP1rw34p8J+FY7vwtr+s6ld6cYLuGwuNXW4EgUMHiKiFHKCMMBEsgwT8oLEV63fXMv9q6eft8Gft5O77QmM/ZZBnPl9O2cYzxjPNS208gmsyLyFdscYBM6DbhJOD8nGM45zjI65BCUdzGdGHImoJNx7vzPNPhHod1pGjWV1qdppUniCazhmuLqS7eGfE91LMUf93kMMqHXopQEZPTv0uLzdL+60//AFif8xaUf8tmP/PPnjnPYfN1NFrPINSlAvIRi0sRjz04xLLgfc7dT6d93SriTybpf9MhGZEP+vTn98xz9z15+hzyDgNJ2NXFQXLyrTl6vsjjvEWgWni7wvd6XrNlp1zbNJeyRsdUk8yGXzm2vHmM4YZOP74zuGCRWDJoXj3TNG1qA+NNLvrB7W4SH7cHmuLeJdwOHQxiSRgQcupDlckDJB9D0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pRr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0pcvuluEZV9Y/afWXd+ZwOq+B9e1CBG1Txzrkt3GNkj2OtrbRyN5OSwjS2HBOQMknHy5PWq0/wANIpr63ttf8Qazr2mz3RSWw1LxRJJbzYgZlZtsKngqMMD1AXHevU76eRluM3kL5kY8Toc/ucZ4QZ447c8deahv7iQ6ppxN9B/yEC277QmM/ZXG7Pl9O2cYzxjPNDjoYRpU5b01s+sux57p/wAOLKxv5pNHurrR7e9i3Paad4jmtYIp3RgZ1VY/lkGBwcoMgbSCAMnTbPS/hvr2krumk36ZqGoXl1PqLzmRzNaSPJIyoGDBIiCFQ9FPzNk169bTyCazIvIV2xxgEzoNuEk4PycYzjnOMjrkEfPv7SpvrvxP4DsdMeH7beW0+nxzPMCmJwkJRhgBMBzk8n5upwKbVtTDERjD31BK1ur7+p2CfFm9OmWOpReAvEs9pqP723aC48w7VlLZZVJZQQw2lwM/eXOc1d+F2j6ppekavqmrw6Ude1q4u7u9K6i6tG24KsGQrblXDbQXYHcee59FSeTdL/pkIzIh/wBenP75jn7nrz9DnkHAp6fPIbC4BvITl78Y89DnM7ZH3O/Uevbb0os77nVGP2mtn3fVHK/EPwtpfivSzJ4i0vTrs2EF7Jbt/bM+YmYg5ChQGPyggH72MnFV5/hv4Sh1G8v4fCHhjz5CY9v255IgoiBG2Ix7B8yj5goJOR3JPZa9PIdC1MfbITm0vBjz05yeR9zv1Hr229KuX08jLcZvIXzIx4nQ5/c4zwgzxx254680cuockLKTgr3fV+RyOr+FdBvdT0/7b4Z8Kz7bowp5l1vHl+RI+zcYuE3Etn+9xjnNRQeB/DJltQ/g3wdhkQvukUAkq+cnyeDkLkdjgd666+uZf7V08/b4M/byd32hMZ+yyDOfL6ds4xnjGealtp5BNZkXkK7Y4wCZ0G3CScH5OMZxznGR1yCBJ66hJLkXuL4e78zz+08D6FDrjXdho2mabdiztELabrNxY5DSuWz5Krkkqu4EfLtUgntm+IdTj8Ea9YTQ2UMkNrpOrXSQjVZpXmYXUFxJmZkLFjtYjOeu7g8H0a1nkGpSgXkIxaWIx56cYllwPudup9O+7pXiH7Sdtdar4u8B6fa38cE2oT3dj9o3hljWeVI2LYA4Ic59Qe2cBJWVzPFKFNOSgk9O/kdPP8Rde0a1Kal8P9WkS4a6EbaZqf2/DtKWcOEHy7SdvPD4JBIGasaPZ69c6p4y8S+ILG0smvLKSxsbSbUUea1towWOJIgwfe8jNsJGSvJI2mvQNPnkNhcA3kJy9+Meehzmdsj7nfqPXtt6Ua9PIdC1MfbITm0vBjz05yeR9zv1Hr229KLPlNoQca0U9bSfV92UvEljFrVpNb6tpeiahAs5lWK51BrhQwgIDBWiIJGcBuuTt6VhXXgjwsuoWa/8If4OVGvCm1ZhtZfs7nBPk/dyM55+YAY71219PIy3GbyF8yMeJ0Of3OM8IM8cdueOvNRX1zL/AGrp5+3wZ+3k7vtCYz9lkGc+X07ZxjPGM802nYmCT+wvhfV9jz69+Fng7VLyzlu/CXh9D5MasINUmtkPyyElhGigHOM8ZGFGcHivYeGPE+kavF/wjfiyOO0SKGSWw1i8e+jIZmWONHCxyokeCdm844OTk59Otp5BNZkXkK7Y4wCZ0G3CScH5OMZxznGR1yCKdrPINSlAvIRi0sRjz04xLLgfc7dT6d93Shx1F7KDcpcivp1ff1PHvCPh3xbqmoa1rF3qMWkeI7LXZvLl8+VbS6jf7Oj/ALt13ywEQLtYOpGA3VRjT0/wb4wvtOuote+IN3cQh7hohpl4unuHWRhJuZYmLq7HcFyAep7Y9aSeTdL/AKZCMyIf9enP75jn7nrz9DnkHAp6fPIbC4BvITl78Y89DnM7ZH3O/Uevbb0o5dRQoxUGnG+q6vXR7rY56y0Oy8L+EdQ03QtM0qwsfs947JDqsrksTjJymXbAAAJ+YKOgAxyWofDzxDpGq6nL8P8AxNYeGtIu5fNk0qOT7XCsvlnc8YdBtDD5cAdfl6BQPTtenkOhamPtkJzaXgx56c5PI+536j17belXL6eRluM3kL5kY8Toc/ucZ4QZ447c8deaFHUvli4RXItHLrLy8zzLTtF+I+m6vbyah470LVi0xjiS7gZY0k8onzcxNG33AyZJI+bGOhCr4f8AiRPrFrO/xA021s2MTNbWkKx+WmGyivIshQ4DDJ3YLjgg4r0e+uZf7V08/b4M/byd32hMZ+yyDOfL6ds4xnjGealtp5BNZkXkK7Y4wCZ0G3CScH5OMZxznGR1yCBJ66kyiuRe70/ml5+Z5cvh7x3/AMJIJbX4gpFYrHZvJbyrA0pj3N8gk8kKCGEh/wBWQoYcNjlP+EX+Iljeu+j+P7WSxhlV47TVGE5l/eE7ZJlRWKlssSoBVWBHNejWs8g1KUC8hGLSxGPPTjEsuB9zt1Pp33dKuJPJul/0yEZkQ/69Of3zHP3PXn6HPIOAJMdWEbv3e32pdl5nzr4F8KeJfE+jT+IBdL4a8RxazqWoRvPuA/fxwrKghkUk5wyqS2T8wOStdlqPgnxJe6Fc/wDCW+OL3UfKhui0djqC2UMsfy7o5I0hJkDYY4LjcDxt5J9M0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pRr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0pW924qWHhCapuKettW9flt+BmQ6TbaX4ffRNN0rRodJjDwraJqcjxlDCdwKmP59xJyTyxJBzkmuBtPh/wCJPD2tW9p4X8Zw6T4aOpGS301ZxObfdEzSBJpIzhSN6glTgtyGOWPrt9PIy3GbyF8yMeJ0Of3OM8IM8cdueOvNRX1zL/aunn7fBn7eTu+0JjP2WQZz5fTtnGM8YzzTcdAjGMre6tIvrLt6kFtcXgls8xaeMRx5zq0q4+STqfL+X6DpkD+I15v8SHkfVNPMywq4sYxiK5aYfebqSBtP+yOBXqltPIJrMi8hXbHGATOg24STg/JxjOOc4yOuQR5f8UHL6vp26VZNthGBtcNtG5+DgDB9uT7morL3T2Mld8Yvdtp3fn3PQLK1vWsLg/btVUZ1AEbbbH+vO4n5M9eWx3+7xRrlrerompM1/qrKLS9JVltsEZ5BwmceuOf7tSafaKLC4P2eYYe/OSkPG2dh29O+OR/DxRr1oo0LUz9nmGLS8OdkPG047enfuP4eKqy5TzVNe2Xw/E+i7sn1G0vtlzu1HVv9a2d62vX7OeuE649OMe9U9f0MatNb2OsPf31rNf4aC5t7OVGYWzMMqybcjGeQR7buRo31mEW4/wBHmXbIw5SEY/c7u358cY/2qivrFf7V09fss/8Ax/lceXb5/wCPWQ49M9/THvTaVjGE01vH4X0XYLS0vvPsNuo6tnyotu1bXONkuMZTp1xnnGc84qpa2t79udRfarxaWB3BbbkebJtHKdM9O+Sd3GK0La0VprMfZ5jujjOAkPOUkPGfp354OecVTtbQHUpT9nmObSxOQkPO6WUd/Xt3P8XFDSuUpr3vh2XRfzE8dpfb5/8AiY6t/rY84W16/aH6/J1zn2znPGKqWVretYXB+3aqozqAI222P9edxPyZ68tjv93itBLQFpf9HmOJEH3IeMzMP6Y44yOflxVPT7RRYXB+zzDD35yUh42zsO3p3xyP4eKLK4KorP4d10XZkeuWt6uiakzX+qsotL0lWW2wRnkHCZx645/u1b1G0vtlzu1HVv8AWtnetr1+znrhOuPTjHvUGvWijQtTP2eYYtLw52Q8bTjt6d+4/h4q5fWYRbj/AEeZdsjDlIRj9zu7fnxxj/aoSVwVRcq+HeXReRXvLW/GrWAN/q5Y6gQCVtdwP2V+R8mN2PwwfWs7XPCsXijSYtG1yfVbvTrmGASQg26bgokZcEKCMFcjnPBz2rUvrFf7V09fss//AB/lceXb5/49ZDj0z39Me9S21orTWY+zzHdHGcBIecpIeM/Tvzwc84pKK1JlNci+H4ey7sz7W1vftzqL7VeLSwO4LbcjzZNo5Tpnp3yTu4xVuO0vt8//ABMdW/1secLa9ftD9fk65z7ZznjFQWtoDqUp+zzHNpYnISHndLKO/r27n+LiriWgLS/6PMcSIPuQ8ZmYf0xxxkc/Limkiqs1d/D9nouyM+ytb1rC4P27VVGdQBG22x/rzuJ+TPXlsd/u8Ua5a3q6JqTNf6qyi0vSVZbbBGeQcJnHrjn+7Umn2iiwuD9nmGHvzkpDxtnYdvTvjkfw8Ua9aKNC1M/Z5hi0vDnZDxtOO3p37j+HilZcpopr2y+H4n0Xdk+o2l9sud2o6t/rWzvW16/Zz1wnXHpxj3pl5a341awBv9XLHUCAStruB+yvyPkxux+GD61YvrMItx/o8y7ZGHKQjH7nd2/PjjH+1UV9Yr/aunr9ln/4/wArjy7fP/HrIceme/pj3oklYxhNW+z8L6LsFpaX3n2G3UdWz5UW3atrnGyXGMp064zzjOecVUtbW9+3OovtV4tLA7gttyPNk2jlOmenfJO7jFaFtaK01mPs8x3RxnASHnKSHjP0788HPOKp2toDqUp+zzHNpYnISHndLKO/r27n+Lim0rlKa974dl0X8xPHaX2+f/iY6t/rY84W16/aH6/J1zn2znPGKqWVretYXB+3aqozqAI222P9edxPyZ68tjv93itBLQFpf9HmOJEH3IeMzMP6Y44yOflxVPT7RRYXB+zzDD35yUh42zsO3p3xyP4eKLK4KorP4d10XZkeuWt6uiakzX+qsotL0lWW2wRnkHCZx645/u1b1G0vtlzu1HVv9a2d62vX7OeuE649OMe9Qa9aKNC1M/Z5hi0vDnZDxtOO3p37j+Hirl9ZhFuP9HmXbIw5SEY/c7u358cY/wBqhJXBVFyr4d5dF5Fe8tb8atYA3+rljqBAJW13A/ZX5HyY3Y/DB9afaWl959ht1HVs+VFt2ra5xslxjKdOuM84znnFF9Yr/aunr9ln/wCP8rjy7fP/AB6yHHpnv6Y96ltrRWmsx9nmO6OM4CQ85SQ8Z+nfng55xSUVqTKa5F8Pw9l3Zn2tre/bnUX2q8WlgdwW25HmybRynTPTvkndxircdpfb5/8AiY6t/rY84W16/aH6/J1zn2znPGKgtbQHUpT9nmObSxOQkPO6WUd/Xt3P8XFXEtAWl/0eY4kQfch4zMw/pjjjI5+XFNJFVZq7+H7PRdkZ9la3rWFwft2qqM6gCNttj/XncT8mevLY7/d4o1y1vV0TUma/1VlFpekqy22CM8g4TOPXHP8AdqTT7RRYXB+zzDD35yUh42zsO3p3xyP4eKNetFGhamfs8wxaXhzsh42nHb079x/DxSsuU0U17ZfD8T6LuyfUbS+2XO7UdW/1rZ3ra9fs564Trj04x70y8tb8atYA3+rljqBAJW13A/ZX5HyY3Y/DB9asX1mEW4/0eZdsjDlIRj9zu7fnxxj/AGqivrFf7V09fss//H+Vx5dvn/j1kOPTPf0x70SSsYwmrfZ+F9F2C0tL7z7DbqOrZ8qLbtW1zjZLjGU6dcZ5xnPOK8f+MGj3knjf4aai9/euLXU9Oto1dYdwM8rMGTACjH2fjcpJzycAA+y21orTWY+zzHdHGcBIecpIeM/Tvzwc84qna2gOpSn7PMc2lichIed0so7+vbuf4uKbihVLVIzi3HZdF/MTx2l9vn/4mOrf62POFtev2h+vydc59s5zxiqlla3rWFwft2qqM6gCNttj/XncT8mevLY7/d4rQS0BaX/R5jiRB9yHjMzD+mOOMjn5cVT0+0UWFwfs8ww9+clIeNs7Dt6d8cj+HiiyuWqis/h3XRdmR65a3q6JqTNf6qyi0vSVZbbBGeQcJnHrjn+7VvUbS+2XO7UdW/1rZ3ra9fs564Trj04x71Br1oo0LUz9nmGLS8OdkPG047enfuP4eKuX1mEW4/0eZdsjDlIRj9zu7fnxxj/aoSVwVRcq+HeXReRXvLW/GrWAN/q5Y6gQCVtdwP2V+R8mN2PwwfWn2lpfefYbdR1bPlRbdq2ucbJcYynTrjPOM55xRfWK/wBq6ev2Wf8A4/yuPLt8/wDHrIceme/pj3qW2tFaazH2eY7o4zgJDzlJDxn6d+eDnnFJRWpMprkXw/D2Xdmfa2t79udRfarxaWB3BbbkebJtHKdM9O+Sd3GK4bx/4H1rxF8RfA2oQyX8thpF5LcXVyzWweBvODR7VwAxZ0x0YA5PAxXe2toDqUp+zzHNpYnISHndLKO/r27n+LiriWgLS/6PMcSIPuQ8ZmYf0xxxkc/LimkgxDU7xdvs9F2Rn2VretYXB+3aqozqAI222P8AXncT8mevLY7/AHeKNctb1dE1Jmv9VZRaXpKsttgjPIOEzj1xz/dqTT7RRYXB+zzDD35yUh42zsO3p3xyP4eKNetFGhamfs8wxaXhzsh42nHb079x/DxSsuU2U17ZfD8T6LuyfUbS+2XO7UdW/wBa2d62vX7OeuE649OMe9MvLW/GrWAN/q5Y6gQCVtdwP2V+R8mN2PwwfWrF9ZhFuP8AR5l2yMOUhGP3O7t+fHGP9qor6xX+1dPX7LP/AMf5XHl2+f8Aj1kOPTPf0x70SSsYwmrfZ+F9F2C0tL7z7DbqOrZ8qLbtW1zjZLjGU6dcZ5xnPOKqWtre/bnUX2q8WlgdwW25HmybRynTPTvkndxitC2tFaazH2eY7o4zgJDzlJDxn6d+eDnnFU7W0B1KU/Z5jm0sTkJDzullHf17dz/FxTaVylNe98Oy6L+YnjtL7fP/AMTHVv8AWx5wtr1+0P1+TrnPtnOeMVUsrW9awuD9u1VRnUARttsf687ifkz15bHf7vFaCWgLS/6PMcSIPuQ8ZmYf0xxxkc/Liqen2iiwuD9nmGHvzkpDxtnYdvTvjkfw8UWVwVRWfw7rouzI9ctb1dE1Jmv9VZRaXpKsttgjPIOEzj1xz/dq3qNpfbLndqOrf61s71tev2c9cJ1x6cY96g160UaFqZ+zzDFpeHOyHjacdvTv3H8PFXL6zCLcf6PMu2RhykIx+53dvz44x/tUJK4KouVfDvLovIr3lrfjVrAG/wBXLHUCAStruB+yvyPkxux+GD60+0tL7z7DbqOrZ8qLbtW1zjZLjGU6dcZ5xnPOKL6xX+1dPX7LP/x/lceXb5/49ZDj0z39Me9S21orTWY+zzHdHGcBIecpIeM/Tvzwc84pKK1JlNci+H4ey7sz7a3vBeyf6fqgC2dgd4Fr082THVegwcd8k7uMVbjtL7fP/wATHVv9bHnC2vX7Q/X5Ouc+2c54xUFraA6lKfs8xzaWJyEh53Syjv69u5/i4q4loC0v+jzHEiD7kPGZmH9MccZHPy4ppIqrNXfw/Z6LsjPsrW9awuD9u1VRnUARttsf687ifkz15bHf7vFGuWt6uiakzX+qsotL0lWW2wRnkHCZx645/u1Jp9oosLg/Z5hh785KQ8bZ2Hb0745H8PFGvWijQtTP2eYYtLw52Q8bTjt6d+4/h4pWXKaKa9svh+J9F3ZPqNpfbLndqOrf61s71tev2c9cJ1x6cY96ZeWt+NWsAb/Vyx1AgEra7gfsr8j5Mbsfhg+tWL6zCLcf6PMu2RhykIx+53dvz44x/tVFfWK/2rp6/ZZ/+P8AK48u3z/x6yHHpnv6Y96JJWMYTVvs/C+i7BaWl959ht1HVs+VFt2ra5xslxjKdOuM84znnFeZfEyOaLVNMWea4mP9nxFWnEYIG5+BsAG368+tepW1orTWY+zzHdHGcBIecpIeM/Tvzwc84ry/4oRCLV9OwjJusI2+YIM5Z+Rt7fXn1qaySievkk741bbdEvM7my0rTnsbhm06wLBr4AnTDkYnIHPbA4B/hHBo1vStOj0XUXj06wV1tbxlZdMKkEHgg9iOx/h6Gs6z8UeH4rOZGvbMOWvGAFjJn5piyc9iVOR/dHBo1fxR4fn0m+hhvbNpZLa5RFFjICWY/IM9iex/hHBovDlMFQxftU7TtzPo+78jcvtH0wLcY0zTxiRummFMfuc9+nPOOx+bpUd5pOmrqliq6bp4Vr4qwGlHBH2Zzgr6ZAO31G6qF34s8OMs3l31mcuxXZYSLx5WBj0G7t680y78U+HZNQs3S+sTHHeGRj/Z8mAn2d1zj03EDHrz0ptwtuZQoYy2sZ7Po+3oa1to+mGWzzpmnnMcec6YWz8knUfxfUdeD/CaqW2k6cb+RTp1gVFrZMAdMJ5MkmT7k4GT/FjAqvB4s8OCW1L31mAqIH3WEhAIV85Hc5K5Pc4Paq1v4o8PrevI17ZhWtrRMmxkJ3LJIXB9wGGT/EDgUNwvuUqGL973Z7Lo+/obiaPpm6X/AIlmn/6xP+YYT/y2Yfh6Y7j5eoqpZaVpz2NwzadYFg18ATphyMTkDntgcA/wjg1XXxZ4c3SZvrPl1IzYSdPNYnHoNuOO4wO1VrPxR4fis5ka9sw5a8YAWMmfmmLJz2JU5H90cGi8LgqGLs/dnuuj7PyNHW9K06PRdRePTrBXW1vGVl0wqQQeCD2I7H+Hoat32j6YFuMaZp4xI3TTCmP3Oe/TnnHY/N0rD1fxR4fn0m+hhvbNpZLa5RFFjICWY/IM9iex/hHBqzd+LPDjLN5d9ZnLsV2WEi8eVgY9Bu7evNCcL7gqGL5V7s930fl5F+80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdUlto+mGWzzpmnnMcec6YWz8knUfxfUdeD/AAmsm78U+HZNQs3S+sTHHeGRj/Z8mAn2d1zj03EDHrz0p8Hizw4JbUvfWYCogfdYSEAhXzkdzkrk9zg9qE4a6kyoYzkXuz27Pz8ixbaTpxv5FOnWBUWtkwB0wnkySZPuTgZP8WMCraaPpm6X/iWaf/rE/wCYYT/y2Yfh6Y7j5eorDt/FHh9b15GvbMK1taJk2MhO5ZJC4PuAwyf4gcCrK+LPDm6TN9Z8upGbCTp5rE49Btxx3GB2oTgVUoYu+kZ9Oj7LyLFlpWnPY3DNp1gWDXwBOmHIxOQOe2BwD/CODRreladHouovHp1grra3jKy6YVIIPBB7Edj/AA9DWdZ+KPD8VnMjXtmHLXjACxkz80xZOexKnI/ujg0av4o8Pz6TfQw3tm0sltcoiixkBLMfkGexPY/wjg0rw5S1QxftU7TtzPo+78jcvtH0wLcY0zTxiRummFMfuc9+nPOOx+bpUd5pOmrqliq6bp4Vr4qwGlHBH2Zzgr6ZAO31G6qF34s8OMs3l31mcuxXZYSLx5WBj0G7t680y78U+HZNQs3S+sTHHeGRj/Z8mAn2d1zj03EDHrz0ptwtuZQoYy2sZ7Po+3oa1to+mGWzzpmnnMcec6YWz8knUfxfUdeD/CaqW2k6cb+RTp1gVFrZMAdMJ5MkmT7k4GT/ABYwKrweLPDgltS99ZgKiB91hIQCFfOR3OSuT3OD2qtb+KPD63ryNe2YVra0TJsZCdyySFwfcBhk/wAQOBQ3C+5SoYv3vdnsuj7+huJo+mbpf+JZp/8ArE/5hhP/AC2Yfh6Y7j5eoqpZaVpz2NwzadYFg18ATphyMTkDntgcA/wjg1XXxZ4c3SZvrPl1IzYSdPNYnHoNuOO4wO1VrPxR4fis5ka9sw5a8YAWMmfmmLJz2JU5H90cGi8LgqGLs/dnuuj7PyNHW9K06PRdRePTrBXW1vGVl0wqQQeCD2I7H+Hoat32j6YFuMaZp4xI3TTCmP3Oe/TnnHY/N0rD1fxR4fn0m+hhvbNpZLa5RFFjICWY/IM9iex/hHBqzd+LPDjLN5d9ZnLsV2WEi8eVgY9Bu7evNCcL7gqGL5V7s930fl5F+80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdUlto+mGWzzpmnnMcec6YWz8knUfxfUdeD/CaybvxT4dk1CzdL6xMcd4ZGP9nyYCfZ3XOPTcQMevPSnweLPDgltS99ZgKiB91hIQCFfOR3OSuT3OD2oThrqTKhjORe7Pbs/PyLFtpOnG/kU6dYFRa2TAHTCeTJJk+5OBk/xYwKtpo+mbpf8AiWaf/rE/5hhP/LZh+HpjuPl6isO38UeH1vXka9swrW1omTYyE7lkkLg+4DDJ/iBwKsr4s8ObpM31ny6kZsJOnmsTj0G3HHcYHahOBVShi76Rn06PsvIsWWlac9jcM2nWBYNfAE6YcjE5A57YHAP8I4NGt6Vp0ei6i8enWCutreMrLphUgg8EHsR2P8PQ1nWfijw/FZzI17Zhy14wAsZM/NMWTnsSpyP7o4NGr+KPD8+k30MN7ZtLJbXKIosZASzH5BnsT2P8I4NK8OUtUMX7VO07cz6Pu/I3L7R9MC3GNM08YkbpphTH7nPfpzzjsfm6VHeaTpq6pYqum6eFa+KsBpRwR9mc4K+mQDt9Ruqhd+LPDjLN5d9ZnLsV2WEi8eVgY9Bu7evNMu/FPh2TULN0vrExx3hkY/2fJgJ9ndc49NxAx689KbcLbmUKGMtrGez6Pt6GtbaPphls86Zp5zHHnOmFs/JJ1H8X1HXg/wAJqpbaTpxv5FOnWBUWtkwB0wnkySZPuTgZP8WMCq8Hizw4JbUvfWYCogfdYSEAhXzkdzkrk9zg9qrW/ijw+t68jXtmFa2tEybGQncskhcH3AYZP8QOBQ3C+5SoYv3vdnsuj7+huJo+mbpf+JZp/wDrE/5hhP8Ay2Yfh6Y7j5eoqpZaVpz2NwzadYFg18ATphyMTkDntgcA/wAI4NV18WeHN0mb6z5dSM2EnTzWJx6DbjjuMDtVaz8UeH4rOZGvbMOWvGAFjJn5piyc9iVOR/dHBovC4Khi7P3Z7ro+z8jR1vStOj0XUXj06wV1tbxlZdMKkEHgg9iOx/h6Grd9o+mBbjGmaeMSN00wpj9znv055x2PzdKw9X8UeH59JvoYb2zaWS2uURRYyAlmPyDPYnsf4Rwas3fizw4yzeXfWZy7FdlhIvHlYGPQbu3rzQnC+4Khi+Ve7Pd9H5eRfvNJ01dUsVXTdPCtfFWA0o4I+zOcFfTIB2+o3VJbaPphls86Zp5zHHnOmFs/JJ1H8X1HXg/wmsm78U+HZNQs3S+sTHHeGRj/AGfJgJ9ndc49NxAx689KfB4s8OCW1L31mAqIH3WEhAIV85Hc5K5Pc4PahOGupMqGM5F7s9uz8/IsW2k6cb+RTp1gVFrZMAdMJ5MkmT7k4GT/ABYwKtpo+mbpf+JZp/8ArE/5hhP/AC2Yfh6Y7j5eorDt/FHh9b15GvbMK1taJk2MhO5ZJC4PuAwyf4gcCrK+LPDm6TN9Z8upGbCTp5rE49Btxx3GB2oTgVUoYu+kZ9Oj7LyLFlpWnPY3DNp1gWDXwBOmHIxOQOe2BwD/AAjg0a3pWnR6LqLx6dYK62t4ysumFSCDwQexHY/w9DWdZ+KPD8VnMjXtmHLXjACxkz80xZOexKnI/ujg0av4o8Pz6TfQw3tm0sltcoiixkBLMfkGexPY/wAI4NK8OUtUMX7VO07cz6Pu/I3L7R9MC3GNM08YkbpphTH7nPfpzzjsfm6VHeaTpq6pYqum6eFa+KsBpRwR9mc4K+mQDt9Ruqhd+LPDjLN5d9ZnLsV2WEi8eVgY9Bu7evNMu/FPh2TULN0vrExx3hkY/wBnyYCfZ3XOPTcQMevPSm3C25lChjLaxns+j7ehrW2j6YZbPOmaecxx5zphbPySdR/F9R14P8JqpbaTpxv5FOnWBUWtkwB0wnkySZPuTgZP8WMCq8Hizw4JbUvfWYCogfdYSEAhXzkdzkrk9zg9qrW/ijw+t68jXtmFa2tEybGQncskhcH3AYZP8QOBQ3C+5SoYv3vdnsuj7+huJo+mbpf+JZp/+sT/AJhhP/LZh+HpjuPl6iqllpWnPY3DNp1gWDXwBOmHIxOQOe2BwD/CODVdfFnhzdJm+s+XUjNhJ081iceg2447jA7VWs/FHh+KzmRr2zDlrxgBYyZ+aYsnPYlTkf3RwaLwuCoYuz92e66Ps/I0db0rTo9F1F49OsFdbW8ZWXTCpBB4IPYjsf4ehq3faPpgW4xpmnjEjdNMKY/c579Oecdj83SsPV/FHh+fSb6GG9s2lktrlEUWMgJZj8gz2J7H+EcGrN34s8OMs3l31mcuxXZYSLx5WBj0G7t680JwvuCoYvlXuz3fR+XkX7zSdNXVLFV03TwrXxVgNKOCPsznBX0yAdvqN1SW2j6YZbPOmaecxx5zphbPySdR/F9R14P8JrJu/FPh2TULN0vrExx3hkY/2fJgJ9ndc49NxAx689KfB4s8OCW1L31mAqIH3WEhAIV85Hc5K5Pc4PahOGupMqGM5F7s9uz8/IsW2k6cb+RTp1gVFrZMAdMJ5MkmT7k4GT/FjAq2mj6Zul/4lmn/AOsT/mGE/wDLZh+HpjuPl6isO38UeH1vXka9swrW1omTYyE7lkkLg+4DDJ/iBwKsr4s8ObpM31ny6kZsJOnmsTj0G3HHcYHahOBVShi76Rn06PsvIsWWlac9jcM2nWBYNfAE6YcjE5A57YHAP8I4NGt6Vp0ei6i8enWCutreMrLphUgg8EHsR2P8PQ1nWfijw/FZzI17Zhy14wAsZM/NMWTnsSpyP7o4NGr+KPD8+k30MN7ZtLJbXKIosZASzH5BnsT2P8I4NK8OUtUMX7VO07cz6Pu/I3L7R9MC3GNM08YkbpphTH7nPfpzzjsfm6VHeaTpq6pYqum6eFa+KsBpRwR9mc4K+mQDt9Ruqhd+LPDjLN5d9ZnLsV2WEi8eVgY9Bu7evNMu/FPh2TULN0vrExx3hkY/2fJgJ9ndc49NxAx689KbcLbmUKGMtrGez6Pt6GtbaPphls86Zp5zHHnOmFs/JJ1H8X1HXg/wmvNviRbQWuqaelrBDAjWMbFYrfygTubk/wB4/wC13rtoPFnhwS2pe+swFRA+6wkIBCvnI7nJXJ7nB7VwXj3UbHUtRspdOmiljSzSNzHC0eHBYkHPU8jnvUVXFrQ9TKKWIji06ila3VO3XyP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram showing inferior myocardial infarction (Q waves and ST elevations in leads II, III, and aVF); with probable posterior extension (reciprocal ST depressions and tall R waves in leads V2 and V3). Reciprocal ST depressions are also seen in leads I and aVL.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_28_25032=[""].join("\n");
var outline_f24_28_25032=null;
var title_f24_28_25033="Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children";
var content_f24_28_25033=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/28/25033/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/28/25033/contributors\">",
"     Manuela Albisetti, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/28/25033/contributors\">",
"     Anthony KC Chan, MBBS, FRCPC, FRCPath",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/28/25033/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/28/25033/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/28/25033/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/28/25033/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/28/25033/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the incidence of venous thromboembolism (VTE) during childhood is remarkably lower than that seen in adults, VTE is increasingly recognized in the pediatric population as a complication of improved treatment strategies for previously lethal childhood diseases. This review summarizes the available information on the incidence, pathogenesis, and clinical manifestation of VTE in children beyond the neonatal period, excluding the central nervous system.",
"   </p>",
"   <p>",
"    Diagnostic and therapeutic strategies for VTE in infants and children are discussed separately. VTE in the newborn is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14234?source=see_link\">",
"     \"Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/16/14600?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of thrombosis in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14986?source=see_link\">",
"     \"Management of thrombosis in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of VTE in children is not precisely known because only a few prospective studies of this subject exist [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In a first analysis of Canadian registry data, the incidence of documented VTE in the upper or lower venous system was 5.3 per 10,000 hospital admissions or 0.07 per 10,000 children aged 1 month to 18 years, with a peak incidence in infants younger than 1 year of age, and a mortality rate of 2.2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/1\">",
"     1",
"    </a>",
"    ]. The mortality rate was predominantly due to associated conditions, which were identified in 96 percent of children; a central (indwelling) venous line was the single most important predisposing factor for VTE, being present in 33 percent of cases.",
"   </p>",
"   <p>",
"    The annual rate of VTE in children in the United States, calculated from data from the National Hospital Discharge Survey (1979-2001), was 0.49 per 10,000 children per year [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/3\">",
"     3",
"    </a>",
"    ]. The rate of diagnosis was higher in children younger than 2 years and in those older than 15 years compared to those between 2 and 14 years of age (1.05, 1.14, and",
"    <span class=\"nowrap\">",
"     0.24/10,000",
"    </span>",
"    children per year, respectively). In teenagers, but not in younger children, the rate was greater in girls than boys (1.49 versus",
"    <span class=\"nowrap\">",
"     0.81/10,000",
"    </span>",
"    children per year) and pregnancy accounted for the difference. For all age groups, the rate of VTE was approximately two times greater among blacks than whites.",
"   </p>",
"   <p>",
"    A study that sampled more tertiary care hospitals in the United States reported substantially higher rates of VTE and that rates rose from 34 cases per 10,000 children in 2001 to 58 per 10,000 children in 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/4\">",
"     4",
"    </a>",
"    ]. This represents a 70 percent increase in the diagnosis of VTE over the seven-year study period. The study was not able to determine whether this increase was due to a true increase in the frequency of VTE versus an increase in the detection of previously undiagnosed VTE, and did not have information about the proportion of VTE that were associated with central venous lines (CVL). A separate study reported similar rates in freestanding children&rsquo;s hospitals (40 per 10,000), and much lower rates in community hospitals (7.9 per 10,000); nearly 80 percent of the episodes of VTE were associated with an underlying chronic condition [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/5\">",
"     5",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    In the Netherlands, the incidence of VTE in children aged &le;18 years has been estimated at 0.14 per 10,000 children, 35 percent of whom were asymptomatic. In 98 percent of all children, at least one risk factor was present. Similar to the Canadian registry data, VTE was related to the presence of a central venous line in one-third of the affected children [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/2\">",
"     2",
"    </a>",
"    ]. A study from Denmark reported 20.9 VTE per 10,000 children per year, with the highest rates in infants and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/6\">",
"     6",
"    </a>",
"    ]. Forty-one percent of the subjects had a thrombophilic condition (eg, factor V Leiden mutation), and 8 percent of the subjects had a central venous line. Use of oral contraceptives was an important risk factor for VTE among adolescent girls (80 percent of girls with VTE used oral contraceptives, as compared with 27 percent in the general population). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virchow's triad (stasis, endothelial injury, and hypercoagulability) is the basic pathological process underlying VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/7\">",
"     7",
"    </a>",
"    ]. In adults, several risk situations are known to induce one or more of the Virchow conditions. These include the presence of a central venous line, prolonged immobilization, surgery, trauma, malignancy, pregnancy and puerperium, treatment with oral contraceptives, hormone replacement therapy, presence of antiphospholipid antibodies, and inherited disorders of coagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link\">",
"     \"Overview of the causes of venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathophysiology of VTE in children is similar, but the contribution of each factor differs among age groups. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Central venous access devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, approximately two-thirds of VTEs are associated with the use of central venous lines or access devices (CVL) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/1,2,9\">",
"     1,2,9",
"    </a>",
"    ]. CVLs are extremely important for the long- and short-term management of pediatric patients with a variety of severe diseases (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    , intensive fluid management, administration of blood products, antibiotics, and chemotherapy). Most CVL-associated VTEs occur in the upper venous system, in association with CVLs inserted percutaneously through a jugular or subclavian vein [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/10\">",
"     10",
"    </a>",
"    ]. Femoral venous catheters are used less commonly but also can be associated with VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/1/29?source=see_link\">",
"     \"Complications of central venous catheters and their prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Indwelling CVLs are thrombogenic because they present a foreign intravascular surface, damage vessel walls, and disrupt blood flow. In one study, the subclavian vein was involved in 18 of the 19 episodes of CVL-associated upper extremity DVT; 14 of the 19 episodes were located on the left side [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=see_link\">",
"     \"Catheter-induced upper extremity venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Inherited hypercoagulable states",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although several studies in adults have demonstrated a strong association between inherited prothrombotic disorders and VTE, the impact of these disorders on the development of VTE in children remains poorly defined and controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/13-17\">",
"     13-17",
"    </a>",
"    ]. In children with VTE, the prevalence of inherited prothrombotic disorders ranges from 10 to 59 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/6,18-24\">",
"     6,18-24",
"    </a>",
"    ]. These include deficiencies of antithrombin, protein C or S, increase of lipoprotein (a), or the presence of the factor V Leiden mutation, the prothrombin G20210A variant, or the TT677 methylenetetrahydrofolate reductase genotype.",
"   </p>",
"   <p>",
"    In two studies of a total of 271 consecutive children with objectively diagnosed VTE, the following inherited conditions were found [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Factor V Leiden &mdash; 4.7 and 13 percent",
"     </li>",
"     <li>",
"      Prothrombin gene mutation &mdash; 2.3 and 3 percent",
"     </li>",
"     <li>",
"      Antithrombin deficiency &mdash; 1 percent (one study)",
"     </li>",
"     <li>",
"      Protein S deficiency &mdash; 1.2 and 1 percent",
"     </li>",
"     <li>",
"      Protein C deficiency &mdash; 0.6 and 1 percent",
"     </li>",
"     <li>",
"      Combined defects &mdash; 2.6 percent (one study)",
"     </li>",
"     <li>",
"      Increased plasma lipoprotein (a) concentration &mdash; 7.5 percent (one study)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one of these two studies, a positive family history was the only significant predictor for a congenital thrombotic disorder (odds ratio 15) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/23\">",
"     23",
"    </a>",
"    ]. The overall mortality rate in these 100 children was 20 percent, with cumulative recurrence-free survivals at one and seven years of 92 and 82 percent, respectively. In the second study, the overall frequency of inherited prothrombotic coagulation proteins was 13 percent, significantly less than that of an underlying medical condition (91 percent) or the presence of a central venous line (77 percent) in these subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/24\">",
"     24",
"    </a>",
"    ]. However, in older children, the frequency of an inherited prothrombotic defect was significantly higher in those with a spontaneous episode of VTE (60 percent) than with VTEs secondary to an underlying medical condition (10 percent).",
"   </p>",
"   <p>",
"    A systematic review and meta-analysis of observational studies showed a statistically significant association between VTE onset and all inherited prothrombotic coagulation disorders with a summary odds ratios ranging from 2.63 (95% CI, 1.61-4.29) for the prothrombin gene mutation to 9.44 (95% CI, 3.34&ndash;26.66) for antithrombin deficiency. A significant association with recurrent VTE was found for all inherited prothrombotic coagulation disorders except the factor V Leiden and elevated lipoprotein [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite this association, screening for thrombophilia in otherwise healthy children younger than 15 years who belong to families with inherited thrombotic disorders is not justified because the actual risk of VTE in such children is low. A prospective cohort study assessed the incidence of VTE (both spontaneous and risk period-related) in 143 asymptomatic children aged 1 to 14 years, who were family members of 63 probands with an inherited prothrombotic coagulation disorder and VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/17\">",
"     17",
"    </a>",
"    ]. Of the 143 children, 81 (56.6 percent) were carriers of inherited prothrombotic coagulation disorders, and 62 (43.4 percent) were free from thrombophilia. Thirty-one risk periods occurred in the carriers group and 20 in noncarriers. Neither spontaneous nor risk period-related VTE occurred in either group during 395 and 296 observation years, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14825?source=see_link\">",
"     \"Screening for inherited thrombophilia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several factors may protect children from VTE, thus contributing to their low incidence throughout childhood:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As compared to adults, plasma concentrations of all vitamin K-dependent factors, almost all contact factors, and the capacity to generate thrombin are decreased throughout childhood [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The capacity to inhibit thrombin is enhanced throughout childhood due to increased plasma concentrations of the thrombin inhibitor alpha-2-macroglobulin [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/26-28\">",
"       26-28",
"      </a>",
"      ]. Elevated levels of alpha-2- macroglobulin may be especially helpful in counteracting the low levels of antithrombin normally seen in the first six months of life and in infants with respiratory distress, necrotizing enterocolitis, sepsis, or disseminated intravascular coagulation [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24136?source=see_link&amp;anchor=H14#H14\">",
"       \"Antithrombin (ATIII) deficiency\", section on 'Plasma AT concentrations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children less frequently develop diseases causing damage to the vascular endothelium (eg, diabetes, dyslipidemias, hypertension).",
"     </li>",
"     <li>",
"      Children are less frequently exposed to acquired prothrombotic risk factors (eg, oral contraceptives, hormone replacement therapy, pregnancy and puerperium, smoking, malignancy, orthopedic surgery).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other acquired conditions that are frequently associated with VTEs in children include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infection",
"     </li>",
"     <li>",
"      Congenital heart disease",
"     </li>",
"     <li>",
"      Trauma",
"     </li>",
"     <li>",
"      Nephrotic syndrome",
"     </li>",
"     <li>",
"      Systemic lupus erythematosus [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/1,2,30\">",
"       1,2,30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Acute lymphoblastic leukemia &ndash; Symptomatic VTE may be a complication of chemotherapy for acute lymphoblastic leukemia (ALL) using L-asparaginase and steroids, with an incidence as high as 12 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. In one study, only the concomitant use of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/1/16405?source=see_link\">",
"       Escherichia coli asparaginase",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      in a Caucasian child with ALL and a prothrombotic risk factor was found to increase the rate of thrombotic manifestations during treatment (odds ratio 35) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/32\">",
"       32",
"      </a>",
"      ]. Prophylactic use of low molecular weight",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       heparin",
"      </a>",
"      may be helpful in preventing such episodes [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/33\">",
"       33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/36/6730?source=see_link&amp;anchor=H3#H3\">",
"       \"Drug-induced thrombosis and vascular disease in patients with malignancy\", section on 'L-asparaginase'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31850?source=see_link&amp;anchor=H7#H7\">",
"       \"Overview of the treatment of acute lymphoblastic leukemia in children\", section on 'Thrombosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Inheritance of a congenital prothrombotic risk factor may significantly influence the clinical phenotype of co-inherited hemophilia A, both in terms of the first episode of severe bleeding as well as development of catheter-related thrombosis during replacement therapy with factor VIII [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Risk factors for recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although much is known about the factors underlying the risk for recurrence of VTE in adults, little is known about these risks in children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of inherited thrombophilia\", section on 'Long-term therapy to prevent recurrence'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link&amp;anchor=H21#H21\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Warfarin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children that have an underlying acquired risk factor for VTE (a CVL or underlying medical condition), recurrence is uncommon if the underlying cause is removed. In a study involving 153 consecutive neonates and children with VTE, 91 percent had an underlying medical condition and 77 percent a central venous line [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/24\">",
"     24",
"    </a>",
"    ]. The risk of VTE recurrence in this study was 10.5 percent; in all children, the same acquired risk factor was present in the first and the recurrent episode of VTE. In this population, the presence of a prothrombotic state or an elevated level of factor VIII was not associated with recurrence.",
"   </p>",
"   <p>",
"    By contrast, a prothrombotic state is a predictor of VTE recurrence among children without an underlying acquired risk factor for VTE. As an example, a large German study included 301 children with an objectively confirmed first episode of spontaneous VTE (ie, not associated with CVLs, immobilization, trauma, infection or cancer) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/36\">",
"     36",
"    </a>",
"    ]. The children were followed for a median of seven years (range: 0.5 to 15 years) following withdrawal of anticoagulation. Recurrent VTE occurred in 64 patients (21 percent) at a median time of 3.5 years after cessation of anticoagulants. When compared to children with no inherited prothrombotic defects, those with a single defect (odds ratio 4.6, 95% CI 2.3-9.0) and those with two or more defects (odds ratio 24, 95% CI 5.3-109) had significantly increased risks for VTE recurrence. Neither gender nor the presence of an acquired predisposing risk factor (eg, immobilization, surgery, trauma) influenced the risk of recurrent VTE in these children (odds ratio 0.86, 95% CI 0.45-1.6). &nbsp;",
"   </p>",
"   <p>",
"    In a study of 82 children with a radiologically confirmed acute thrombotic event, elevated plasma levels of factor VIII, D-dimer, or both at the time of diagnosis (odds ratio 6.1, 95% CI 2.1-18), and a persistent elevation of at least one of these two factors after standard-duration anticoagulant therapy (odds ratio 4.7, 95% CI 1.8-13) predicted for a poor outcome (ie, lack of thrombus resolution, recurrent thrombosis, or the post-thrombotic syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations of VTE in children vary, depending on both the location and extension of the thrombus. The vast majority of VTE in children are CVL-related and thus tend to be located in the upper venous system where most CVLs are placed. Non-CVL-related VTEs can occur in any venous system, but most commonly present in the lower extremities, especially in the iliac, femoral,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    popliteal veins. VTE may also develop in specific organ systems, including the lung, liver, and kidney.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Central venous line",
"    </span>",
"    &nbsp;&mdash;&nbsp;CVL-related VTE are usually asymptomatic or manifests with chronic symptoms, including repeated loss of CVL patency, CVL-related sepsis, and prominent collateral circulation in the skin over the chest, back, neck, and face [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/1,38,39\">",
"     1,38,39",
"    </a>",
"    ]. Symptomatic VTE manifests acutely with swelling and discoloration of the related limb, swelling of the face, pulmonary embolism, chylothorax,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    superior vena cava syndrome (which is characterized by dyspnea, a sensation of fullness in the head, dilated neck veins and mediastinal widening on chest x-ray) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/40-43\">",
"     40-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of asymptomatic CVL-related VTE is estimated at 66 percent of all children with a CVL, and up to 40 percent of pediatric oncologic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Deep vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;VTE in the lower extremities manifests with leg pain, inguinal or abdominal pain, swelling, and reddish or purple discoloration of the legs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis of suspected deep vein thrombosis of the lower extremity\", section on 'Clinical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pulmonary embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case series, retrospective, and autopsy studies show that pulmonary embolism (PE) is rarely diagnosed in children [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. As in adults, PE can manifest with pleuritic chest pain, tachypnea, cough, tachycardia, acute dyspnea, and sudden collapse. Most commonly, however, the clinical manifestations of PE in children, especially younger ones, are not specific and often mimic the clinical symptoms of the underlying disease. For this reason and because younger children cannot verbalize their symptoms, PE should be considered in the differential diagnosis of cardiorespiratory deterioration in all critically ill children [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27241?source=see_link&amp;anchor=H14#H14\">",
"     \"Approach to chest pain in children\", section on 'Pulmonary embolism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data are limited on the incidence, risk factors, and clinical features of pediatric PE.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a small retrospective study in which 18 patients with PE were identified over a 15-year period, the incidence of PE was estimated as 78 per 100,000 hospitalized adolescents [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/50\">",
"       50",
"      </a>",
"      ]. In this series, major risk factors for PE were oral contraceptive use and pregnancy termination in females, and trauma in males. Other predisposing causes include immobility, ventriculoatrial shunts for hydrocephalus, central venous catheters, solid tumors, heart disease, infection, dehydration, hypercoagulable states, low cardiac output, and obesity [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/46,51\">",
"       46,51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a larger case series of 56 patients with radiologically proven PE, risk factors associated with PE were immobility, central venous line, and recent surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/52\">",
"       52",
"      </a>",
"      ]. In a subsequent report, the authors reported the use of the Wells' score and D-dimer measurement were not useful in diagnosing PE in a similar cohort of children [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/53\">",
"       53",
"      </a>",
"      ]. These patients had a 14 percent chance of reoccurrence of PE, and a mortality rate of 21 percent. Two of the deaths were related to pulmonary hemorrhage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Renal vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal vein thrombosis (RVT) is the most prevalent non-catheter related VTE during the neonatal period and accounts for 16 to 20 percent of all thromboembolic events in newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/54\">",
"     54",
"    </a>",
"    ]. RVT can also develop in older children, usually secondary to the nephrotic syndrome, burns, systemic lupus erythematosus, or renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/55-59\">",
"     55-59",
"    </a>",
"    ]. RVT may manifest with hematuria, anuria, vomiting, hypovolemia, proteinuria, and thrombocytopenia. However, RVT most often has an insidious onset and produces no symptoms referable to the kidney. In this case the RVT may first be diagnosed when the patient presents with a pulmonary embolus. When the thrombus extends from the renal vein into the inferior vena cava, both lower extremities may become cyanotic and edematous. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3273?source=see_link&amp;anchor=H7#H7\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\", section on 'Renal vein thrombosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Portal vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombosis of the hepatic venous system mostly occurs within the portal venous system. In neonates, the incidence of portal vein thrombosis (PVT) ranges from 1 in 100,000 live births to 36 per 1000 neonatal intensive care unit admissions. Neonatal PVT is mostly related to umbilical catheterization and sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/60\">",
"     60",
"    </a>",
"    ]. Older children may develop PVT secondary to liver transplantation, infections, splenectomy, sickle cell disease, chemotherapy, or the presence of antiphospholipid antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/61-66\">",
"     61-66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PVT in neonates may be asymptomatic or present with thrombocytopenia or liver serum biochemical abnormalities. As a result of the lack of symptoms, the diagnosis may not be suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/60\">",
"     60",
"    </a>",
"    ]. PVT also may manifest acutely with symptoms of an acute abdomen, particularly in adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/67\">",
"     67",
"    </a>",
"    ], or be asymptomatic for long periods of time until symptoms reflecting chronic portal hypertension occur (eg, splenomegaly or gastrointestinal bleeding secondary to esophageal varices) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     POST-THROMBOTIC SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The post-thrombotic syndrome (PTS) is a chronic complication of VTE. It is characterized by chronic venous insufficiency, with symptoms varying from mild edema to chronic pain and ulceration of the affected limb [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/68\">",
"     68",
"    </a>",
"    ]. PTS occurs secondary to a combination of pathophysiologic mechanisms, including an initial inflammatory process within the involved vein, venous outflow obstruction, destruction of venous valves, and venous reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43365?source=see_link\">",
"     \"Pathophysiology of chronic venous disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23127?source=see_link\">",
"     \"Post-thrombotic (postphlebitic) syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diagnosis of PTS is primarily based upon clinical symptoms including localized edema, pain, alterations in skin temperature, differences in limb circumference, and the presence of varicose veins, trophic skin changes (stasis dermatitis), and skin ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13592?source=see_link\">",
"     \"Clinical evaluation of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No accurate information is available on the incidence, clinical features, long-term outcome, and risk factors of PTS in children. Estimates of the risk of PTS developing after VTE in children range from 10 to 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/23,38,72,73\">",
"     23,38,72,73",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial follow-up data from the Canadian registry suggests an incidence of clinically detected PTS in children of approximately 10 to 12 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a cross-sectional study using a pediatric PTS score, 52 percent and 10 percent of 153 non-selected children with a previous episode of deep vein thrombosis showed a mild or moderate degree of PTS, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/72\">",
"       72",
"      </a>",
"      ]. In particular, occlusive venous thrombosis is identified as a predictor of PTS. About 10 percent of patients with occlusive disease have PTS.",
"     </li>",
"     <li>",
"      In a third study, PTS was detected in approximately 50 percent of children with congenital heart disease 5 to 10 years after their first cardiac catheterization [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      PTS was also identified in 77 percent of patients receiving standard anticoagulation therapy compared to 22 percent of patients receiving thrombolytic therapy. Although the increased incidence of PTS may be related to patient selection, thrombolytic therapy should not be used as standard therapy for VTE in children [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pediatric PTS scales for both the upper and the lower venous system have been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. However, all current scales have limitations, and further efforts to standardize the diagnosis of PTS in children are needed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15808452\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children, approximately two-thirds of venous thromboembolisms (VTEs) are associated with the use of central venous lines or access devices (CVL). Indwelling CVLs are thrombogenic because they present a foreign intravascular surface, damage vessel walls, and disrupt blood flow. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Central venous access devices'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      The association between inherited prothrombotic disorders and VTE in children is less well-established than in adults. In children with VTE, the prevalence of inherited prothrombotic disorders ranges from 10 to 59 percent. These include mutations in factor V Leiden and the prothrombin gene (G20210A), and deficiencies in protein S, protein C, or antithrombin. The value of screening for inherited prothrombotic disorders in otherwise healthy children belonging to families with inherited defects is debatable [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25033/abstract/78\">",
"       78",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Inherited hypercoagulable states'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14825?source=see_link\">",
"       \"Screening for inherited thrombophilia in children\"",
"      </a>",
"      .) &nbsp; &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      Other acquired conditions that frequently are associated with VTEs in children include infection, congenital heart disease, trauma, protein-losing condition (eg, nephrotic syndrome or inflammatory bowel disease), systemic lupus erythematosus, and acute lymphoblastic leukemia. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Other conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations of VTE in children depend on the location and extension of the thrombus:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      CVL-related VTEs tend to be located in the upper venous system where most CVLs are placed. CVL-related VTE are usually asymptomatic or manifest with chronic symptoms, including repeated loss of CVL patency, CVL-related sepsis, and prominent collateral circulation in the skin over the chest, back, neck, and face. Symptomatic VTE manifests acutely with swelling and discoloration of the related limb, swelling of the face, pulmonary embolism, chylothorax,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      superior vena cava syndrome. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Central venous line'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Non-CVL-related VTEs can occur in any venous system, but most commonly present in the lower extremities, especially in the iliac, femoral,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      popliteal veins. VTE in the lower extremities manifests with leg pain, inguinal or abdominal pain, swelling, and reddish or purple discoloration of the legs. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Deep vein thrombosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=see_link&amp;anchor=H6#H6\">",
"       \"Diagnosis of suspected deep vein thrombosis of the lower extremity\", section on 'Clinical examination'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The clinical manifestations of pulmonary embolism (PE) in children are not specific and often mimic the clinical symptoms of the underlying disease. PE can manifest with pleuritic chest pain, tachypnea, cough, tachycardia, acute dyspnea, and sudden collapse. A high index of clinical suspicion is warranted in children with risk factors for PE, including oral contraceptive use and pregnancy termination, trauma, central venous line, and immobility. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pulmonary embolism'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Renal vein thrombosis (RVT) most often has an insidious onset and produces no symptoms referable to the kidney. In this case the RVT may first be diagnosed when the patient presents with a pulmonary embolus. When the thrombus extends from the renal vein into the inferior vena cava, both lower extremities may become cyanotic and edematous. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Renal vein thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Portal vein thrombosis (PVT) may manifest acutely with symptoms of an acute abdomen, or be asymptomatic for long periods of time until symptoms of chronic portal hypertension occur (eg, splenomegaly or gastrointestinal bleeding secondary to esophageal varices).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The post-thrombotic syndrome (PTS) is a chronic complication of VTE. It is characterized by chronic venous insufficiency, with symptoms varying from mild edema to chronic pain and ulceration of the affected limb. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Post-thrombotic syndrome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/1\">",
"      Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994; 83:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/2\">",
"      van Ommen CH, Heijboer H, B&uuml;ller HR, et al. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr 2001; 139:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/3\">",
"      Stein PD, Kayali F, Olson RE. Incidence of venous thromboembolism in infants and children: data from the National Hospital Discharge Survey. J Pediatr 2004; 145:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/4\">",
"      Raffini L, Huang YS, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007. Pediatrics 2009; 124:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/5\">",
"      Setty BA, O'Brien SH, Kerlin BA. Pediatric venous thromboembolism in the United States: a tertiary care complication of chronic diseases. Pediatr Blood Cancer 2012; 59:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/6\">",
"      Tuckuviene R, Christensen AL, Helgestad J, et al. Pediatric venous and arterial noncerebral thromboembolism in Denmark: a nationwide population-based study. J Pediatr 2011; 159:663.",
"     </a>",
"    </li>",
"    <li>",
"     Virchow, R. Phlogose und Thrombose im Gef&auml;sssystem. In: Gesammelte Abhandlungen zur Wissenschaftlichen Medizin, Virchow, R (Ed), Frankfurt 1856. p.458.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/8\">",
"      Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost 2001; 86:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/9\">",
"      Kuhle S, Massicotte P, Chan A, et al. Systemic thromboembolism in children. Data from the 1-800-NO-CLOTS Consultation Service. Thromb Haemost 2004; 92:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/10\">",
"      Massicotte MP, Dix D, Monagle P, et al. Central venous catheter related thrombosis in children: analysis of the Canadian Registry of Venous Thromboembolic Complications. J Pediatr 1998; 133:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/11\">",
"      Worly JM, Fortenberry JD, Hansen I, et al. Deep venous thrombosis in children with diabetic ketoacidosis and femoral central venous catheters. Pediatrics 2004; 113:e57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/12\">",
"      Male C, Chait P, Ginsberg JS, et al. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children: results of the PARKAA study. Prophylactic Antithrombin Replacement in Kids with ALL treated with Asparaginase. Thromb Haemost 2002; 87:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/13\">",
"      Middeldorp S, Henkens CM, Koopman MM, et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998; 128:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/14\">",
"      Simioni P, Sanson BJ, Prandoni P, et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/15\">",
"      Kosch A, Koch HG, Heinecke A, et al. Increased fasting total homocysteine plasma levels as a risk factor for thromboembolism in children. Thromb Haemost 2004; 91:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/16\">",
"      Chalmers EA. Heritable thrombophilia and childhood thrombosis. Blood Rev 2001; 15:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/17\">",
"      Tormene D, Simioni P, Prandoni P, et al. The incidence of venous thromboembolism in thrombophilic children: a prospective cohort study. Blood 2002; 100:2403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/18\">",
"      Nowak-G&ouml;ttl U, D&uuml;bbers A, Kececioglu D, et al. Factor V Leiden, protein C, and lipoprotein (a) in catheter-related thrombosis in childhood: a prospective study. J Pediatr 1997; 131:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/19\">",
"      Bonduel M, Hepner M, Sciuccati G, et al. Prothrombotic abnormalities in children with venous thromboembolism. J Pediatr Hematol Oncol 2000; 22:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/20\">",
"      Bonduel M, Hepner M, Sciuccati G, et al. Factor V Leiden and prothrombin gene G20210A mutation in children with venous thromboembolism. Thromb Haemost 2002; 87:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/21\">",
"      Lawson SE, Butler D, Enayat MS, Williams MD. Congenital thrombophilia and thrombosis: a study in a single centre. Arch Dis Child 1999; 81:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/22\">",
"      van Ommen CH, Peters M. Venous thromboembolic disease in childhood. Semin Thromb Hemost 2003; 29:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/23\">",
"      van Ommen CH, Heijboer H, van den Dool EJ, et al. Pediatric venous thromboembolic disease in one single center: congenital prothrombotic disorders and the clinical outcome. J Thromb Haemost 2003; 1:2516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/24\">",
"      Revel-Vilk S, Chan A, Bauman M, Massicotte P. Prothrombotic conditions in an unselected cohort of children with venous thromboembolic disease. J Thromb Haemost 2003; 1:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/25\">",
"      Young G, Albisetti M, Bonduel M, et al. Impact of inherited thrombophilia on venous thromboembolism in children: a systematic review and meta-analysis of observational studies. Circulation 2008; 118:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/26\">",
"      Andrew M, Vegh P, Johnston M, et al. Maturation of the hemostatic system during childhood. Blood 1992; 80:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/27\">",
"      Massicotte P, Leaker M, Marzinotto V, et al. Enhanced thrombin regulation during warfarin therapy in children compared to adults. Thromb Haemost 1998; 80:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/28\">",
"      Mitchell L, Piovella F, Ofosu F, Andrew M. Alpha-2-macroglobulin may provide protection from thromboembolic events in antithrombin III-deficient children. Blood 1991; 78:2299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/29\">",
"      Manco-Johnson MJ. Neonatal antithrombin III deficiency. Am J Med 1989; 87:49S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/30\">",
"      Levy DM, Massicotte MP, Harvey E, et al. Thromboembolism in paediatric lupus patients. Lupus 2003; 12:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/31\">",
"      Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thromb Res 2003; 111:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/32\">",
"      Nowak-G&ouml;ttl U, Heinecke A, von Kries R, et al. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res 2001; 103:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/33\">",
"      Elhasid R, Lanir N, Sharon R, et al. Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis 2001; 12:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/34\">",
"      Nowak-G&ouml;ttl U, Escuriola C, Kurnik K, et al. Haemophilia and thrombophilia. What do we learn about combined inheritance of both genetic variations? Hamostaseologie 2003; 23:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/35\">",
"      Journeycake JM, Quinn CT, Miller KL, et al. Catheter-related deep venous thrombosis in children with hemophilia. Blood 2001; 98:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/36\">",
"      Nowak-G&ouml;ttl U, Junker R, Kreuz W, et al. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 2001; 97:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/37\">",
"      Goldenberg NA, Knapp-Clevenger R, Manco-Johnson MJ, Mountain States Regional Thrombophilia Group. Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children. N Engl J Med 2004; 351:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/38\">",
"      Monagle P, Adams M, Mahoney M, et al. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr Res 2000; 47:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/39\">",
"      Journeycake JM, Buchanan GR. Catheter-related deep venous thrombosis and other catheter complications in children with cancer. J Clin Oncol 2006; 24:4575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/40\">",
"      Marie I, L&eacute;vesque H, Cailleux N, et al. [Deep venous thrombosis of the upper limbs. Apropos of 49 cases]. Rev Med Interne 1998; 19:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/41\">",
"      Mulvihill SJ, Fonkalsrud EW. Complications of superior versus inferior vena cava occlusion in infants receiving central total parenteral nutrition. J Pediatr Surg 1984; 19:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/42\">",
"      Rockoff MA, Gang DL, Vacanti JP. Fatal pulmonary embolism following removal of a central venous catheter. J Pediatr Surg 1984; 19:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/43\">",
"      Derish MT, Smith DW, Frankel LR. Venous catheter thrombus formation and pulmonary embolism in children. Pediatr Pulmonol 1995; 20:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/44\">",
"      Glaser DW, Medeiros D, Rollins N, Buchanan GR. Catheter-related thrombosis in children with cancer. J Pediatr 2001; 138:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/45\">",
"      Wilimas JA, Hudson M, Rao B, et al. Late vascular occlusion of central lines in pediatric malignancies. Pediatrics 1998; 101:E7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/46\">",
"      Buck JR, Connors RH, Coon WW, et al. Pulmonary embolism in children. J Pediatr Surg 1981; 16:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/47\">",
"      Byard RW, Cutz E. Sudden and unexpected death in infancy and childhood due to pulmonary thromboembolism. An autopsy study. Arch Pathol Lab Med 1990; 114:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/48\">",
"      Matthew DJ, Levin M. Pulmonary thromboembolism in children. Intensive Care Med 1986; 12:404.",
"     </a>",
"    </li>",
"    <li>",
"     Andrew, M, Monagle, P, Brooker, LA. Thromboembolic complications during infancy and childhood. BC Decker Inc, Hamilton, Ontario 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/50\">",
"      Bernstein D, Coupey S, Schonberg SK. Pulmonary embolism in adolescents. Am J Dis Child 1986; 140:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/51\">",
"      Goldsby RE, Saulys AJ, Helton JG. Pediatric pulmonary artery thromboembolism: an illustrative case. Pediatr Emerg Care 1996; 12:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/52\">",
"      Biss TT, Brand&atilde;o LR, Kahr WH, et al. Clinical features and outcome of pulmonary embolism in children. Br J Haematol 2008; 142:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/53\">",
"      Biss TT, Brand&atilde;o LR, Kahr WH, et al. Clinical probability score and D-dimer estimation lack utility in the diagnosis of childhood pulmonary embolism. J Thromb Haemost 2009; 7:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/54\">",
"      Brand&atilde;o LR, Simpson EA, Lau KK. Neonatal renal vein thrombosis. Semin Fetal Neonatal Med 2011; 16:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/55\">",
"      Tinaztepe K, Buyan N, Tinaztepe B, Akk&ouml;k N. The association of nephrotic syndrome and renal vein thrombosis: a clinicopathological analysis of eight pediatric patients. Turk J Pediatr 1989; 31:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/56\">",
"      Chugh KS, Malik N, Uberoi HS, et al. Renal vein thrombosis in nephrotic syndrome--a prospective study and review. Postgrad Med J 1981; 57:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/57\">",
"      Waymack JP, Tweddell JS, Warden GD. Renal vein thrombosis in burned children. J Burn Care Rehabil 1988; 9:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/58\">",
"      Asherson RA, Lanham JG, Hull RG, et al. Renal vein thrombosis in systemic lupus erythematosus: association with the \"lupus anticoagulant\". Clin Exp Rheumatol 1984; 2:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/59\">",
"      Harmon WE, Stablein D, Alexander SR, Tejani A. Graft thrombosis in pediatric renal transplant recipients. A report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation 1991; 51:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/60\">",
"      Williams S, Chan AK. Neonatal portal vein thrombosis: diagnosis and management. Semin Fetal Neonatal Med 2011; 16:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/61\">",
"      Brady L, Magilavy D, Black DD. Portal vein thrombosis associated with antiphospholipid antibodies in a child. J Pediatr Gastroenterol Nutr 1996; 23:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/62\">",
"      Arav-Boger R, Reif S, Bujanover Y. Portal vein thrombosis caused by protein C and protein S deficiency associated with cytomegalovirus infection. J Pediatr 1995; 126:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/63\">",
"      Skarsgard E, Doski J, Jaksic T, et al. Thrombosis of the portal venous system after splenectomy for pediatric hematologic disease. J Pediatr Surg 1993; 28:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/64\">",
"      Arnold KE, Char G, Serjeant GR. Portal vein thrombosis in a child with homozygous sickle-cell disease. West Indian Med J 1993; 42:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/65\">",
"      Harper PL, Edgar PF, Luddington RJ, et al. Protein C deficiency and portal thrombosis in liver transplantation in children. Lancet 1988; 2:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/66\">",
"      Brisse H, Orbach D, Lassau N, et al. Portal vein thrombosis during antineoplastic chemotherapy in children: report of five cases and review of the literature. Eur J Cancer 2004; 40:2659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/67\">",
"      Stringer MD, Marshall MM, Muiesan P, et al. Survival and outcome after hepatic artery thrombosis complicating pediatric liver transplantation. J Pediatr Surg 2001; 36:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/68\">",
"      Prandoni P, Lensing AW, Prins MR. The natural history of deep-vein thrombosis. Semin Thromb Hemost 1997; 23:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/69\">",
"      Thulesius O. [The pathophysiology of post-thrombotic syndrome]. Wien Med Wochenschr 1994; 144:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/70\">",
"      Immelman EJ, Jeffery PC. The postphlebitic syndrome. Pathophysiology, prevention and management. Clin Chest Med 1984; 5:537.",
"     </a>",
"    </li>",
"    <li>",
"     Ginsberg, JS. Prevention and management of post-thrombotic syndrome. In: Critical Decision in Thrombosis and Hemostasis, Ginsberg, JS, Kearon, C, Hirsh, J (Eds), BC Decker Inc, Hamilton 1998. p.174.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/72\">",
"      Kuhle S, Koloshuk B, Marzinotto V, et al. A cross-sectional study evaluating post-thrombotic syndrome in children. Thromb Res 2003; 111:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/73\">",
"      van Ommen CH, Ottenkamp J, Lam J, et al. The risk of postthrombotic syndrome in children with congenital heart disease. J Pediatr 2002; 141:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/74\">",
"      Goldenberg NA, Durham JD, Knapp-Clevenger R, Manco-Johnson MJ. A thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of postthrombotic syndrome in children. Blood 2007; 110:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/75\">",
"      Manco-Johnson M, Knapp-Clevenger R, Miller B, et al. Post-thrombotic syndrome (PTS) in children: Validation of a new pediatric outcome instrument and results in a comprehensive cohort of children with extremity deep vein thrombosis (DVT). Blood 2003; 102:553a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/76\">",
"      Goldenberg NA, Pounder E, Knapp-Clevenger R, Manco-Johnson MJ. Validation of upper extremity post-thrombotic syndrome outcome measurement in children. J Pediatr 2010; 157:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/77\">",
"      Goldenberg NA, Brand&atilde;o L, Journeycake J, et al. Definition of post-thrombotic syndrome following lower extremity deep venous thrombosis and standardization of outcome measurement in pediatric clinical investigations. J Thromb Haemost 2012; 10:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25033/abstract/78\">",
"      Holzhauer S, Goldenberg NA, Junker R, et al. Inherited thrombophilia in children with venous thromboembolism and the familial risk of thromboembolism: an observational study. Blood 2012; 120:1510.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5918 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-189A616C48-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_28_25033=[""].join("\n");
var outline_f24_28_25033=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15808452\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Central venous access devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Inherited hypercoagulable states",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Risk factors for recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Central venous line",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Renal vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Portal vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      POST-THROMBOTIC SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15808452\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24136?source=related_link\">",
"      Antithrombin (ATIII) deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27241?source=related_link\">",
"      Approach to chest pain in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=related_link\">",
"      Catheter-induced upper extremity venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13592?source=related_link\">",
"      Clinical evaluation of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/1/29?source=related_link\">",
"      Complications of central venous catheters and their prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14234?source=related_link\">",
"      Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=related_link\">",
"      Diagnosis of suspected deep vein thrombosis of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/36/6730?source=related_link\">",
"      Drug-induced thrombosis and vascular disease in patients with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=related_link\">",
"      Management of inherited thrombophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14986?source=related_link\">",
"      Management of thrombosis in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31850?source=related_link\">",
"      Overview of the treatment of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/16/14600?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of thrombosis in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43365?source=related_link\">",
"      Pathophysiology of chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23127?source=related_link\">",
"      Post-thrombotic (postphlebitic) syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3273?source=related_link\">",
"      Renal vein thrombosis and hypercoagulable state in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14825?source=related_link\">",
"      Screening for inherited thrombophilia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_28_25034="Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders";
var content_f24_28_25034=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/28/25034/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/28/25034/contributors\">",
"     M Michael Wolfe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/28/25034/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/28/25034/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/28/25034/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/28/25034/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/28/25034/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The introduction of proton pump inhibitors (PPIs) in the late 1980s optimized the medical treatment of acid-related disorders. In addition, PPIs have allowed clinicians to evaluate the role of gastric acid in several extraesophageal manifestations of gastroesophageal reflux disease, including noncardiac chest pain and tracheopulmonary diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will provide an overview of the pharmacology and clinical efficacy of the proton pump inhibitors for a variety of acid-related disorders and address issues related to the comparison of these agents. It will also discuss issues related to stopping these medications. The pharmacology of other drugs used in the treatment of acid-related diseases is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/47/13049?source=see_link\">",
"     \"Pharmacology of antiulcer medications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY OF ACID SECRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal human stomach contains approximately one billion parietal cells that secrete 0.16 M hydrochloric acid (HCl) into the gastric lumen in response to three principal physiological stimuli: acetylcholine, histamine, and gastrin (",
"    <a class=\"graphic graphic_figure graphicRef65068 \" href=\"UTD.htm?18/29/18902\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29160?source=see_link\">",
"     \"Physiology of gastric acid secretion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acetylcholine is the chief neurocrine transmitter, which is released by vagal postganglionic neurons and appears to stimulate hydrogen ion generation directly via a parietal cell muscarinic M3 receptor.",
"     </li>",
"     <li>",
"      Histamine is the primary paracrine transmitter that binds to H2-specific receptors on the parietal cell basolateral membrane, while gastrin, secreted from antral G-cells, comprises the primary endocrine pathway.",
"     </li>",
"     <li>",
"      Gastrin stimulates the generation of hydrogen ions both directly and indirectly, the latter by stimulating histamine secretion from enterochromaffin-like (ECL) cells in the proximate vicinity of parietal cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although interactions among these three pathways are coordinated to promote or inhibit hydrogen ion generation, histamine appears to represent the dominant route as gastrin stimulates acid secretion principally by promoting the release of histamine from ECL cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/5\">",
"     5",
"    </a>",
"    ]. Because of the dominance of this pathway, H2-receptor blockade became the principal means by which acid secretion was inhibited in the mid-1970s.",
"   </p>",
"   <p>",
"    During the unstimulated (basal) state, a large percentage of the parietal cell volume is occupied by tubulovesicles, which are elongated tubes with smooth surface membranes, and by the secretory canaliculus, a small invaginated area of the apical membrane. Upon meal stimulation, these tubulovesicles decrease in number and become transformed into microvilli around the secretory canaliculus, which serves to greatly expand the surface area of the parietal cell in preparation for the active transport of large quantities of hydrogen ions against a 3,000,000:1 ionic gradient [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/5\">",
"     5",
"    </a>",
"    ]. Hydrogen ions are actively secreted in exchange for potassium ions by means of an H-K-ATPase, the so-called proton pump located on the apical surface of the parietal cell. H-K-ATPase comprises the final pathway by which HCl is secreted into the gastric lumen, where it serves to both hydrolyze dietary protein and maintain a sterile environment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Structure of the parietal cell H-K-ATPase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The parietal cell H-K-ATPase is a member of the family of ion-motive transport enzymes that includes F1, V, and P ATPases. The last is further divided into P1 or P2 types based either on the transport of transition metals (P1) or small cations (P2) or alternatively on the number of transmembrane segments [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/1\">",
"     1",
"    </a>",
"    ]. The P2 family possesses one catalytic subunit with 10 transmembrane segments and a beta subunit with one transmembrane segment, and exists as two principal forms: H-K-ATPase and Na-K-ATPase. These isoforms are tightly bound to a beta-subunit that is smaller than the catalytic alpha-subunit and are glycosylated to a different extent depending upon the isoform.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY OF THE PROTON PUMP INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recognition that H-K-ATPase was the final step of acid secretion culminated in the development of a class of drugs, the proton pump inhibitors (PPIs), which are targeted at inhibiting this enzyme. PPIs all share a common structural motif, but vary in terms of their substitutions. They are all weak protonatable pyridines, with a pKa of about 4.0 for",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"      omeprazole",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15993?source=see_link\">",
"      esomeprazole",
"     </a>",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"      lansoprazole",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/9/27799?source=see_link\">",
"      dexlansoprazole",
"     </a>",
"     ,",
"    </span>",
"    about 3.9 for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"     pantoprazole",
"    </a>",
"    , and about 5.0 for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/18/44327?source=see_link\">",
"     rabeprazole",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef72598 \" href=\"GAST_72598\">",
"     table 1",
"    </a>",
"    ). As a result, they accumulate specifically and selectively in the secretory canaliculus, the highly acid space of the parietal cell [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/1\">",
"     1",
"    </a>",
"    ]. Within that space, PPIs undergo an acid catalyzed conversion to a reactive species, the thiophilic sulfenamide, which are permanent cations.",
"   </p>",
"   <p>",
"    The rate of conversion varies among the compounds and is inversely proportional to the pKa of the benzimidazole [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/18/44327?source=see_link\">",
"     rabeprazole",
"    </a>",
"    &gt;",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"      omeprazole",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15993?source=see_link\">",
"      esomeprazole",
"     </a>",
"    </span>",
"    =",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"      lansoprazole",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/9/27799?source=see_link\">",
"      dexlansoprazole",
"     </a>",
"    </span>",
"    &gt;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"     pantoprazole",
"    </a>",
"    . The reactive species interacts with the external surface of the H-K-ATPase that faces the lumen of the secretory space of the parietal cell, resulting in disulfide bond formation with cysteine 813 located within the alpha-subunit of the enzyme; this is the residue that is intimately involved in hydrogen ion transport. This covalent inhibition of the enzyme by the thiophilic sulfenamide results in a specific and long-lasting impairment of gastric acid secretion.",
"   </p>",
"   <p>",
"    In vitro studies using rat microsomal membrane preparations containing H-K-ATPase have demonstrated that, in addition to cysteine 813,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"     pantoprazole",
"    </a>",
"    binds to cysteine 822, which is situated deeper in the membrane domain TM6 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/7\">",
"     7",
"    </a>",
"    ]. Recovery of acid secretion following pantoprazole was prolonged compared to other PPIs possibly as a result of its binding to cysteine 822. Neither in vivo nor clinical studies have been performed to determine whether these observations are clinically relevant.",
"   </p>",
"   <p>",
"    The PPIs are the most potent inhibitors of gastric acid secretion available [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/1\">",
"     1",
"    </a>",
"    ]. They are most effective when the parietal cell is stimulated to secrete acid postprandially, a relationship that has important clinical implications for timing of administration. Because the amount of H-K-ATPase present in the parietal cell is greatest after a prolonged fast, PPIs should be administered before the first meal of the day. In most individuals, once-daily dosing is sufficient to produce the desired level of acid inhibition, and a second dose, which is occasionally necessary, should be administered before the evening meal [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/1\">",
"     1",
"    </a>",
"    ]. PPIs should",
"    <strong>",
"     not",
"    </strong>",
"    be given concomitantly with H2-antagonists, prostaglandins, somatostatin analogues (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    ), or other antisecretory agents because of the marked reduction in their acid inhibitory effects when administered simultaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/1,8\">",
"     1,8",
"    </a>",
"    ]. An H2 antagonist can be used with a PPI provided that there is a sufficient time interval between administration of the H2 antagonist and the PPI (although the precise minimal time interval has not been established). As an example, an H2 antagonist can be taken before bedtime or during the night by individuals who report nocturnal breakthrough symptoms such as heartburn after taking a PPI in the morning.",
"   </p>",
"   <p>",
"    During meals, neither all parietal cells nor all proton pumps are active. Since PPIs inhibit only activated enzyme present in the canalicular membrane, the reduction of gastric acid secretion after an initial dose will probably be suboptimal. As inactive enzyme is recruited into the secretory canaliculus, acid secretion will resume, albeit at a reduced level. After the second dose is given on the next day, more H-K-ATPase will have been recruited and subsequently inhibited, and after the third dose, additional recruitment and further acid inhibition will probably occur.",
"   </p>",
"   <p>",
"    Once-daily PPI dosing inhibits maximal acid output by about 66 percent after five days. Thus, the occasional use of a PPI taken on an \"as needed\" basis does not reliably provide adequate acid inhibition and does not produce a consistent or satisfactory clinical response (in contrast to the H2 antagonists, which have a more rapid onset of action) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/1\">",
"     1",
"    </a>",
"    ]. Because of the delay in optimal acid inhibition, the initial use of twice-daily PPI dosing (for the first two to three days) may be helpful in achieving more rapid inhibition of gastric acid secretion. In addition to their delay in onset, and because PPI-derived thiophilic sulfenamides bind covalently to H-K-ATPase, the restoration of acid secretion will likewise be delayed, depending upon enzyme turnover and the biological reversibility of the disulfide bond. Maximal acid secretory capacity may not be restored for 24 to 48 hours after discontinuing PPIs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Rebound acid hypersecretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rebound acid hypersecretion after withdrawal of PPIs is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29160?source=see_link\">",
"     \"Physiology of gastric acid secretion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT OF ACID-RELATED DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PPIs are effective for treatment of all acid-related disorders. The following sections will summarize data demonstrating the efficacy of the PPIs in a variety of clinical settings. Detailed discussions on each of these disorders are also presented separately on the corresponding topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Peptic ulcer disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;PPIs heal gastroduodenal ulcers more rapidly than H2-receptor antagonists. A meta-analysis comparing the healing of duodenal ulcers found that 20 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    every morning for four weeks was superior to both 300 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    and 800 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    , both administered at bedtime [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/9\">",
"     9",
"    </a>",
"    ]. Similarly, another meta-analysis found that 30 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"     lansoprazole",
"    </a>",
"    every morning healed significantly more ulcers than 300 mg of ranitidine and 40 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/45/728?source=see_link\">",
"     famotidine",
"    </a>",
"    , both administered at bedtime [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/10\">",
"     10",
"    </a>",
"    ]. The pooled healing rates were 60 and 85 percent for lansoprazole at two and four weeks, respectively, while the corresponding figures for the H2-antagonists were 40 and 75 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=see_link\">",
"     \"Overview of the natural history and treatment of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"     Pantoprazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/18/44327?source=see_link\">",
"     rabeprazole",
"    </a>",
"    have also demonstrated superior and accelerated ulcer healing compared with H2-antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The optimal duration of therapy with PPIs should be four and eight weeks for acute duodenal ulcer and gastric ulcer, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Eradication of Helicobacter pylori",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of PPIs in treatment of",
"    <em>",
"     Helicobacter pylori",
"    </em>",
"    (",
"    <em>",
"     H. pylori",
"    </em>",
"    ) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=see_link\">",
"     \"Treatment regimens for Helicobacter pylori\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Treatment and prevention of gastroduodenal ulcers associated with NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have demonstrated that the PPIs are more effective than H2 antagonists for healing gastroduodenal ulcers associated with nonsteroidal antiinflammatory drugs (NSAIDs) when NSAIDs cannot be discontinued. PPIs also appear to be as or more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    . PPIs are also effective for primary prevention of NSAID-associated ulcers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Zollinger-Ellison syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of therapy in individuals with Zollinger-Ellison syndrome (ZES) is surgical gastrinoma excision, which is possible in about 50 percent of those with sporadic disease. However, all patients with ZES require antisecretory therapy after the diagnosis is established and during tumor localization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6968?source=see_link\">",
"     \"Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Treatment of gastroesophageal reflux disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous studies have documented the marked efficacy of PPIs in controlling symptoms of gastroesophageal reflux disease (GERD) and healing esophagitis. Comparative trials show a clear advantage of PPIs over H2-antagonists. As a general rule, doses of PPIs recommended by the manufacturers all administered before breakfast will relieve symptoms and heal esophagitis in approximately 85 to 90 percent of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At least 10 to 15 percent of patients with GERD respond suboptimally to PPIs, particularly those with more advanced grades of esophagitis. The reasons for such failures are not entirely clear but may often be due to their suboptimal administration. Another potential reason stems from the variable antisecretory properties of PPIs based on individual pharmacogenomic differences [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/13\">",
"     13",
"    </a>",
"    ]. Polymorphisms in the",
"    <em>",
"     CYP2C19",
"    </em>",
"    gene, which encodes the cytochrome P450 isoenzyme that metabolizes different PPI preparations, are common in Asian and other populations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/13\">",
"     13",
"    </a>",
"    ]. Such gene mutations would render an individual a \"slow metabolizer\" and prolong the antisecretory effect of PPIs. In contrast, the duration of acid inhibition would be decreased in a \"rapid metabolizer\", and differences in PPI metabolism might account for incomplete inhibition of acid secretion and a high prevalence of nocturnal breakthrough symptoms in GERD patients.",
"   </p>",
"   <p>",
"    A careful history regarding the timing of PPI administration should be obtained in individuals who do not respond to PPIs. As noted above, the optimal time is immediately before breakfast. Once the correct timing is established, a second dose of the PPI (before the evening meal) may be helpful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/18/17706?source=see_link\">",
"     \"Approach to refractory gastroesophageal reflux disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    New PPI prodrugs with longer biological half-lives are under development and may address some of the present shortcomings of PPIs. These prodrugs are converted to active sulfenamides by acid in the secretory canaliculus [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/14\">",
"     14",
"    </a>",
"    ]. The substitution of a benzimidazole with an imidazopyridine moiety [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/4-6,14\">",
"     4-6,14",
"    </a>",
"    ] reduces the rate of metabolism, increasing both the plasma and biological half-lives significantly, the former from approximately 60 to 90 minutes to 9.3 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/14\">",
"     14",
"    </a>",
"    ]. The ultimate benefit of such preparations, if any, will require careful examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with GERD, particularly those with grade III and IV esophagitis, will relapse once therapy is discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/15\">",
"     15",
"    </a>",
"    ]. A landmark study of maintenance therapy compared five regimens:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    , cisapride (no longer available by prescription in the United States and several other countries), ranitidine plus cisapride,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    , and omeprazole plus cisapride [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/16\">",
"     16",
"    </a>",
"    ]. All patients had esophagitis on initial endoscopy and were treated with omeprazole 40 mg daily for eight weeks before initiating one of the maintenance regimens. After 12 months of treatment, remission was maintained in 80 to 90 percent of the omeprazole groups, versus 49 to 60 percent in the other groups. This study demonstrated the superiority of PPIs in maintaining remission and further showed that effective prophylactic doses are generally the same as those required for initial healing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Complications of GERD",
"    </span>",
"    &nbsp;&mdash;&nbsp;PPIs are effective in treating a number of complications related to GERD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Esophageal strictures &ndash; PPIs decrease the eventual number of esophageal dilations required to relieve dysphagia more effectively than H2 antagonists [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19253?source=see_link\">",
"       \"Complications of gastroesophageal reflux in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Barrett's esophagus &ndash; PPIs are frequently used in patients with Barrett's metaplasia, although no studies have shown unequivocal regression of Barrett's esophagus or a decrease in the risk of esophageal malignancy with any medical or surgical therapy. PPI doses are generally the same as those used for healing esophagitis without metaplasia. Individuals with Barrett's metaplasia require continued surveillance for the development of dysplasia or frank adenocarcinoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=see_link\">",
"       \"Management of Barrett's esophagus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Extraesophageal symptoms &ndash; A number of extraesophageal symptoms can occur as a result of acid reflux. As an example, acid reflux is the most common cause of noncardiac chest pain, accounting for 25 to 50 percent of cases in several studies [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/19\">",
"       19",
"      </a>",
"      ]. The association of GERD with other extraesophageal disorders such as idiopathic hoarseness, chronic laryngitis, asthma, and cough has also been suggested in a number of studies. However, because these disorders and GERD are very common, an etiologic relationship has been difficult to establish unequivocally. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19253?source=see_link\">",
"       \"Complications of gastroesophageal reflux in adults\"",
"      </a>",
"      .) See other appropriate topic reviews.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     COMPARISON OF PROTON PUMP INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding discussion underscores that the proton pump inhibitors (PPIs) are similar in structure and mechanism of action, although different doses of the available PPIs are recommended (",
"    <a class=\"graphic graphic_table graphicRef65374 \" href=\"UTD.htm?28/19/28988\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The PPIs differ in their pKa, bioavailability, peak plasma levels, and route of excretion, with",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"      lansoprazole",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/9/27799?source=see_link\">",
"      dexlansoprazole",
"     </a>",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"     pantoprazole",
"    </a>",
"    being the most bioavailable and achieving the highest plasma levels (",
"    <a class=\"graphic graphic_table graphicRef72598 \" href=\"GAST_72598\">",
"     table 1",
"    </a>",
"    ). Because of its higher pKa,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/18/44327?source=see_link\">",
"     rabeprazole",
"    </a>",
"    possesses a slightly faster onset of action, while pantoprazole is often touted as being the most \"gastro-specific\" because of its binding only to cysteine residues 813 and 822 within the alpha-subunit of the proton pump. However, the clinical relevance of these differences has not been established.",
"   </p>",
"   <p>",
"    A number of studies have compared the various proton pump inhibitors to one another [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/20-33\">",
"     20-33",
"    </a>",
"    ]. While some differences have been reported, the magnitude of differences has been small and of uncertain clinical importance. In particular, the degree to which any of the reported differences would justify the selection of one versus another PPI, particularly when considering cost-effectiveness, is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/32\">",
"     32",
"    </a>",
"    ]. One trial that looked at cost-effectiveness found the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the randomized trial, 1564 patients with GERD symptoms despite treatment with a PPI or H2 receptor antagonist were assigned to switch to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15993?source=see_link\">",
"       esomeprazole",
"      </a>",
"      or to continue on their current medication(s) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/34\">",
"       34",
"      </a>",
"      ]. At baseline, 73 percent of the patients were taking a PPI. After four weeks of treatment, patients who switched to esomeprazole had a statistically higher mean quality-adjusted life month (QALM) gain compared with patients who did not switch (0.86 versus 0.82 QALM). The mean cost in Canadian dollars was $763 per QALM gained. However, the mean QALM gain was lower among patients on a PPI at baseline (0.84 for those switched to esomeprazole versus 0.81 for the controls), and the mean cost per QALM gained was $1213. It is important to note that the advantage of switching to esomeprazole was quite small (an additional 0.03 to 0.04 QALMs gained compared with controls) and came at a significant cost.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Importantly, most of the comparative trials evaluated doses of the various PPIs that have been approved by the United States Food and Drug Administration (FDA). However, the doses of various PPIs that would be considered pharmacologically equivalent have not been well established and thus it is possible that all the various PPIs could be equivalent when administered at certain doses. A systematic review of the various PPI comparisons prepared on behalf of the Agency for Healthcare Research and Quality is available on the internet [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A separate question is the effectiveness of substituting one PPI for another in patients who have stabilized on therapy. This issue is important since substitution may be required when health plans change their formulary based upon cost considerations. This issue was examined in a study involving 105 patients with GERD who had stabilized on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    but were converted to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"     lansoprazole",
"    </a>",
"    in equivalent doses by their health plan [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/36\">",
"     36",
"    </a>",
"    ]. A telephone assessment suggested that following conversion the mean symptom severity score increased significantly. Furthermore, 33 percent of patients consumed more over-the-counter heartburn medications, 13 percent changed their diet more frequently due to heartburn, and overall patient satisfaction decreased significantly. These results should be interpreted cautiously since the study was uncontrolled and subject to a number of biases, which were acknowledged by the authors. As an example, patients could have been dissatisfied with the substitution since it may have been perceived as a cost-cutting measure; as a result, they may have been influenced to report negative outcomes on the self-reported questionnaire. Despite these limitations, the study suggests that the similar efficacy of PPIs that has been observed in controlled clinical trials may not necessarily translate into equivalent effectiveness when these drugs are substituted for one another.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Over-the-counter and on-demand PPIs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two unpublished, randomized controlled trials led to the approval of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    magnesium (Prilosec-OTC&reg;) for use without a prescription. The studies, involving a total of 1047 subjects with frequent heartburn, compared Prilosec-OTC&reg; once daily with placebo for 14 days. On day 14, significantly more patients taking omeprazole were free of heartburn (approximately 70 versus 43 percent). The incidence of heartburn was similar to placebo within five days of stopping the drug.",
"   </p>",
"   <p>",
"    Other studies of \"on-demand\" use of PPIs have suggested they can help maintain symptom control better than placebo in patients with mild or no esophagitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/33,37-39\">",
"     33,37-39",
"    </a>",
"    ]. However, the clinical endpoints of such \"on-demand\" trials have not defined success as timely, complete relief of heartburn, which could be considered the most important objective in patients with intermittent symptoms. Rather, they have compared overall assessments of heartburn and medication use at various time points.",
"   </p>",
"   <p>",
"    Furthermore, heartburn control is less effective than with continuous therapy, even though intermittent dosing may be associated with greater overall satisfaction compared with regular use of a PPI [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/37\">",
"     37",
"    </a>",
"    ]. A meta-analysis evaluated the rapidity of heartburn control with PPIs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/40\">",
"     40",
"    </a>",
"    ]. Complete heartburn relief occurred in approximately 30 percent of patients after their first PPI dose compared with 9 percent of patients receiving placebo (RR 0.41, 95% CI 0.28-0.58). The authors concluded that most patients will not have symptom relief after one to two days of PPI therapy. Most studies that the authors included assessed heartburn relief at 24 hours. The 21 percent benefit compared with placebo may be even less important clinically when considering that patients with intermittent symptoms seek rapid relief of heartburn (within minutes) and it is not clear what proportion of patients achieve such timely relief after taking a PPI.",
"   </p>",
"   <p>",
"    As noted in the discussions above, the pharmacokinetics of the PPIs suggest that they are best suited for long-term prevention of heartburn rather than for treatment of acute symptoms. However, labeling of Prilosec-OTC&reg; warns against its use for more than 14 days. Similar considerations apply to other PPIs targeted for the OTC market.",
"   </p>",
"   <p>",
"    Thus, the role of PPIs in the treatment of patients with troubling, intermittent heartburn is uncertain. H2 receptor antagonists may be better suited for this role. No studies have directly compared \"on-demand\" use of PPIs with H2RAs.",
"   </p>",
"   <p>",
"    Three other issues related to the comparison of these drugs are relevant clinically: safety, convenience, and cost.",
"   </p>",
"   <p>",
"    The long-term safety of these drugs has been best established with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    since it was the first to become available clinically. These data suggest that its use for more than 15 years is safe, although some risks have been described. (See",
"    <a class=\"local\" href=\"#H59974871\">",
"     'Safety'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Differences in drug metabolism and drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;While overall proton pump inhibitors are an extremely safe class of drugs, differences in their metabolism may lead to specific drug interactions.",
"   </p>",
"   <p>",
"    As discussed above, some differences among the PPIs do exist with regard to the pKa, bioavailability, peak plasma levels, and route of excretion (",
"    <a class=\"graphic graphic_table graphicRef72598 \" href=\"GAST_72598\">",
"     table 1",
"    </a>",
"    ). In addition, PPIs are metabolized by somewhat different routes, which might affect their clinical efficacy in certain ethnic groups and potentially lead to differences in drug interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PPIs are metabolized via hepatic cytochrome P450 enzymes, with CYP2C19 having the dominant role. However, the dominance of this route varies significantly among the PPIs. The activity of CYP2C19 is determined to some extent by gene polymorphism, and two known inactivating mutations which occur most commonly in Asian populations have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/41\">",
"     41",
"    </a>",
"    ]. Five percent of Caucasians are homozygous for this mutation; as a result, the metabolism of drugs by this route may be delayed in these individuals. About two-thirds of Caucasians are homozygous for the wild type gene; such persons rapidly metabolize drugs, while heterozygotes are intermediate metabolizers.",
"   </p>",
"   <p>",
"    Plasma levels of PPI correlate with their metabolism, and differences may contribute to dose requirements and clinical efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/41\">",
"     41",
"    </a>",
"    ]. As an example, one study examined the effect of variable metabolism of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    when using this agent to treat",
"    <em>",
"     H. pylori",
"    </em>",
"    in Japanese patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/41\">",
"     41",
"    </a>",
"    ]. While eradication was achieved in all individuals homozygous for a CYP2C19 mutation (ie, slow metabolizers), successful treatment was achieved in only 60 and 29 percent of heterozygotes and wild type homozygotes, respectively. Another report from Japan evaluated the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"     lansoprazole",
"    </a>",
"    in the treatment of GERD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/42\">",
"     42",
"    </a>",
"    ]. Slow metabolizers were much more likely to be cured than heterozygotes and wild type homozygotes (85 versus 68 and 46 percent, respectively). The cure rate was only 16 percent in wild type homozygotes who had severe GERD. Furthermore, wild type homozygotes (rapid metabolizers) had the lowest plasma lansoprazole concentrations.",
"   </p>",
"   <p>",
"    Although the presence of a",
"    <em>",
"     CYP2C19",
"    </em>",
"    gene mutation may appear beneficial because of higher plasma levels, deleterious consequences may ensue. If this metabolic pathway becomes saturated, the isoenzyme may become a major target for interactions with many drugs, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef53616 \" href=\"GAST_53616\">",
"     table 3",
"    </a>",
"    ). CYP3A4-mediated metabolism also may be activated under such conditions and may become the principal route of drug elimination. Furthermore, induction of CYP1A, another P450 isoenzyme, may occur in CYP2C19 deficient or saturated individuals, making them susceptible to interference with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    metabolism (",
"    <a class=\"graphic graphic_table graphicRef53616 \" href=\"GAST_53616\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The specific P450 enzymes involved in PPI metabolism and the potential for interactions among these agents varies considerably (",
"    <a class=\"graphic graphic_table graphicRef72565 \" href=\"GAST_72565\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/43-49\">",
"     43-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       Omeprazole",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15993?source=see_link\">",
"       esomeprazole",
"      </a>",
"      are metabolized largely via CYP2C19, and the potential for interactions thus appears to be the greatest among the PPIs. However, R-omeprazole is a more potent inhibitor of CYP2C19 than the S-enantiomer, and thus esomeprazole appears to interfere to a lesser extent with the metabolism of other drugs metabolized by this route than the racemic mixture comprising omeprazole.",
"     </li>",
"     <li>",
"      While",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/18/44327?source=see_link\">",
"       rabeprazole",
"      </a>",
"      is also metabolized by this isoenzyme, it apparently possesses significant affinity for CYP3A4; in any event, very few interactions have been documented with this agent.",
"     </li>",
"     <li>",
"      Although",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"        lansoprazole",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?27/9/27799?source=see_link\">",
"        dexlansoprazole",
"       </a>",
"      </span>",
"      is a potent inhibitor of CYP2C19, as well as other cytochrome P450 isoforms, it is metabolized in vivo principally via CYP3A4, and as predicted, interactions with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      have been reported.",
"     </li>",
"     <li>",
"      Although the metabolism of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"       pantoprazole",
"      </a>",
"      primarily involves CYP2C19 O-demethylation, this step is followed rapidly by sulfate conjugation. As a result, significant CYP3A4 and CYP1A induction is not apparent, and this agent has the lowest potential for P450 metabolism and drug interactions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these differences in drug metabolism, for the most part significant and clinically relevant interactions are uncommon. However, there is particular concern regarding the potential for interactions between PPIs and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    . Clinicians and patients should be cognizant of possible interactions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44569?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction\", section on 'Gastrointestinal prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    None of the PPIs require dose-adjustment for hepatic or renal insufficiency. PPIs may decrease the absorption of certain HIV protease inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Convenience",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the PPIs are available in oral, delayed release formulations. An exception is Zegerid (a formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/28/10697?source=see_link\">",
"     omeprazole-sodium bicarbonate",
"    </a>",
"    ), which is designed for immediate release. There appears to be little, if any, benefit from this formulation except possibly in the occasional patient unable to swallow pills or capsules; other choices under such circumstances include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"     lansoprazole",
"    </a>",
"    (Prevacid SoluTab7) or intravenous PPIs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Intravenous formulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"     Pantoprazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15993?source=see_link\">",
"     esomeprazole",
"    </a>",
"    are the only PPIs available as an intravenous formulation in the United States; intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    is used in other countries, and intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"     lansoprazole",
"    </a>",
"    has been removed from the world market. Although intravenous PPIs have been approved for the treatment of erosive esophagitis in patients unable to tolerate oral treatment, they are more frequently used in management of patients with bleeding peptic ulcers and for the prevention of stress-related mucosal damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=see_link\">",
"     \"Overview of the treatment of bleeding peptic ulcers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Costs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major issue related to the choice among the various PPIs is their relative costs. The costs to the patient and the health plan vary locally depending upon contracting and whether use of over-the-counter (rather than prescription) PPIs is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59974871\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance antisecretory therapy is used in many patients, particularly those with gastroesophageal reflux disease. With the long-term use of any medication, drug safety becomes an important issue. The three main concerns regarding the long-term safety of proton pump inhibitors (PPIs) include the effects of prolonged hypochlorhydria and hypergastrinemia, and the possible association of PPIs with gastric atrophy. In particular, hypochlorhydria is of concern since it may predispose to infections and malabsorption. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25751?source=see_link&amp;anchor=H7#H7\">",
"     \"Physiology of gastrin\", section on 'Causes of hypergastrinemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After a critical review of all available safety data, a 2008 guideline on gastroesophageal reflux disease (GERD) management developed by the American Gastroenterological Association Institute found insufficient evidence to recommend for or against bone density studies, calcium supplementation,",
"    <em>",
"     H. pylori",
"    </em>",
"    screening, or any other routine precaution in patients taking proton pump inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/50\">",
"     50",
"    </a>",
"    ]. However, studies subsequent to that guideline continue to raise concerns about possible infectious complications, electrolyte disturbances, and metabolic bone disease associated with PPI use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59976608\">",
"    <span class=\"h2\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;A concern with any form of gastric acid inhibition is an increased risk of enteric infections since gastric acidity normally protects against these infections. In addition, a reduction in gastric acid secretion permits pathogens to more easily colonize the upper gastrointestinal tract, which may predispose to pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59974951\">",
"    <span class=\"h3\">",
"     Clostridium difficile and other enteric infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best documented association of PPI use with enteric infections has been with",
"    <em>",
"     Clostridium difficile",
"    </em>",
"    (",
"    <em>",
"     C. difficile",
"    </em>",
"    ) diarrhea, even in patients not exposed to antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/51-57\">",
"     51-57",
"    </a>",
"    ].",
"    <em>",
"     C. difficile",
"    </em>",
"    is an anaerobic organism that sporulates; acid-resistant spores are presumed to be the major vector of disease transmission. The role of potent acid suppression and the pathophysiologic mechanisms involved in increasing the risk of",
"    <em>",
"     C. difficile",
"    </em>",
"    by PPI use are unclear.",
"   </p>",
"   <p>",
"    Three meta-analyses of observational studies have demonstrated an increased risk of",
"    <em>",
"     C. difficile",
"    </em>",
"    infections in patients treated with PPIs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. A 2012 meta-analysis of 42 observational studies that included 313,000 patients found that PPI use was significantly associated with an increased risk of both incident and recurrent",
"    <em>",
"     C. difficile",
"    </em>",
"    infection (odds ratio [OR] 1.7; 95% CI 1.5-2.9 and 2.5; 95% CI 1.2-5.4, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/59\">",
"     59",
"    </a>",
"    ]. However, significant heterogeneity was noted among the studies included in the meta-analysis. Both this study and a 2007 meta-analysis found that the risk of",
"    <em>",
"     C. difficile",
"    </em>",
"    infection was greater with PPIs than with H2 receptor antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link&amp;anchor=H7#H7\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\", section on 'Gastric acid suppression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The US Food and Drug Administration (FDA) has issued a safety alert encouraging providers to consider a diagnosis of",
"    <em>",
"     C. difficile",
"    </em>",
"    -associated disease in PPI users with persistent diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/61\">",
"     61",
"    </a>",
"    ]. Given the potential risk of",
"    <em>",
"     C. difficile",
"    </em>",
"    infection, the FDA has also recommended that providers prescribe the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.",
"   </p>",
"   <p>",
"    Associations with other enteric infections, including Campylobacter and Salmonella, have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/62-65\">",
"     62-65",
"    </a>",
"    ], but the magnitude of risk is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/62,66\">",
"     62,66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59974958\">",
"    <span class=\"h3\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of pneumonia in PPI users may be increased due to a reduction in gastric acid secretion, permitting pathogens to more easily colonize the upper gastrointestinal tract. The increased risk has been seen with both community acquired pneumonia (CAP) and health care associated pneumonia (HCAP) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults\", section on 'Predisposing host conditions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13433?source=see_link&amp;anchor=H6#H6\">",
"     \"Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\", section on 'Role of gastric pH'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A meta-analysis of 31 studies found that patients taking PPIs or H2 receptor antagonists (H2RAs) were at increased risk for pneumonia, with an odds ratio of 1.27 (95% CI 1.11-1.46) with PPIs and 1.22 (95% CI 1.09-1.36) with H2RAs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/70\">",
"     70",
"    </a>",
"    ]. One large case-control study found an increased risk of CAP only among patients who started a PPI within the previous 30 days and particularly in those who initiated therapy within the previous 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/69\">",
"     69",
"    </a>",
"    ]. The significance of this finding is uncertain since maximum anti-secretory effects take at least one week to develop.",
"   </p>",
"   <p>",
"    While these observational studies suggest an association between PPI use and pneumonia, the observed association may be due to confounding such that individuals prescribed PPIs may be more likely to have other unobserved health characteristics that predispose them to pneumonia as compared with nonusers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59976220\">",
"    <span class=\"h2\">",
"     Malabsorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concern has been expressed regarding the effects of long-term PPI use on iron and vitamin B12 absorption, though any effects are generally mild, clinically insignificant, and addressed by supplement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/72\">",
"     72",
"    </a>",
"    ]. On the other hand, magnesium and calcium malabsorption may be bigger problems, predisposing to hypomagnesia and metabolic bone disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59977009\">",
"    <span class=\"h3\">",
"     Magnesium absorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypomagnesemia due to reduced intestinal absorption has been described with PPI use [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/73\">",
"     73",
"    </a>",
"    ]. In March 2011, the FDA issued a safety alert warning providers of the risk of hypomagnesemia in patients who have been on PPIs long-term (generally longer than one year) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/74\">",
"     74",
"    </a>",
"    ]. The FDA suggests that providers consider obtaining serum magnesium levels prior to starting a PPI in patients who are expected to be on the medication for long periods of time, or in patients who take PPIs in conjunction with other medications associated with hypomagnesemia (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    or diuretics). The FDA also suggests that providers consider obtaining levels periodically in such patients while they are taking a PPI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15000?source=see_link\">",
"     \"Causes of hypomagnesemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59976497\">",
"    <span class=\"h3\">",
"     Hip fracture and calcium malabsorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term use of PPIs may influence bone metabolism. Hypochlorhydria could theoretically reduce calcium absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/75\">",
"     75",
"    </a>",
"    ] and inhibit osteoclastic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/76,77\">",
"     76,77",
"    </a>",
"    ], thereby decreasing bone density. A case-control trial suggested that long-term use of PPIs was associated with a slightly increased risk of hip fractures in those older than 50 years of age and that the magnitude of the risk increase was proportional to both PPI dose and duration of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/78\">",
"     78",
"    </a>",
"    ]. In another case control study, excess fracture risk for PPI use was only present among persons with at least one other fracture risk factor [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/79\">",
"     79",
"    </a>",
"    ]. However, in a prospective cohort study, chronic PPI use was not associated with osteoporosis or accelerated bone mineral density loss [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=see_link&amp;anchor=H16#H16\">",
"     \"Drugs that affect bone metabolism\", section on 'Proton pump inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A meta-analysis that included 11 cohort and case-control studies examined the risk of fractures associated with PPI use [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/82\">",
"     82",
"    </a>",
"    ]. The 11 studies included 1,084,560 patients with 62,210 PPI users, 71,339 patients with hip fractures, 161,179 patients with any-site fractures, and 5728 patients with spine fractures. The risk of hip fracture was increased among PPI users compared with nonusers (relative risk [RR] 1.30, 95% CI 1.19-1.43). There was also an increased risk of spine fracture (RR 1.56, 95% CI 1.31-1.85) and any-site fracture (RR 1.16, 95% CI 1.02-1.32).",
"   </p>",
"   <p>",
"    Subsequent to the meta-analysis, the Nurses' Health Study reported on the association of hip fracture with PPI use [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/83\">",
"     83",
"    </a>",
"    ]. The study included 79,899 postmenopausal women with 565,786 person-years of follow-up. The absolute risk of hip fracture was 2.02 events per 1000 person-years among regular PPI users, compared with 1.51 events per 1000 person-years for nonusers. The risk of hip fracture was 36 percent higher among women who regularly used PPIs for at least two years compared with nonusers (adjusted hazard ratio [HR] 1.36; 95% CI 1.13-1.63). The difference was more pronounced in current and former smokers, where PPI use was associated with a 51 percent increase in hip fracture (HR 1.51; 95% CI 1.20-1.91). On the other hand, there was no significant increase in hip fracture risk among nonsmokers who used PPIs (HR 1.06; 95% CI 0.77-1.46). The authors then performed a meta-analysis that included these results and 10 prior studies and found that the pooled odds ratio for hip fracture associated with PPI use was 1.30 (95% CI 1.25-1.36).",
"   </p>",
"   <p>",
"    The FDA has mandated revised safety information on all PPIs about a possible increased risk of fractures of the hip, wrist, and spine with the use of these medications [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/84\">",
"     84",
"    </a>",
"    ]. The FDA also recommends that healthcare professionals who prescribe PPIs consider whether a lower dose or shorter duration of therapy would adequately treat the patient's condition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59976227\">",
"    <span class=\"h3\">",
"     Vitamin B12 malabsorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    has been associated with vitamin B12 malabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/85\">",
"     85",
"    </a>",
"    ]. Thus, it is reasonable to assess vitamin B12 levels periodically (eg, annually) in patients who are on long-term treatment with PPIs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59976234\">",
"    <span class=\"h3\">",
"     Iron malabsorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric acid plays a role in the absorption of nonheme iron, and the use of PPIs has been associated with decreased iron absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/72,87-89\">",
"     72,87-89",
"    </a>",
"    ]. However, in most cases the decreased absorption does not appear to be of clinical significance. One exception may be in patients who require oral iron supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of anemia due to iron deficiency\", section on 'General principles'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59974965\">",
"    <span class=\"h2\">",
"     Hypergastrinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;An initial concern with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    was the induction of hypergastrinemia and gastric carcinoid tumors in rats, changes also demonstrated with chronic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    exposure or subtotal resection of the gastric fundus [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/91\">",
"     91",
"    </a>",
"    ]. However, these observations have not generalized to species with gastrin physiology more analogous to humans [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/91\">",
"     91",
"    </a>",
"    ]. While patients treated with omeprazole for up to 11 years have shown some argyrophil cell hyperplasia, no dysplasia or neoplastic changes have been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical significance of other theoretical risks related to hypergastrinemia (such as colon cancer) has not been established. One study found no increased risk of colon cancer in long-term users of a PPI [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/93\">",
"     93",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25751?source=see_link\">",
"     \"Physiology of gastrin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59974972\">",
"    <span class=\"h2\">",
"     Atrophic gastritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving maintenance therapy have a propensity to develop chronic atrophic gastritis. Although the risk of atrophic gastritis in this context remains unclear, it could theoretically lead to an increased incidence of gastric cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/38/618?source=see_link\">",
"     \"Risk factors for gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study, for example, atrophy developed in over 30 percent of patients after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    therapy for a five-year period, changes not evident in a cohort of Scandinavians treated with anti-reflux surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/94\">",
"     94",
"    </a>",
"    ]. However, since the omeprazole-treated patients developed atrophy only in the presence of a concomitant",
"    <em>",
"     H. pylori",
"    </em>",
"    infection, it was suggested that only the",
"    <em>",
"     H. pylori",
"    </em>",
"    infected group was at risk.",
"   </p>",
"   <p>",
"    Thus, an argument can be made for the detection and eradication of",
"    <em>",
"     H. pylori",
"    </em>",
"    in patients who will be given maintenance therapy with a proton pump inhibitor. Although some clinicians subsequently adopted this practice, an FDA panel reviewing these data in November 1996 concluded that there was insufficient evidence to warrant that approach. This recommendation was supported by a subsequent controlled trial involving 155 patients who were randomly assigned to anti-reflux surgery or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/95\">",
"     95",
"    </a>",
"    ]. After three years, no significant differences were observed in the development of gastric glandular atrophy or the occurrence of intestinal metaplasia, irrespective of",
"    <em>",
"     H. pylori",
"    </em>",
"    status. Furthermore, follow-up data (up to 10 years) from the study discussed above [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/94\">",
"     94",
"    </a>",
"    ] revealed that although the annual incidence of gastric corpus mucosal atrophy was higher in",
"    <em>",
"     H. pylori",
"    </em>",
"    positive patients (4.7 versus 0.7 percent), corpus intestinal metaplasia was rare, and no dysplasia or neoplasms were observed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, we do not routinely test for",
"    <em>",
"     H. pylori",
"    </em>",
"    in patients who require long-term therapy with a proton pump inhibitor since the risk of atrophic gastritis is small and, in the uncommon patient who develops it, the clinical consequences are uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59975007\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically important drug interactions with PPIs are rare. However, some data suggest decreased activation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    when used in conjunction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    on the basis of a shared hepatic metabolic pathway. Although the relevance of these in vitro data remains highly controversial, the FDA advised against co-prescribing these medications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=see_link\">",
"     \"Nonresponse and resistance to clopidogrel\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H17\">",
"     'Differences in drug metabolism and drug interactions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27968048\">",
"    <span class=\"h1\">",
"     DISCONTINUING PROTON PUMP INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with gastroesophageal reflux disease (GERD) and dyspepsia are maintained on proton pump inhibitors (PPIs), but some concerns have been expressed regarding the long-term safety of these medications, as well as potentially important drug interactions. As a result, some asymptomatic patients who do not have other indications for being on a PPI may be candidates for having their PPI discontinued, though many relapse once the medication is stopped. (See",
"    <a class=\"local\" href=\"#H59974871\">",
"     'Safety'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=see_link&amp;anchor=H32#H32\">",
"     \"Nonresponse and resistance to clopidogrel\", section on 'Proton pump inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link&amp;anchor=H8#H8\">",
"     \"Medical management of gastroesophageal reflux disease in adults\", section on 'Maintenance therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Previous studies have demonstrated rebound gastric acid hypersecretion following the discontinuation of PPIs in patients managed for prolonged periods of time with these agents. The reasons are not entirely clear, but appear to be due in part to the suppression of antral somatostatin expression, resulting in an increase in antral gastrin release and subsequent disruption of normal pH-related feedback inhibition of acid secretion that occurs after a meal [",
"    <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As discussed below, no specific method for discontinuing the use of PPIs has been proven effective, and no approach is universally accepted. Moreover, despite the definition of &ldquo;prolonged therapy&rdquo; being likewise unclear, patients treated for a period of six months might be considered candidates for dose tapering. The following are general guidelines that may be employed when stopping a PPI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with GERD or dyspepsia are considered for a taper after being asymptomatic for a minimum of three months.",
"     </li>",
"     <li>",
"      Patients treated for acute duodenal and gastric ulcers for four to eight weeks do not require a taper.",
"     </li>",
"     <li>",
"      Patients receiving a PPI as part of a course of treatment for",
"      <em>",
"       H. pylori",
"      </em>",
"      do not require a taper.",
"     </li>",
"     <li>",
"      For patients on a moderate- to high-dose PPI (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      40 mg daily or twice daily), we cut the dose by 50 percent every week (for patients on twice daily dosing, the initial reduction can be accomplished by decreasing the dosing to once in the morning before breakfast) until the patient is on the lowest dose of the medication. Once on the lowest dose for one week, the patient is instructed to stop the medication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data are limited regarding the success of attempts at stopping therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one randomized trial, 97 patients on a long-term PPI were assigned to either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      20 mg daily for three weeks, or omeprazole 20 mg daily for one week, followed by 10 mg daily for one week, followed by 10 mg every other day for one week [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/96\">",
"       96",
"      </a>",
"      ]. At the end of three weeks the PPI was stopped. After one year of follow-up, 26 patients (27 percent) remained off of PPIs, two of whom used H2 receptor antagonists occasionally. Patients with GERD were more likely to resume taking a PPI compared with patients taking a PPI for dyspepsia or another indication (79, 67, and 42 percent, respectively). No significant difference in the rate of PPI resumption was detected based upon the discontinuation strategy (tapering versus nontapering).",
"     </li>",
"     <li>",
"      A second, earlier trial evaluated the feasibility of step-down therapy in 71 patients with uncomplicated GERD [",
"      <a class=\"abstract\" href=\"UTD.htm?24/28/25034/abstract/97\">",
"       97",
"      </a>",
"      ]. Step-down therapy consisted of a 50 percent reduction in the prescribed dose of PPI, unless the patient was already on the lowest dose available, in which case it was stopped. If symptoms returned during a two-week period, the PPI was resumed at the original dose. If no GERD symptoms were reported, the medication was stopped. If symptoms recurred after two weeks, patients were initially treated with high-dose H2 receptor antagonists, followed by the addition",
"      <span class=\"nowrap\">",
"       of/switch",
"      </span>",
"      to a prokinetic agent (cisapride or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      ) if needed. If those measures failed, the patient&rsquo;s PPI was resumed (at the pre-study dose).",
"      <br/>",
"      <br/>",
"      After one year of follow-up, 41 patients (58 percent) were asymptomatic either on non-PPI therapy (30 patients) or no therapy (11 patients). However, it must be emphasized that cisapride is no longer available, and the long-term use of metoclopramide is generally not recommended because of the drug&rsquo;s serious adverse effects. For patients in whom step-down therapy failed, the median time to resumption of the PPI was 14 days (all but one of these patients had recurrent symptoms within four months of follow-up).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/2/24610?source=see_link\">",
"       \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=see_link\">",
"       \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      H-K-ATPase comprises the final pathway by which HCl is secreted into the gastric lumen, where it serves to both hydrolyze dietary protein and maintain a sterile environment. Proton pump inhibitors (PPIs) inhibit this enzyme. The PPIs are the most potent inhibitors of gastric acid secretion available. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pharmacology of the proton pump inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PPIs are effective for treatment of all acid-related disorders including peptic ulcer disease, gastroesophageal reflux disease and Zollinger-Ellison syndrome. They are also effective in treating and preventing nonsteroidal antiinflammatory drug (NSAID)-associated gastroduodenal mucosal injury and, when used in combination with various antimicrobial agents, in eradicating",
"      <em>",
"       Helicobacter pylori",
"      </em>",
"      (",
"      <em>",
"       H. pylori",
"      </em>",
"      ) infection. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment of acid-related disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of studies have compared the various proton pump inhibitors to one another. While some differences have been reported, the magnitude of differences has been small and of uncertain clinical importance. In particular, the degree to which any of the reported differences would justify the selection of one versus another PPI, particularly when considering cost-effectiveness, is unclear. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Comparison of proton pump inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main concerns regarding the long-term safety of the PPIs include the effects of prolonged hypochlorhydria and hypergastrinemia, and the possible association of PPIs with gastric atrophy. In particular, hypochlorhydria is of concern since it may predispose to infections and malabsorption. (See",
"      <a class=\"local\" href=\"#H59974871\">",
"       'Safety'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Due to a possible increased risk of fractures it is recommended that healthcare professionals who prescribe proton pump inhibitors should consider whether a lower dose or shorter duration of therapy would adequately treat the patient's condition. (See",
"      <a class=\"local\" href=\"#H59976497\">",
"       'Hip fracture and calcium malabsorption'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      PPI use may increase the risk of",
"      <em>",
"       Clostridium difficile",
"      </em>",
"      (",
"      <em>",
"       C. difficile",
"      </em>",
"      )-associated diarrhea. In 2012, the US Food and Drug Administration (FDA) issued a safety alert encouraging providers to consider",
"      <em>",
"       C. difficile",
"      </em>",
"      infection in PPI users with persistent diarrhea. Given the potential risk of",
"      <em>",
"       C. difficile",
"      </em>",
"      infection, the FDA has also recommended that providers prescribe the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. (See",
"      <a class=\"local\" href=\"#H59974951\">",
"       'Clostridium difficile and other enteric infections'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Hypomagnesemia due to reduced intestinal absorption has been described with PPI use. It is recommended that serum magnesium levels be obtained prior to starting a PPI when patients are expected to be on the medication for long periods of time, or in patients who take PPIs in conjunction with other medications associated with hypomagnesemia (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      or diuretics). The FDA also suggests that providers consider obtaining magnesium levels periodically in such patients while they are on a PPI. (See",
"      <a class=\"local\" href=\"#H59977009\">",
"       'Magnesium absorption'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients treated with PPIs for a period of six months or longer, a dose taper should be considered prior to discontinuation. Patients with GERD or dyspepsia should also be considered for a taper after being asymptomatic for a minimum of three months. For patients on a moderate- to high-dose PPI (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      40 mg daily or twice daily), we reduce the dose by 50 percent every week until the patient is on the lowest dose of the medication. Once on the lowest dose for one week, the patient is instructed to stop the medication. (See",
"      <a class=\"local\" href=\"#H27968048\">",
"       'Discontinuing proton pump inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/1\">",
"      Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000; 118:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/2\">",
"      Harding SM, Richter JE, Guzzo MR, et al. Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome. Am J Med 1996; 100:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/3\">",
"      Wo JM, Grist WJ, Gussack G, et al. Empiric trial of high-dose omeprazole in patients with posterior laryngitis: a prospective study. Am J Gastroenterol 1997; 92:2160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/4\">",
"      Fass R, Fennerty MB, Ofman JJ, et al. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology 1998; 115:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/5\">",
"      Wolfe MM, Soll AH. The physiology of gastric acid secretion. N Engl J Med 1988; 319:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/6\">",
"      Shin JM, Cho YM, Sachs G. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors. J Am Chem Soc 2004; 126:7800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/7\">",
"      Shin JM, Sachs G. Restoration of acid secretion following treatment with proton pump inhibitors. Gastroenterology 2002; 123:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/8\">",
"      De Graef J, Woussen-Colle MC. Influence of the stimulation state of the parietal cells on the inhibitory effect of omeprazole on gastric acid secretion in dogs. Gastroenterology 1986; 91:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/9\">",
"      Holt S, Howden CW. Omeprazole. Overview and opinion. Dig Dis Sci 1991; 36:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/10\">",
"      Poynard T, Lemaire M, Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995; 7:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/11\">",
"      Dekkers CP, Beker JA, Thjodleifsson B, et al. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. Aliment Pharmacol Ther 1999; 13:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/12\">",
"      Bader JP, Delchier JC. Clinical efficacy of pantoprazole compared with ranitidine. Aliment Pharmacol Ther 1994; 8 Suppl 1:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/13\">",
"      Wolfe MM, Lowe RC. Investing in the future of GERD. J Clin Gastroenterol 2007; 41:S209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/14\">",
"      Shin JM, Homerin M, Domagala F, et al. Characterization of the inhibitory activity of tenatoprazole on the gastric H+,K+ -ATPase in vitro and in vivo. Biochem Pharmacol 2006; 71:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/15\">",
"      Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/16\">",
"      Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/17\">",
"      Marks RD, Richter JE, Rizzo J, et al. Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 1994; 106:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/18\">",
"      Swarbrick ET, Gough AL, Foster CS, et al. Prevention of recurrence of oesophageal stricture, a comparison of lansoprazole and high-dose ranitidine. Eur J Gastroenterol Hepatol 1996; 8:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/19\">",
"      Hewson EG, Sinclair JW, Dalton CB, Richter JE. Twenty-four-hour esophageal pH monitoring: the most useful test for evaluating noncardiac chest pain. Am J Med 1991; 90:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/20\">",
"      Lind T, Rydberg L, Kyleb&auml;ck A, et al. Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/21\">",
"      Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000; 14:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/22\">",
"      Wilder-Smith C, Rohss K, Lundin C, et al. Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg (abstract). Gastroenterology 2000; 118:A22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/23\">",
"      Rohss K, Claar-Nilsson C, Rydholm H, et al. Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg (abstract). Gastroenterology 2000; 118:A20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/24\">",
"      Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/25\">",
"      Dammann HG, Burkhardt F. Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion. Eur J Gastroenterol Hepatol 1999; 11:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/26\">",
"      Hartmann M, Theiss U, Huber R, et al. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment Pharmacol Ther 1996; 10:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/27\">",
"      Bruley des Varannes S, Levy P, Lartigue S, et al. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers. Aliment Pharmacol Ther 1994; 8:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/28\">",
"      Mee AS, Rowley JL. Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. Aliment Pharmacol Ther 1996; 10:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/29\">",
"      Hatlebakk JG, Berstad A, Carling L, et al. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial. Scand J Gastroenterol 1993; 28:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/30\">",
"      Mulder CJ, Dekker W, Gerretsen M. Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial). Dutch Study Group. Eur J Gastroenterol Hepatol 1996; 8:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/31\">",
"      Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/32\">",
"      Vakil N, Fennerty MB. Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease. Aliment Pharmacol Ther 2003; 18:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/33\">",
"      Fennerty MB, Johanson J, Hwang C, et al. Esomeprazole 40 mg verus lansoporazole 30 mg in healing and symptom relief in patients with moderate to severe erosive esophagitis (Los Angeles Grades C or D) (abstract). Am J Gastroenterol 2004; 99:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/34\">",
"      Moayyedi P, Armstrong D, Hunt RH, et al. The gain in quality-adjusted life months by switching to esomeprazole in those with continued reflux symptoms in primary care: EncomPASS--a cluster-randomized trial. Am J Gastroenterol 2010; 105:2341.",
"     </a>",
"    </li>",
"    <li>",
"     Ip S, Bonis P, Tatsioni A, et al. Comparative Effectiveness of Management Strategies for Gastroesophageal Reflux Disease. Evidence Report/Technology Assessment No. 1. (Prepared by Tufts-New England Medical Center. Evidence-based Practice Center under Contract No. 290-02-0022.) Rockville, MD: Agency for Healthcare Research and Quality. December 2005 www.effectivehealthcare.ahrq.gov/reports/final.cfm (Accessed on December 05, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/36\">",
"      Nelson WW, Vermeulen LC, Geurkink EA, et al. Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole. Arch Intern Med 2000; 160:2491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/37\">",
"      Tsai HH, Chapman R, Shepherd A, et al. Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study. Aliment Pharmacol Ther 2004; 20:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/38\">",
"      Talley NJ, Venables TL, Green JR, et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002; 14:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/39\">",
"      Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. Aliment Pharmacol Ther 2001; 15:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/40\">",
"      McQuaid KR, Laine L. Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials. Clin Gastroenterol Hepatol 2005; 3:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/41\">",
"      Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998; 129:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/42\">",
"      Furuta T, Shirai N, Watanabe F, et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 2002; 72:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/43\">",
"      Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 1985; 89:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/44\">",
"      Diaz D, Fabre I, Daujat M, et al. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology 1990; 99:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/45\">",
"      Meyer UA. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol 1996; 8 Suppl 1:S21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/46\">",
"      Parsons ME. Pantoprazole, a new proton-pump inhibitor, has a precise and predictable profile of activity. Eur J Gastroenterol Hepatol 1996; 8 Suppl 1:S15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/47\">",
"      Lew EA. Review article: pharmacokinetic concerns in the selection of anti-ulcer therapy. Aliment Pharmacol Ther 1999; 13 Suppl 5:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/48\">",
"      Li XQ, Andersson TB, Ahlstr&ouml;m M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004; 32:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/49\">",
"      Liu KH, Kim MJ, Shon JH, et al. Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro. Xenobiotica 2005; 35:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/50\">",
"      Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/51\">",
"      Naggie S, Miller BA, Zuzak KB, et al. A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors. Am J Med 2011; 124:276.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/52\">",
"      Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010; 170:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/53\">",
"      Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol 2008; 103:2308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/54\">",
"      Vaishnavi C. Established and potential risk factors for Clostridum difficile infection. Indian J Med Microbiol 2009; 27:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/55\">",
"      Dial S, Alrasadi K, Manoukian C, et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004; 171:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/56\">",
"      Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003; 54:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/57\">",
"      Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294:2989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/58\">",
"      Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007; 102:2047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/59\">",
"      Kwok CS, Arthur AK, Anibueze CI, et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012; 107:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/60\">",
"      Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012; 107:1001.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). Available at: file://www.fda.gov/Drugs/DrugSafety/ucm290510.htm (Accessed on February 08, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/62\">",
"      Neal KR, Scott HM, Slack RC, Logan RF. Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study. BMJ 1996; 312:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/63\">",
"      Kader SA, Mansour AM, Mohran Z, et al. A study on the relation between proton pump inhibitor and gastric giardiasis. J Egypt Soc Parasitol 1998; 28:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/64\">",
"      Reynaert H, Fernandes E, Bourgain C, et al. Proton-pump inhibition and gastric giardiasis: a causal or casual association? J Gastroenterol 1995; 30:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/65\">",
"      Garc&iacute;a Rodr&iacute;guez LA, Ruig&oacute;mez A, Pan&eacute;s J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol 2007; 5:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/66\">",
"      Garcia Rodr&iacute;guez LA, Ruig&oacute;mez A. Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk? Epidemiology 1997; 8:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/67\">",
"      Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007; 167:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/68\">",
"      Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/69\">",
"      Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008; 149:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/70\">",
"      Eom CS, Jeon CY, Lim JW, et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011; 183:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/71\">",
"      Jena AB, Sun E, Goldman DP. Confounding in the association of proton pump inhibitor use with risk of community-acquired pneumonia. J Gen Intern Med 2013; 28:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/72\">",
"      McColl KE. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol 2009; 104 Suppl 2:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/73\">",
"      Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther 2012; 36:405.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm245275.htm (Accessed on March 02, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/75\">",
"      Recker RR. Calcium absorption and achlorhydria. N Engl J Med 1985; 313:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/76\">",
"      Tuukkanen J, V&auml;&auml;n&auml;nen HK. Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro. Calcif Tissue Int 1986; 38:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/77\">",
"      Mizunashi K, Furukawa Y, Katano K, Abe K. Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 1993; 53:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/78\">",
"      Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296:2947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/79\">",
"      Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010; 139:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/80\">",
"      Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010; 138:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/81\">",
"      Targownik LE, Leslie WD, Davison KS, et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol 2012; 107:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/82\">",
"      Yu EW, Bauer SR, Bain PA, Bauer DC. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med 2011; 124:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/83\">",
"      Khalili H, Huang ES, Jacobson BC, et al. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ 2012; 344:e372.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm213321.htm (Accessed on June 02, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/85\">",
"      Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med 1994; 120:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/86\">",
"      Laine L, Ahnen D, McClain C, et al. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2000; 14:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/87\">",
"      Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut 2007; 56:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/88\">",
"      Sarzynski E, Puttarajappa C, Xie Y, et al. Association between proton pump inhibitor use and anemia: a retrospective cohort study. Dig Dis Sci 2011; 56:2349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/89\">",
"      Ajmera AV, Shastri GS, Gajera MJ, Judge TA. Suboptimal response to ferrous sulfate in iron-deficient patients taking omeprazole. Am J Ther 2012; 19:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/90\">",
"      Sharma VR, Brannon MA, Carloss EA. Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. South Med J 2004; 97:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/91\">",
"      Freston JW. Omeprazole, hypergastrinemia, and gastric carcinoid tumors. Ann Intern Med 1994; 121:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/92\">",
"      Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/93\">",
"      van Soest EM, van Rossum LG, Dieleman JP, et al. Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol 2008; 103:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/94\">",
"      Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/95\">",
"      Lundell L, Miettinen P, Myrvold HE, et al. Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. Gastroenterology 1999; 117:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/96\">",
"      Bj&ouml;rnsson E, Abrahamsson H, Simr&eacute;n M, et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006; 24:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/28/25034/abstract/97\">",
"      Inadomi JM, Jamal R, Murata GH, et al. Step-down management of gastroesophageal reflux disease. Gastroenterology 2001; 121:1095.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.38",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Queens Family Health Team - Mike L",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-178.173.141.104-B0F0CA9818-S317699.12.14-178433663]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_28_25034=[""].join("\n");
var outline_f24_28_25034=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSIOLOGY OF ACID SECRETION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Structure of the parietal cell H-K-ATPase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PHARMACOLOGY OF THE PROTON PUMP INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Rebound acid hypersecretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT OF ACID-RELATED DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Eradication of Helicobacter pylori",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Treatment and prevention of gastroduodenal ulcers associated with NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Zollinger-Ellison syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Treatment of gastroesophageal reflux disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Complications of GERD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      COMPARISON OF PROTON PUMP INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Over-the-counter and on-demand PPIs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Differences in drug metabolism and drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Convenience",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Intravenous formulations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Costs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H59974871\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59976608\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H59974951\">",
"      - Clostridium difficile and other enteric infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H59974958\">",
"      - Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59976220\">",
"      Malabsorption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H59977009\">",
"      - Magnesium absorption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H59976497\">",
"      - Hip fracture and calcium malabsorption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H59976227\">",
"      - Vitamin B12 malabsorption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H59976234\">",
"      - Iron malabsorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59974965\">",
"      Hypergastrinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59974972\">",
"      Atrophic gastritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59975007\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27968048\">",
"      DISCONTINUING PROTON PUMP INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/5\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/29/18902\" title=\"figure 1\">",
"      Regulation of acid secretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"GAST_72598\" title=\"table 1\">",
"      Pharmacokinetic properties PPIs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/19/28988\" title=\"table 2\">",
"      PPI recommended doses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"GAST_53616\" title=\"table 3\">",
"      PPI drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"GAST_72565\" title=\"table 4\">",
"      PPI cytochrome metabolism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/18/17706?source=related_link\">",
"      Approach to refractory gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15000?source=related_link\">",
"      Causes of hypomagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=related_link\">",
"      Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19253?source=related_link\">",
"      Complications of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=related_link\">",
"      Drugs that affect bone metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=related_link\">",
"      HIV protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6968?source=related_link\">",
"      Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=related_link\">",
"      Management of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=related_link\">",
"      Nonresponse and resistance to clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=related_link\">",
"      Overview of the natural history and treatment of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44569?source=related_link\">",
"      Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=related_link\">",
"      Overview of the treatment of bleeding peptic ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/2/24610?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/47/13049?source=related_link\">",
"      Pharmacology of antiulcer medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29160?source=related_link\">",
"      Physiology of gastric acid secretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25751?source=related_link\">",
"      Physiology of gastrin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13433?source=related_link\">",
"      Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/38/618?source=related_link\">",
"      Risk factors for gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=related_link\">",
"      Treatment of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=related_link\">",
"      Treatment regimens for Helicobacter pylori",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_28_25035="Montreal classification of severity of ulcerative colitis";
var content_f24_28_25035=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F86284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F86284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Montreal classification of severity of ulcerative colitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Severity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        S0",
"       </td>",
"       <td>",
"        Clinical remission",
"       </td>",
"       <td>",
"        Asymptomatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        S1",
"       </td>",
"       <td>",
"        Mild UC",
"       </td>",
"       <td>",
"        Passage of four or fewer stools/day (with or without blood), absence of any systemic illness, and normal inflammatory markers (ESR)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        S2",
"       </td>",
"       <td>",
"        Moderate UC",
"       </td>",
"       <td>",
"        Passage of more than four stools per day but with minimal signs of systemic toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        S3",
"       </td>",
"       <td>",
"        Severe UC",
"       </td>",
"       <td>",
"        Passage of at least six bloody stools daily, pulse rate of at least 90 beats per minute, temperature of at least 37.5&deg;C, haemoglobin of less than 10.5 g/dL, and ESR of at least 30 mm/hour",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     UC: ulcerative colitis; ESR: erythrocyte sedimentation rate.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Gut, Satsangi J, Silverberg MS, Vermere S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications, 55:749-53, copyright &copy; 2006, with permission from BMJ Publishing Group Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_28_25035=[""].join("\n");
var outline_f24_28_25035=null;
var title_f24_28_25036="Complications corticosteroid Rx";
var content_f24_28_25036=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F71400&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F71400&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Complications of corticosteroid therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neurologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Behavioral changes, insomnia, myopathy, hallucinations, hiccups, tremor, reduced taste and smell, cerebral atrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Uncommon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Psychosis, dementia, seizures, dependence, paraparesis (epidural lipomatosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Dermatologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thin, fragile skin, purpura, echymosis, striae, hirsuitism, acne, inhibition of wound healing, Kaposi's sarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Rheumatologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osteoporosis, avascular necrosis, growth retardation, tendinous rupture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Gastrointestinal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased appetite, abdominal bloating, gastrointestinal bleeding and perforation, pancreatitis, liver hypertrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Opthalmologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Visual blurring, cataract, glaucoma, exophthalmos, uveitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardiovascular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertension, atherosclerosis, arrhythmia (with IV push)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Endocrine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperglycemia, hypokalemia, hypophosphatemia, hypernatremia, hyperlipidemia, redistribution of body fat (centripetal obesity, buffalo hump, etc), amenorrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Urogenital",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyuria, genital burning (with IV push)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Miscellaneous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Opportunistic infections (including candidiasis, PCP), hypersensitivity reactions, neutrophilia, lymphopenia, night sweats",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Steroid withdrawal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pseudorheumatism (very common), headache, lethargy, low-grade fever, adrenal insufficiency, pseudotumor cerebri",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data adapted from Delattre, JY, Posner, JB, Neurological complications of chemotherapy and radiation therapy. In: Neurology and General Medicine, Aminoff MJ, (Ed), Churchill Livingstone, New York, 1994. p.421-446.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_28_25036=[""].join("\n");
var outline_f24_28_25036=null;
var title_f24_28_25037="Peripheral blood and BM findings in MDS";
var content_f24_28_25037=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F85790&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F85790&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Peripheral blood and bone marrow findings in myelodysplastic syndromes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Blood findings",
"       </td>",
"       <td class=\"subtitle1\">",
"        Bone marrow findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Refractory cytopenias with unilineage dysplasia (RCUD)",
"       </td>",
"       <td class=\"sublist_other_start\" rowspan=\"2\">",
"        <p>",
"         Unicytopenia or bicytopenia*",
"        </p>",
"        <span class=\"sublist_other\">",
"         No or rare blasts (&lt;1 percent)",
"         <sup>",
"          &bull;",
"         </sup>",
"        </span>",
"       </td>",
"       <td class=\"sublist_other_start\" rowspan=\"2\">",
"        <p>",
"         Unilineage dysplasia: &ge;10 percent of the cells in one myeloid lineage",
"        </p>",
"        <p>",
"         <span class=\"sublist_other\">",
"          &lt;5 percent blasts",
"         </span>",
"        </p>",
"        <span class=\"sublist_other\">",
"         &lt;15 percent of erythroid precursors are ring sideroblasts",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Refractory anemia (RA); refractory neutropenia (RN); refractory thrombocytopenia (RT)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Refractory anemia with ring sideroblasts (RARS)",
"       </td>",
"       <td>",
"        <p>",
"         Anemia",
"        </p>",
"        No blasts",
"       </td>",
"       <td>",
"        <p>",
"         &ge;15 percent of erythroid precursors are ring sideroblasts",
"        </p>",
"        <p>",
"         Erythroid dysplasia only",
"        </p>",
"        &lt;5 percent blasts",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Refractory cytopenia with multilineage dysplasia (RCMD)",
"       </td>",
"       <td>",
"        <p>",
"         Cytopenia(s)",
"        </p>",
"        <p>",
"         No or rare blasts (&lt;1 percent)",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         No Auer rods",
"        </p>",
"        &lt;1x10",
"        <sup>",
"         9",
"        </sup>",
"        /L monocytes",
"       </td>",
"       <td>",
"        <p>",
"         Dysplasia in &ge;10 percent of the cells in &ge;two myeloid lineages (neutrophil and/or erythroid precursors and/or megakaryocytes)",
"        </p>",
"        <p>",
"         &lt;5 percent blasts in marrow",
"        </p>",
"        <p>",
"         No Auer rods",
"        </p>",
"        &plusmn;15 percent ring sideroblasts",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Refractory anemia with excess blasts-1 (RAEB-1)",
"       </td>",
"       <td>",
"        <p>",
"         Cytopenia(s)",
"        </p>",
"        <p>",
"         &lt;5 percent blasts",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         No Auer rods",
"        </p>",
"        &lt;1x10",
"        <sup>",
"         9",
"        </sup>",
"        /L monocytes",
"        <p>",
"         &nbsp;",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unilineage or multilineage dysplasia",
"        </p>",
"        <p>",
"         5 to 9 percent blasts",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        No Auer rods",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Refractory anemia with excess blasts-2 (RAEB-2)",
"       </td>",
"       <td>",
"        <p>",
"         Cytopenia(s)",
"        </p>",
"        <p>",
"         5 to 19 percent blasts",
"        </p>",
"        <p>",
"         Auer rods &plusmn;",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"        &lt;1x10",
"        <sup>",
"         9",
"        </sup>",
"        /L monocytes",
"        <p>",
"         &nbsp;",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unilineage or multilineage dysplasia",
"        </p>",
"        <p>",
"         10 to 19 percent blasts",
"        </p>",
"        Auer rods &plusmn;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Myelodysplastic syndrome - unclassified (MDS-U)",
"       </td>",
"       <td>",
"        <p>",
"         Cytopenias",
"        </p>",
"        &le;1 percent blasts",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Unequivocal dysplasia in less than 10 percent of cells in one or more myeloid cell lines when accompanied by a cytogenetic abnormality considered as presumptive evidence for a diagnosis of MDS",
"        </p>",
"        &lt;5 percent blasts",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        MDS associated with isolated del(5q)",
"       </td>",
"       <td>",
"        <p>",
"         Anemia",
"        </p>",
"        <p>",
"         Usually normal or increased platelet count",
"        </p>",
"        No or rare blasts (&lt;1 percent)",
"       </td>",
"       <td>",
"        <p>",
"         Normal to increased megakaryocytes with hypolobated nuclei",
"        </p>",
"        <p>",
"         &lt;5 percent blasts",
"        </p>",
"        <p>",
"         Isolated del(5q) cytogenetic abnormality",
"        </p>",
"        No Auer rods",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Bicytopenia may occassionally be observed. Cases with pancytopenia should be classified as MDS-U.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      If the marrow myeloblast percentage is &lt;5 percent but there are 2 to 4 percent myeloblasts in the blood, the diagnostic classification is RAEB-1. Cases of RCUD and RCMD with 1 percent myeloblasts in the blood should be classified as MDS-U.",
"      <br>",
"       &Delta; Cases with Auer rods and &lt;5 percent myeloblasts in the blood and &lt;10 percent in the marrow should be classified as RAEB-2.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     From Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC, Lyon, 2008. Reproduced with permission. Copyright &copy; 2008 IARC.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_28_25037=[""].join("\n");
var outline_f24_28_25037=null;
var title_f24_28_25038="Contents: Drug allergy";
var content_f24_28_25038=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?43/1/44061\">",
"       Allergy and Immunology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Drug allergy",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Drug allergy",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Antibiotics",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/46/23274\">",
"           Allergy to penicillins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/2/26663\">",
"           Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/55/11130\">",
"           Cephalosporin allergy: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/17/5400\">",
"           Cephalosporin-allergic patients: Subsequent use of cephalosporins and related antibiotics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/7/20600\">",
"           Penicillin skin testing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/19/15672\">",
"           Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/5/1110\">",
"           Penicillins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/2/23594\">",
"           Sulfonamide allergy in non HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/59/1978\">",
"           Vancomycin hypersensitivity",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         NSAIDs",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/0/39944\">",
"           Aspirin exacerbated respiratory disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/54/18281\">",
"           Aspirin exacerbated respiratory disease: NSAID challenge and desensitization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/25/26006\">",
"           Diagnostic challenge and desensitization protocols for NSAID reactions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/59/31672\">",
"           NSAIDs (including aspirin): Allergic and pseudoallergic reactions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/49/17177\">",
"           Nonselective NSAIDs: Overview of adverse effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/48/13066\">",
"           Overview of selective COX-2 inhibitors",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/62/34792\">",
"           Allergic reactions to local anesthetics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/5/43097\">",
"           Allergic reactions to vaccines",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/62/24554\">",
"           An approach to the patient with drug allergy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/36/27209\">",
"           Clinical manifestations and diagnosis of acute interstitial nephritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/11/1210\">",
"           Drug allergy: Classification and clinical features",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/35/38456\">",
"           Drug allergy: Pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/17/41241\">",
"           Drug eruptions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/25/2456\">",
"           Drug fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/39/26232\">",
"           Hypersensitivity reactions to clopidogrel",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/22/8553\">",
"           Hypersensitivity reactions to fluoroquinolones antimicrobials",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/40/2698\">",
"           Hypersensitivity reactions to macrolides, aminoglycosides, tetracyclines, clindamycin, and metronidazole",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/34/30247\">",
"           Hypersensitivity reactions to systemic glucocorticoids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/36/31305\">",
"           Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/49/38680\">",
"           Immediate hypersensitivity reactions to radiocontrast media: Prevention of recurrent reactions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/57/43930\">",
"           Infusion reactions to systemic chemotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/51/42809\">",
"           Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/27/442\">",
"           Perioperative anaphylaxis: Evaluation and prevention of recurrent reactions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/62/29672\">",
"           Rapid drug desensitization for immediate hypersensitivity reactions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/40/8842\">",
"           Serum sickness and serum sickness-like reactions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/29/17882\">",
"           Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/0/33801\">",
"           Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-F357E3DA09-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f24_28_25038=[""].join("\n");
var outline_f24_28_25038=null;
var title_f24_28_25039="Vulvar varicosity";
var content_f24_28_25039=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F86312&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F86312&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvar varicosity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 237px; height: 318px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Natasha R Johnson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_28_25039=[""].join("\n");
var outline_f24_28_25039=null;
